New international business centre – Stockholm South Business District – to be developed in Flemingsberg

On Monday 13 August, the Municipal Executive Board in Huddinge decided to approve an letter of intent between the municipality and the consortium, in which the real estate company Fabege AB has a leading role. This signals the start of an exciting journey, which will transform the current Flemingsberg over the course of the next 10 years. International town open to everyone The aim of the collaboration is to renew and develop Flemingsberg’s station area and associated areas to create a venue for 50,000 jobs, 50,000 residents and 50,000 visitors in Flemingsberg. A venue where knowledge and creativity combine with business, local residents and visitors to create sustainable growth in an open and inviting environment. -          “This is a gigantic development project, one of the largest in Sweden in fact, which will makeFlemingsberg a real centre in southern Stockholm. We are planning for thousands of new workplaces and housing in an attractive urban environment, says Daniel Dronjak, Chairman of the Municipal Executive Board.” Broad support enables strong regional and national development Today, Flemingsberg is already a location that brings together higher education, world-leading research, government agencies and companies. Flemingsberg is therefore designated as a regional centre and promoted as an obvious hub for the infrastructure of tomorrow. With regional and national investments already approved and the local conditions that are already in place, Flemingsberg has unique opportunities to grow and create a balance in the Stockholm region. -        “A powerful option to the southern side of Stockholm will not only create jobs and local growth, but also better balance and competitiveness for the entire Stockholm region, The new Stockholm South Business District will provide a real boost, not only for Huddinge and Stockholm, but for all of Sweden,” according to Daniel Dronjak. The consortium currently consists of Fabege and WA Fastigheter, both of which focus heavily on urban development. The latter also owns property in the area in question. -        “Together with Huddinge Municipality and other stakeholders, we want to transform the Flemingsberg area from being a strong regional centre into a dynamic international star,” says Klaus Hansen Vikström, CEO of the consortium. Further information and details about the planning work and the rest of the process will be published on an ongoing basis. The final decision regarding the letter of intent will be taken by the Municipal Council on 20 August. In terms of Fabege’s interests, large-scale investments will be made at the earliest in 2021/2022, which is when planning permission is expected to be approved.

Handicare Group appoints Staffan Ternström as new President and CEO

Staffan Ternström has a solid background as an accomplished commercial leader in medical devices. For the past four years, he has worked as EVP Global Commercial and Strategy for Mölnlycke Healthcare. Prior to that, he spent nearly 25 years in various positions within Johnson & Johnson including President Cordis EMEA, VP Emerging Markets, DACH and Nordics, and other senior positions based in Belgium as well as in Sweden. Staffan Ternström was born in 1965 and is a graduate in Business Administration of the University of Gothenburg.  “On behalf of the Board, I want to welcome Staffan to the position as President and CEO of Handicare Group. In Staffan Ternström, Handicare has found a President and CEO who in his previous positions has demonstrated strong leadership and strategic skills and who is well acquainted with global businesses within the field of medical devices,” says Lars Marcher, Chairman of the Board of Handicare Group AB. Staffan Ternström will start as President and CEO on August 14 2018.   Press contact: Lars Marcher Tel: + 45 5136 2490   lm@ambu.com  Boel SundvallTel: +46 723 747 487  boel.sundvall@handicare.com This information is information that Handicare Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 18:45 CET on 13 August 2018.  About Handicare Handicare offers solutions to increase the independence of disabled or elderly people, and to facilitate for their care providers and family. The offering encompasses a comprehensive range of curved and straight stairlifts, transfer, lifting and repositioning aids, vehicle adaptations and medical equipment. Handicare is a global company with sales in more than 20 countries and is a market leader in this field. The head office is in Stockholm, Sweden and manufacturing is located at six sites distributed across North America, Asia and Europe. In the 12-month period to March 2018, revenue amounted to MEUR 283 and the adjusted EBITA margin was 8.7%. Employees numbered around 1,200 and the share is listed on Nasdaq Stockholm. For more information, see www.handicaregroup.com.

Press release from the Extra General Meeting August 13, 2018

Dividends of shares in I-Tech AB (publ) It was resolved that a dividend in kind of one share in I-Tech AB (publ) (“I-Tech”) is to be distributed for eight shares in Vicore Pharma Holding AB (publ). That is equivalent to a total of 1,983,563 shares in I-Tech. Based on the shares’ booked value in the Company’s quarterly report on 31 March 2018, the proposed dividend corresponds to approximately SEK 0.77 per share and in total approximately SEK 12,189,492. The shareholders whose possession per the record day is not equally divisible with eight shall be entitled to a fraction of an I-Tech share as follows. Each surplus fraction shall entitle to an eighth of a share in I-Tech. All such fractions of shares in I-Tech shall be consolidated to whole shares which thereafter are to be sold by the Company on the market. The payment, without subtraction for brokerage, is to be paid to the relevant shareholders.  Considering that the Company’s present lock-up obligation regarding the shares in I-Tech shall remain in force when the shares are distributed to the Company’s shareholders, it was decided to authorize the Board of Directors to (i) through an issuing house supervise that technical measures are taken at Euroclear to prevent that those who receive shares in I-Tech are able to transfer such shares before 28 May 2019, and (ii) that Euroclear is authorized to disclose the necessary details of the Company’s shareholders’ reconciliation account in order for the issuing house to take the above-mentioned technical measures.  17 August 2018 was decided as the record day for the distribution in kind. The shares in I-Tech are expected to be available on safe custody accounts 24 August 2018.  Issue in kind regarding the acquisition of INIM Pharma AB It was resolved That the Company’s share capital shall increase by approximately SEK 4,425,750.96 upon issuance of 8,851,502 new shares. The subscription price for each share shall be SEK 8 per share by an issue in kind of all shares in INIM Pharma AB, reg.no. 559156-8471 (”INIM Pharma”). The premium for the issued shares shall be placed in the share premium reserve. By deviating from the shareholders’ pre-emptive rights INIM Pharma shall have the sole right to subscribe for the shares (pro rata in accordance with their proportional possession in INIM Pharma). Subscription for shares shall be made from 18 August 2018 up to and including 24 August 2018.  Payment for shares subscribed for shall be made no later than 24 August, 2018, by issue in kind, consisting of all shares in INIM Pharma, provided to the Company.  The Board of Directors reserves the right to extend the time for when subscription and payment shall take place.  The new shares shall be entitled to a part of the Company’s profits from the first record day after the shares have been registered at the Swedish Companies Registration Office.  The subscription price has been determined through negotiations and represents a fair market value.  Adoption of new articles of association It was resolved to amend the number of directors in the articles of association to no less than three directors and no more than nine directors. Pre-emptive rights issue It was resolved to realise a rights issue  upon confirmation and registration of approximately SEK 4,120,000.96 by issue of a maximum of 8,240,002 new shares. The subscription price for each share shall be SEK 10. The Company’s shareholders shall have pre-emptive rights to subscribe for new shares in proportion to the number of old shares held, whereby each shareholder shall have pre-emptive rights to subscribe for one (1) new share for each third old share held (primary pre-emptive rights). Each held share per the record day entitles to one (1) new subscription right. Three (3) subscription rights thus entitles to subscription of one (1) new share.  Only shareholders recorded in the share register on 17 September 2018, shall be deemed entitled to subscribe for the new shares by pre-emptive right (record day).  Subscription for shares shall be made from 19 September 2018 up to and including 3 October, 2018.  Shareholders shall be entitled to transfer their primary pre-emptive rights to other shareholders as well as third parties. Trading with subscription rights will be made via Nasdaq First North Stockholm during a limited time, from 19 September 2018 up to and including 1 October 2018. Subscription rights not exercised for subscription in the issue must be sold before 1 October 2018, or be exercised for subscription of shares no later than 3 October 2018, in order not to be invalid or lose their value. By assignment of the subscription right, the right to subscribe for shares in the rights issue is transferred to the new holder of the subscription right.  Shares not subscribed for through subscription rights shall primarily be offered to those who have subscribed for shares through subscription rights and applied to subscribe for additional shares without subscription rights in relation to that number of subscription rights each holder has exercised as subscription for shares and secondarily to others who have registered for subscription without subscription rights.  The Board of Directors shall be reserved the right to extend the time for when subscription and payment shall take place. The Board of Directors shall also be reserved the right to extend the time for trading with subscription rights according to (vii) above.  The new shares shall be entitled to a part of the Company’s profits from the first record day after the shares have been registered at the Swedish Companies Registration Office.  In total, around 61.4 percent of the rights issue is covered through subscription intentions and undertakings.  Long-term incentive program for the Company´s senior management and key persons It was resolved to implement an incentive program for certain of the Company’s senior management and key persons.  A total of a maximum of 2,000,000 warrants will be issued. The Company’s share capital will be increased by a maximum of approximately SEK 999,999.99. For more information regarding the terms for the incentive program for senior management and key persons, view our website; www.vicorepharma.com   Principles for the Nomination Committee It was resolved to adopt a Nomination Committee consisting of four persons. Each of the Company’s three largest shareholders determined by votes as per 30 September 2018, shall each be entitled to appoint a member of the Nomination Committee. Affiliated to shareholder (Sw. närstående), as this concept is defined in chapter 21, clause 1 of the Swedish Companies Act, shall be included in the assessment when determining the three largest shareholders. None of the three persons appointed as members of the Nomination Committee in this respect may be directors on the Company's Board of Directors. In addition, the chairman of the Board of Directors shall be a member of the Nomination Committee who will also convene meetings of the Nomination Committee. Board of Directors It was resolved to elect Hans Schikan and Jacob Gunterberg as directors of the Board of Directors until the close of the next Annual General Meeting. The honorarium was decided to SEK 85 000 until next AGM 2019. Long-term incentive program for certain members of the Board of Directors  It was resolved to allocate 475,000 share awards by issuing of 475,000 warrants. The share capital may be increased by a maximum of approximately SEK 250,000. The share awards shall be awarded in accordance to the following board members:Leif Darner                            125,000Hans Schikan                       125,000Maarten Kraan                    125,000Peter Ström                          50,000Sara Malcus                         50,000  The sharehare capital may be increased by a maximum of approximately SEK 250,000  For more information regarding the terms for the incentive program for certain board members, view our website; www.vicorepharma.com   For further information, please contact: Leif Darner, Chairman of the BoardTel: +46 70 579 04 62 or e-mail: leif.darner@vicorepharma.com Per Jansson, CEOTel: +46 70 917 47 46 or e-mail: per.jansson@vicorepharma.com This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 19:00 CET on August 13, 2018 About Vicore Pharma HoldingVicore Pharma AB develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. I-Tech AB has developed and commercialized a substance, Selektope® for use as an antifouling ingredient in antifouling paints. The companies are based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com 

LINK Mobility Group ASA: Financial report second quarter 2018

LINK achieved an operating revenue of NOK 497 million in the quarter, up 77 percent compared with corresponding period last year. The organic growth is driven by a strong demand from enterprise clients. LINK experienced a slightly lower usage than anticipated from some larger clients in our new markets due to the implementation and adaption to the GDPR Directive which came into force during May and June. The effect from lower volumes are calculated to a revenue loss of NOK 12 million in the quarter. The adjusted EBITDA is reported at NOK 54 million or a margin of 10,8 percent, negatively impacted by a NOK 6 million non-recurring cost related to the implementation of the GDPR Directive. Adjusted EBITDA excluding GDPR costs of NOK 60 million, or a margin of 12,0 percent, which is a representative run-rate profitability level for the second quarter, and 1,2 percentage points higher than corresponding period last year. LINK has a scalable business model whereby OPEX does not increase in relativity to revenue and gross margin  “Another strong quarter for LINK, upset only slightly by some of our customers not yet fully GDPR ready, but encouraging to see them reactivated, some with consent services delivered by LINK. We also had a strong inflow of more than 800 new customers & contracts signed during the quarter. LINK is well positioned in the European market to capture the growth within mobile messaging and solutions services.” Says Arild Hustad, CEO of LINK. A presentation will be held by CEO Arild Hustad and CFO Thomas Berge regarding the second quarter reporting through live webcast. The webcast will be held at 10.00 a.m. August 14. The presentation and subsequent Q&A session may be viewed at hegnarTV at the following link; http://webtv.hegnar.no/presentation.php?webcastId=92018254 

Ripasso Energy AB has been asked to submit a detailed proposal in South Africa – the company is preparing for listing on a regulated market.

Last winter, Swedish clean tech company Ripasso Energy signed an agreement with the South African ferrochrome producer Afarak South Africa (Pty) Ltd for the sale of 7 PWR BLOK 400-Fs. This summer, the company has been asked to submit a detailed proposal for installations at two major production facilities for another South African ferrochrome producer. In total this would involve 72 PWR BLOK units worth EUR 36 million.  Following a successful evaluation of PWR BLOK’s ability to generate electricity using syngas and low-quality LPG, Ripasso has also started marketing the PWR BLOK for these gases in South Africa. The response has been positive, and the goal is to provide technology for local projects in South Africa where distributed electricity supply can be accomplished at a lower cost than purchasing from the national electric utility.  In light of developments in South Africa, Ripasso Energy’s Board of Directors has decided to prepare to have the company listed on a regulated market. A marketplace will be selected in 1H 2019 and the intention is for the listing to occur in 3Q 2019.   “Ripasso Energy has been a public company for nearly 2 years. It has an organisation in place that will soon be able to meet the demands imposed by a regulated market. Because the company is poised for rapid growth, we want to make it possible for a broader-based and more institutional group of investors to become shareholders in the company. In consultation with the major shareholders, I have asked the nomination committee to evaluate the composition of the board ahead of this initiative and, if appropriate, to identify new candidates who possess the relevant skill set and experience,” says Sven Sahle, Ripasso Energy AB’s Chairman of the Board and largest shareholder.

NRC Group ASA acquires NSS Holding AS

NRC Group ASA ("NRC Group" or the "Company") has on 14 August 2018 entered into a definitive agreement for the acquisition of NSS Holding AS, the sole shareholder of Norsk Saneringsservice AS ("NSS") and the owner of 70% of the issued and outstanding shares in Miljøvakta AS, ("Miljøvakta") for an enterprise value of NOK 103 million on a cash and debt free basis. Construction and infrastructure development is associated with major climate and environmental responsibility. There is a clear trend of increased regulations and expectations from the authorities related to sustainability and environmental impact. The same trend is reflected among customers and other stakeholders, which has led to a higher weighting of environmental and safety considerations in tendering processes. The acquisition of NSS and Miljøvakta strengthens NRC Group’s Norwegian operations and broadens the company’s overall capabilities as a turnkey contractor. “Infrastructure development projects are increasingly subject to environmental regulations, requirements and expectations. We are committed to operate in the most sustainable manner with the competence and capacity needed to provide a full range of services, from planning and project management to the actual physical work of decommissioning, remediation and waste logistics, says Øivind Horpestad, CEO of NRC Group ASA. “We see this as a growth opportunity for NRC Group as the acquisition of NSS and Miljøvakta strengthens our competitive position, both on our own projects and as a third-party supplier,” adds Horpestad. NSS is one of Norway's largest companies within demolition and environmental remediation, and Miljøvakta offers environmental consultancy and remediation services. NSS and Miljøvakta have currently approximately 90 employees. NRC Group will acquire 100% of the shares in NSS Holding AS. The enterprise value is NOK 103 million on a cash and debt free basis and assuming a normalized working capital. The enterprise value is based on a consolidated estimated average EBIT for 2018 and 2019 of NOK 20 million. The seller has guaranteed an average EBIT of 2018 and 2019 of NOK 20 million. Assuming no adjustments in the enterprise value, 50% of the purchase price will be settled by payment of NOK 51.5 million in cash (of which NOK 10 million will be placed in escrow) and the remaining 50% of the purchase price of NOK 51.5 million will be settled by issuance of 779.122 shares in the Company at a price of NOK 66.10 per share (the "Consideration Shares"). The Consideration Shares are subject to a lock-up period, whereby 1/3 of the Consideration shares are subject to a lock-up undertaking of 24 months and the remaining 2/3 for 36 months after the closing date. The seller will pledge a number of Consideration Shares that represent in aggregate a value of NOK 10 million as security for claims the Company may have against the seller. The transaction is expected to be completed during September 2018. The indirect seller of NSS Holding AS (owning NSS Holding AS through holding companies) is the founder of NSS and a key employee. The indirect seller is also member of the current boards of directors of both NSS and Miljøvakta. The following table provides key financial information (based on local statutory accounts) for NSS Holding AS on a proforma and consolidated basis: (NOK million) FY 2017 FY 2016Revenue 242.6 168.5EBITDA 14.9 6.2EBIT 12.1 4.3EBIT margin (%) 5.0 2.5 Cash and cash equivalents 8.7 22.7Total assets 74.8 61.3 NSS Holding AS will be organized as a separate subsidiary under NRC Norge AS, a wholly owned subsidiary of NRC Group ASA. There are no special agreements or arrangements that have been or will be entered into with the directors or executive management of NSS Holding AS, NSS or Miljøvakta or the Company in connection with the transaction. *** For further information, please contact CEO Øivind Horpestad, telephone: +47 91 00 06 26 About NRC Group ASA: NRC Group is a leading contractor within railway infrastructure in Norway and Sweden. The company is a supplier of all track-related infrastructure services, including groundworks, specialized track work, safety, electro, telecom- and signaling systems. The company works within rail, metro, tram segments and close related infrastructure. NRC Group has experienced significant growth since its inception in 2011 and has a vision of becoming the leading Nordic entrepreneur within railway infrastructure. For more information: www.nrcgroup.com. About NSS Holding AS, NSS and Miljøvakta NSS is one of Norway's largest companies within demolition and environmental remediation and Miljøvakta offers environmental consultancy and remediation services. Both companies are headquartered in Oslo and had a consolidated revenue of approximately 242.6 million NOK in 2017. For more information: www.nss.no. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Audited revenue 2017 for core holdings of Loudspring Plc and update on Nocart

THE COMBINED REVENUE OF LOUDSPRING CORE HOLDING COMPANIES GREW BY 72% DURING 2017 (AUDITED). Loudspring Plc has received the audited annual accounts of its core holdings. The combined revenue of core holdings (Swap.com Services, Nuuka Solutions, Enersize, Eagle filters, Sofi filtration, ResQ Club and Nocart) for 2017 was 45 609 618€ (audited). The combined revenue for core holdings has continued its growth during 2017. Revenue is highly dependent on Nocart and for the most part, 2017 its revenue is in receivables. The core portfolio revenue growth for 2013 – 2017 is presented in the graph below.  The audited revenue and net profit/loss for Loudspring core holdings in 2017 was as follows: Company Revenue 2017 (EUR) Net profit 2017 Net profit 2016 (EUR) (EUR)Swap.com 14 210 729 -18 985 956 -17 337 501ServicesOyNuuka 433 298 -455 191 -387 133SolutionsOyEnersize 223 989 -1 820 407 -335 010OyNocart Oy 28 199 548(previous 595 306 (previous 3 122 374 estimate:30 505 521 estimate: 2 426 ) 384)Sofi 388 416 -226 819 -16 531FiltrationOyEagle 1 854 113 -151 522 293 397Filters OyResq Club 299 525 -1 315 103 -475 621OyTotal 45 609 618 -22 359 691 -15 136 026 Comments regarding Nocart’s situation Nocart has experienced delays in its African projects, and the slow realization of receivables has had a direct impact on the company’s cash flow. During the last months Nocart has secured additional funding but it still requires, and is negotiating, further funding with investors to bridge payments from pending projects. Nocart states in its annual report the following: Currently the majority of the company’s business is coming from big projects in Africa and Asia. Nocart is also working on smaller deliveries and projects where contracts are being finalized. With these smaller projects Nocart is striving to move away from relying solely on big, single projects. Nocart’s revenue was 28 million euros in 2017, 134% growth from 2016. The revenue continued its strong growth, although the growth was somewhat smaller than previous years. Nocart’s net result continued to be positive despite the strong growth. The result improved from 2016 when the credit loss correction made to the shareholder’s equity 2017 is taken into account. The revenue recognition for 2017 has been done with prudence due to the receivables in Africa. Nocart published the following press release today: Nocart’s 35 MW waste-to-energy plant deal in Kenya confirmed Nocart’s 35 MW waste-to-energy plant deal in Kenya has been confirmed. Nocart has previously signed a sales contract for the delivery of a waste-to-energy plant but the advancement of the project has been awaiting completion of the buyer’s permitting processes and PPA-contract process. The purchase price of the plant is 62 MEUR. In addition, Nocart is involved in the project as a co-owner (35%) of the founded IPP (Independent Power Producer) power plant company. The IPP company has a 20-year contract for selling electricity to Kenya’s national grid. The permitting processes and PPA (Power Purchase Agreement) -process for the plant have now been completed and the plant’s financing arrangements are currently being finalized. The plant will be constructed in multiple stages with the first 10MW of the project being completed by the end of 2020 and the remaining 25MW being completed in the beginning of 2023. The project marks a significant starting point for the use of Nocart’s gasification technology and this particular waste-to-energy project is the first of its kind in Africa in terms of its type and size. Land for the plant has been acquired and construction work on the land area has begun. Other preliminary construction work for the project has also been conducted, with the actual preparation of the power plant technology estimated to start later in the fall of 2018. The CEO of Nocart, Vesa Korhonen comments: “This is a significant opening in many respects. We have, together with our local partner, been able to complete the challenging PPA-process successfully. This also constitutes an important starting point for our waste-to-energy technology. We are now able to make energy from waste in a commercially viable, profitable way. This is also a big step forward for our PPA-business model.“

Ripasso Energy AB (publ): Interim report

Swedish clean tech company Ripasso Energy AB is publishing its interim report for the period 01-01-2018 – 30-06-2018 today. The report is available for download in its entirety on the company’s website. Significant events during the period include the following:  · Ripasso Energy has been asked to submit a detailed proposal regarding installations at two ferrochrome production facilities in South Africa. In total this would involve 72 PWR BLOK units worth EUR 36 million. · The company has been strengthened across the organisation by recruiting qualified candidates to the management team, the development and production teams, as well as the dedicated sales organisation in South Africa. The company is now well-equipped to deliver on both ordered and anticipated future projects.  · The PWR BLOK 400-F has been successfully evaluated for power generation using syngas and low-quality LPG. During the period, Ripasso has therefore commenced marketing the PWR BLOK for these gases in South Africa – efforts which have met with a good response. The goal is to provide technology for local projects in South Africa where distributed electricity supply can be accomplished at a lower cost than can purchasing from the national electric utility. “Ripasso Energy is well-equipped to meet a growing order backlog. We are seeing major interest and strong demand for the PWR BLOK without any direct competition, which gives me plenty of confidence for the next half of 2018,” says Gunnar Larsson, CEO of Ripasso Energy AB.

Smart Cards Using NEXT Biometrics Fingerprint Sensors Now Shipping from Tactilis to Key Customers

OSLO, Aug. 14, 2018 -- NEXT Biometrics (Oslo Bors: NEXT), a global leader in fingerprint sensor technology and Tactilis Pte. Limited, a Singapore-based trusted partner in authentication and ID management services, today announced Tactilis has begun first volume shipments of biometric smart card products incorporating NEXT’s unique fingerprint sensor technology.                   An initial run of 25,000 smart cards has been produced at Tactilis’ new dedicated manufacturing facility in Penang, Malaysia. The cards incorporate both advanced large-area fingerprint sensors and integrated circuit (ASIC) technology from NEXT Biometrics.                   “NEXT has worked closely with Tactilis to deliver its fingerprint sensors and ASICs for Tactilis to build into their high-performance biometric smart card products,” said Ritu Favre, CEO, NEXT Biometrics. “We look forward to continuing our work with Tactilis to deliver these essential smart card components in the form of finished solutions, to customers worldwide. Biometric smart cards represent the future for secure ID and payment-related transactions and these first volume shipments to end-users are an important first step in making that future a reality.”                   NEXT is now gearing up to provide additional fingerprint sensors and components to Tactilis as the company ramps production and shipments from their manufacturing facility that opened in April. NEXT has provided Tactilis with more than 30,000 sets of fingerprint sensors and ASICs for product development and initial production.                   “We’re extremely pleased to be able to verify quality manufacturing, high yields and delivery to our customers within a few months of opening our new factory,” said Tactilis founder and CEO, Michael Gardiner. “Working with NEXT Biometrics has placed Tactilis in a strong position to take the lead in promoting the use of biometric system-on-cards in a wide and fast-growing range of government, corporate and payment applications around the world. NEXT’s large-area sensor provides our smart card users with one-touch convenience and government grade performance at the highest level of security in demanding real-life conditions.” About NEXT Biometrics NEXT provides advanced fingerprint sensor technology that delivers uncompromised security and accuracy for the best possible user experience in the smart card, government ID, access control and notebook markets. The company’s patented NEXT Active Thermal™ principle allows the development of large, high quality fingerprint sensors in both rigid and flexible formats. NEXT Biometrics Group ASA (www.nextbiometrics.com) is headquartered in Oslo, with sales, support and development operations in Seattle, Silicon Valley, Taipei, Prague, Bengaluru and Shanghai. About Tactilis Tactilis believes that living in a connected world is a good thing and offers simple, quick and easy-to-scale solutions that make it easier than ever to authenticate and manage identities, protect precious data and create trustworthy environments for citizens, businesses and government organizations. With extensive technological know-how and cutting-edge manufacturing processes, Tactilis helps you get the most out of the open world while securing your interests with just one fingerprint. # # # # #

Altia partners with Hernö Gin, the most awarded gin in Europe

Hernö Gin was founded in Dala, Sweden, in 2011. Today, Hernö Gin is the most awarded gin in Europe. The brand has won over 70 awards, including the World’s Best Gin award in 2017 and 2018, and the Gin Producer of the Year award in 2016 and 2017. “We are very excited to start cooperating with Hernö Gin, whose premium organic gins are an excellent addition to our portfolio of partner brands. Hernö Gin is a prominent brand in Sweden, which is the largest gin market in the Nordics. The gin category has also been growing in Finland and Norway, in addition to Sweden. Authenticity, craft and premiumisation are in the centre of the current consumer trends and Hernö Gin responds perfectly to these trends”, says Janne Halttunen, senior vice president for Scandinavia at Altia. “As a leading company in the industry, Altia can help us to further grow Hernö Gin in Sweden and build the brand, as well as to expand distribution in other Nordic countries as well as in the Baltics and travel retail. I am looking forward to starting to work with Altia, especially with communication, brand strategies, trend analyses and consumer insights”, says Jon Hillgren, founder and CEO of Hernö Gin. More about Hernö Gin: hernogin.com Further information: Janne Halttunen, Senior Vice President, Scandinavia, Altia Contacts: Niina Ala-Luopa, Communications Manager, Altia, tel. +358 400 728 957, niina.ala-luopa(a)altiagroup.com

Minesto completes initial commissioning trials of its DG500 marine energy kite

The results of the initial commissioning tests have been analysed and the main conclusion is that Minesto’s DG500 marine energy kite, which produces renewable energy from tidal streams and ocean currents, is ready to commence “flying” full subsea trajectories. Commenting on the progress, Minesto’s Chief Operating Officer David Collier said: “This is a very significant step towards our ultimate goal of proving the complete DG500 system. I am very proud of the team as this accomplishment has been made possible only by the hard work and endeavour of everyone that has been involved in the design and development of the Deep Green technology over a number of years. The commissioning efforts have been performed in a safe and robust manner, which is especially important considering the many innovations involved in this first-of-its-kind project”. Minesto will next continue the commissioning program of the DG500 device to achieve the milestones of flying full subsea trajectories and verifying the power take-off system and electricity generation. For additional information please contact: Magnus MatssonCommunications Manager, Minesto AB+46 31 774 14 88press@minesto.com About Minesto Minesto is a marine energy technology company with the mission to minimise the global carbon footprint of the energy industry by enabling commercial power production from the ocean. Minesto’s award winning and patented product, Deep Green, is the only verified marine power plant that operates cost efficiently in areas with low-flow tidal streams and ocean currents. In May 2015, Minesto secured a €13m investment from the European Regional Development Fund through the Welsh European Funding Office, for the commercial rollout of Deep Green. Minesto was founded in 2007 and has operations in Sweden, Wales, Northern Ireland and Taiwan. The major shareholders in Minesto are BGA Invest and Midroc New Technology. The Minesto share (MINEST) is traded on the Nasdaq First North Stockholm stock exchange, with G&W Fondkommission as Certified Adviser. Read more about Minesto at www.minesto.com Press images and other media material is available for download via bit.ly/minestomedia.

Interim report January – June 2018

Strong organic growth and improved marginsApril-June 2018  · Revenue increased to MEUR 75.3 (71.4) · Organic growth was 7.3% · The gross margin was 43.2% (43.2) · Adjusted EBITA amounted to MEUR 7.6 (6.9), corresponding to a margin of 10.1% (9.7) · EBIT amounted to MEUR 4.3 (4.6), corresponding to a margin of 5.7% (6.5) · Adjusted operating cash flow amounted to MEUR 7.9 (4.5) · Vehicle Accessibility recovered revenue of approximately MEUR 0.5 on the deliveries postponed in the first quarter · Expenses relating to the announced (in the interim report for the first quarter) reorganisation amounted to MEUR 2.0 during the quarter · In August, President and CEO Asbjørn Eskild announced his decision to leave Handicare Group. Staffan Ternström has been appointed President and CEO effective 14 August January-June 2018  · Revenue increased to MEUR 146.9 (144.7) · Organic growth was 5.0% · The gross margin was 42.3% (42.9) · Adjusted EBITA amounted to MEUR 12.8 (13.7), corresponding to a margin of 8.7% (9.5) · EBIT amounted to MEUR 8.2 (9.3), corresponding to a margin of 5.6% (6.4) · Adjusted operating cash flow amounted to MEUR 8.2 (4.8) · The net effect of postponed deliveries in Vehicle Accessibility is estimated at approximately MEUR -1.5 in terms of revenue and about MEUR -0.8 in terms of EBITA · Expenses relating to the reorganisation amounted to MEUR 2.0                                                                   Summary of the quarterOrganic growth amounted to 7.3% for the second quarter and 5.0% for the six-month period. The adjusted EBITA margin was 10.1% for the second quarter and 8.7% for the six-month period. The deliveries in Vehicle Accessibility that were postponed during the first quarter have started to be resumed, with corresponding revenue estimated at MEUR 0.5 for the second quarter. As previously announced, initiatives began during the quarter aimed at intensifying the sales focus and reducing administrative expenses. This generated costs of MEUR 2.0, which were charged to the quarter in their entirety.We continued to strengthen our market position in stairlifts. Organic growth totalled 13% for stairlifts and the increase in North America alone was 47%. Volkswagen’s deliveries of minibuses in Norway resumed in the second quarter. Our estimate is that we have recovered approximately MEUR 0.5 of the MEUR 2.0 in revenue lost in the first quarter. Our assessment is that most of the remaining revenue loss will be recovered during the coming three quarters. The revenue development in Patient Handling remains challenging. We have identified and implemented a number of initiatives to increase revenues. Patient Handling Europe displayed organic growth. Continued strong project sales in Puls resulted in organic revenue growth of 9.4%.A distributor was acquired in Patient Handling, North America at the start of the year. The ambition is to transition fully to our product portfolio. The adjustment to our product portfolio continued during the quarter and revenue in the second quarter grew compared with the first quarter.Lars Marcher - Chairman of the Board of DirectorsOur medium-term aim is to grow by 10% per year, of which 4–6% organic, and with an adjusted EBITA margin exceeding 12%. During the first six months, we launched initiatives to further strengthen our sales focus and to reduce the resources within administration. Costs of approximately MEUR 2.0 were incurred in the second quarter and these primarily pertain to redundancies. In the long term, this will benefit sales and result in cost-savings of at least MEUR 3.0 annually as of 2019. We continue to identify and evaluate new acquisition targets as M&A is an important part of our growth strategy.We would like to thank Asbjørn Eskild for his contribution to Handicare and welcome Staffan Ternström as the new President and CEO. Staffan has extensive experience from the medical device industry and I am convinced that he is well suited to lead Handicare in the next phase. Staffan’s first day is 14 August 2018. With sales growth that is well in line with our financial targets and an improved margin as well as favourable macro trends I am highly confident that we will achieve our financial targets in the medium term.Asbjørn Eskild (outgoing President and CEO): ”As this is my last quarterly report as President and CEO of Handicare, I would like to thank our owners, Board of Directors, and employees for all their support during my period as CEO. I am proud of what we have accomplished and the second quarter implies that Handicare is on track. It has been a great privilege to work with all motivated and committed leaders and employees at Handicare. I wish Staffan all the best in his new role as CEO.”Audit reviewThis interim report has not been reviewed by the company’s auditors.Telephone conferenceA telephone conference, hosted by Lars Marcher, Chairman of the Board of Directors, and Stephan Révay, CFO, will be held at 10:00 a.m. CET on 14 August 2018.To participate, please register in advance using the following linkhttp://emea.directeventreg.com/registration/ 9295958 A presentation will be available at www.handicaregroup.com/investors. Dates for financial reportsInterim report January – September 2018   24 October 2018Year-end report 2018                                19 February 2019For more information, contact:Stephan Révay, CFO, Tel: +46 729 666 532Boel Sundvall, IR, Tel: +46 723 747 487This information is information that Handicare Group AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CET on 14 August 2018. About HandicareHandicare offers solutions to increase the independence of disabled or elderly people, and to facilitate for their care providers and family. The offering encompasses a comprehensive range of curved and straight stairlifts, transfer, lifting and repositioning aids, vehicle adaptations and medical equipment. Handicare is a global company with sales in more than 20 countries and is a market leader in this field. The head office is in Stockholm, Sweden and manufacturing is located at six sites distributed across North America, Asia and Europe. In the 12-month period to June 2018, revenue amounted to MEUR 287 and the adjusted EBITA margin was 8.8%. Employees numbered around 1,200 and the share is listed on Nasdaq Stockholm. For more information, www.handicaregroup.com.

Interim report January - June 2018

Second quarter 2018 ·Revenues amounted to SEK 298.8 (289.4) million, an increase by 3 % compared to the same period last year. ·Operating profit amounted to SEK 99.4 (162.3) million, a decrease by 39 %. ·Profit before tax amounted to SEK 99.5 (162.3) million, and profit after tax amounted to SEK 77.9 (126.3) million. ·Cash flow from operating activities amounted to SEK 182.3 (139.7) million, and cash flow from investing activities amounted to SEK -121.2 (-68.9) million. ·By the end of the period cash and short-term placements amounted to SEK 329.3 (253.2) million. ·Earnings per share amounted to SEK 0.74 (1.20) per share. ·Revenue from the second quarter of 2018 are mainly attributable to Cities: Skylines, BATTLETECH, Stellaris, Hearts of Iron IV and Europa Universalis IV. Important events in the second quarter ·June 7, 100 % of the shares in Seattle-based development studio Harebrained Schemes were acquired. Purchase price was set to USD 7.5 million and a contingent consideration. ·One new game was released during the period, BATTLETECH, developed by Harebrained Schemes. ·Several expansions were released during the period; Parklife for Cities: Skylines, Distant Stars Story Pack for Stellaris and Natural Disasters for Cities: Skylines on console. ·Paradox own game convention took place in Stockholm in May. ·The new game Imperator: Rome, developed by Paradox Development Studio was announced with a planned release in 2019. ·The new game Age of Wonders: Planetfall, developed by Triumph Studios was announced with a planned release in 2019. ·Steam Summer Sale started June 21 and continued until July 5. Words from CEO Investing in our future The second quarter of the year saw us release one new game and several expansions. BATTLETECH released to strong reviews and strong concurrent player numbers. Stellaris continued its run of successful releases with its latest story pack Distant Stars. Parklife for Cities: Skylines became the fastest-selling Cities: Skylines expansion ever during its first 24 hours after release, and Cities: Skylines players on console received a new expansion in Natural Disasters. During the quarter we also released a version of Cities: Skylines aimed for the educational market, in partnership with Teachergaming LLC. Thanks to these releases, we are posting our highest-ever revenue numbers this quarter. At the same time, margins are lower than at the same time last year. There are a number of primary reasons for this: Increased royalty payments (as third-party titles accounted for a comparatively large percentage of total sales in the quarter), and one-time write-offs of two unannounced projects that have now been cancelled. This is nothing out of the ordinary. We always have many concurrent projects in early development, with regular evaluation points, and we prefer early cancellations for those projects that we do not feel are likely to meet our high-quality standards. Cash flow from operating activities during the quarter was our strongest so far. We also saw increased investments in development, publishing and marketing during the quarter. As we mentioned in our Q4 2017 report, this means lower margins in the short term but builds the company for healthy, long-term growth through larger and more frequent releases of both first- and third-party games. One of the things we’re most proud of at Paradox is the passionate and growing community around us and our games. For us, constant interaction with and feedback from our community is a key part of who we are. It helps us understand what our audience wants from us, which in turn ensures relevancy in our expansions and content updates, keeping players active in our games for months and years post-launch. This philosophy is a key reason for why we invest in PDXCon, the annual gathering of Paradox fans, partners, media and influencers. This year, PDXCon took place in May and attracted over 1100 attendees from 46 countries, with record ticket sales, record media coverage and record live viewership figures throughout the event. But beyond the numbers, the real value of PDXCon lies in the unique opportunity for us to meet and discuss face-to-face with Paradox fans from all over the world. For this year’s event, we invited a small group of Emperor-class ticket holders (PDXCon Emperor tickets, priced at 499 euros each, sold out within 45 minutes of being released) to a full extra day at the Paradox offices, where they took part in workshops on sound design, character creation and game design with the Paradox Development Studio teams. At PDXCon, we announced two new games developed by our internal studios – Age of Wonders:  Planetfall from Triumph Studios and Imperator: Rome, the hotly-anticipated new IP from Paradox Development Studio – both slated for a 2019 release. We also announced a new move into board games, whereby Paradox Interactive is partnering with tabletop publishers to develop board games based on our IP catalogue. The first project to come out of this is an official Crusader Kings board game developed by Free League Publishing, set for release later this year. The game attracted nearly 10 times its funding goal on Kickstarter in the weeks following the announcement. Board games based on the Cities: Skylines, Hearts of Iron and Europa Universalis IPs are next in development. Our community-centric approach also plays an important part in our M&A strategy. When looking at potential acquisition targets we are particularly interested in game developers that, much like Paradox, have spent time cultivating an active fanbase around themselves and their games. This was true for Triumph Studios, creators of the Age of Wonders-series, that Paradox Interactive acquired last year. This is also true for Harebrained Schemes, creators of the recently-released BATTLETECH, that Paradox acquired in June of this year. The studio gives us additional production capacity, adds new IP to our catalogue and new fans to the wider Paradox ecosystem. Harebrained Schemes will continue to support BATTLETECH with updates and additional content. The studio has also started concept development for a new title, to be revealed at a later date. In april, we ran a free-to-play promotion on Steam with Crusader Kings 2, one of our longest-running live games, where the base game was made free to download and keep for 48 hours. The promotion drove a significant influx of new players and a healthy increase in revenue from expansion sales. At one point during the promotion, Crusader Kings 2 became one of the top 5 most played titles on Steam worldwide. Going forward we will see more experiments of a similar nature, as we continue to tweak revenue models and price points for the best possible results. Starting this August, Ebba Ljungerud will take over as CEO of Paradox Interactive, while Fredrik Wester will move into a new role as executive chairman of the board. In the short-term, this is unlikely to bring significant change. Our focus will be on stability, delivering on our existing product pipeline and building an organisation that can scale quickly to manage continued growth. Long-term, we look forward to working closely together on finding new business opportunities and ways of accelerating our growth even further.  For us, this is a very natural move and a logical next step in the story of the company. The only constant during the history of Paradox so far has been change. We are confident that will continue to be true in the future as well. Fredrik Wester, Executive Chairman of the Board Ebba Ljungerud, Chief Executive Officer Presentation of interim report Ebba Ljungerud, Fredrik Wester and Alexander Bricca will host a live stream to answer report and financial related questions on our Twitch channel on August 14 at 12:00 PM CET https://www.twitch.tv/paradoxinteractive. Submit your questions before via our forum https://forum.paradoxplaza.com/forum/index.php?threads/paradox-q2-2018-quarterly-report-and-livestream.1113401/, by e-mailing them to ir@paradoxplaza.com or directly in the Twitch chat. The Twitch chat is open for anyone to view but to post comments or question you will need to create an account.

WULFF ACQUIRES MAVECOM PALVELUT LTD AND WILL OFFER CANON BUSINESS CENTER SERVICES TO ITS CUSTOMERS

STOCK EXCHANGE RELEASE     August 14, 2018 at 9.00 A.M. Wulff, the expert in products for the workplace, acquires Mavecom Palvelut Ltd. With the transaction, Wulff´s position as the most versatile supplier of products and services in its field will strengthen: Wulff’s range of products and services will grow with the quality services offered by Canon Business Center. Mavecom sells and produces printing services, data management solutions, ICT outsourcing services and large format printing in the Helsinki metropolitan area. Mavecom also offers customers modern maintenance and remote monitoring for its solutions. Wulff Group Plc has signed today, August 14, 2018, an agreement to acquire the entire share capital of Mavecom Palvelut Ltd that specializes in printing solutions. In 2017, Mavecom Palvelut Ltd’s net sales totalled EUR 2.3 million, EBITDA EUR 0.3 million, operating profit EUR 0.2 million, share equity EUR 0.1 million and the balance sheet EUR 0.7 million. Mavecom Palvelut Ltd operates the Canon Business Center services in the Helsinki metropolitan area where it has a notable amount of customers. The acquisition is a significant competitive advantage for Wulff and in line with the company’s growth strategy, enabling the development of the Contract Customer concept for domestic customers. The preliminary purchase price for the share capital of Mavecom is approximately EUR 1.5 million. With the authorization granted by the Annual General Meeting to the Board of Directors, Wulff Group Plc carried out a directed share issue of 300,000 shares to the owners of Mavecom Palvelut Ltd. With the share issue the number of Wulff Group Plc’s shares grew from 6 607 628 to 6 907 628 shares. The shares will be applied to be admitted for trading together with the other shares of the company by August 31, 2018. Approximately EUR 0.5 million of the purchase price was paid with Wulff Group Plc’s shares. The share subscription price corresponds to the volume weighted average price of the company’s shares quoted on NASDAQ OMX Helsinki Ltd (”Helsinki Stock Exchange”) between May 1, 2018 and July 31, 2018. The final additional purchase price of the shares will be paid in cash based on the profitability of Mavecom Palvelut Ltd’s business during 2018-2022. The unpaid portion of the estimated additional purchase price will be presented in non-interest-bearing liabilities.   Mavecom, established in 2012, employs 12 printing service experts in the Helsinki metropolitan area. The company will continue its business as an independent unit within Wulff Group Plc. Business synergies will be sought with common development projects, for example IT-systems and logistics among other things. “It is great to expand Wulff’s range with new services and get more salespeople to the company. Our customers have expressed requests for printing services and Canon’s quality and products are an excellent way of meeting these wishes”, summarises CEO Heikki Vienola the reasons for the acquisition. Wulff serves over 100 000 customers in Scandinavia yearly. The acquisition will improve Wulff’s capability to serve especially its customers in the Helsinki metropolitan area more diversely. The outlook for the comparable operating profit (EBIT) will remain unchanged; Wulff estimates the comparable operating profit (EBIT) to grow in 2018. The strategy of the group was renewed in 2018 and the group will invest heavily in development and growth. The net sales target for 2020 is EUR 80 million. In addition to organic growth, net sales growth is sought with strategic acquisitions. Further information:CEO Heikki Vienolatel. 0300 870 414 or +358 50 65 110e-mail: heikki.vienola@wulff.fi DISTRIBUTIONNASDAQ OMX Helsinki OyKey mediawww.wulff-group.com     A better world – one workplace at a time. Wulff’s goal is a perfect workday! We enable better working environments and create workplaces, wherever you are. More comfortable, healthier, safer, more enjoyable, more active and more diverse? How do you want to better you workday and working environment? Wulff has the solution. We offer our customers office supplies, facility management products, catering solutions, IT supplies, ergonomics, first aid, air purifiers, and innovative products for worksites. Customers can also acquire international exhibition services from Wulff. New: Canon Business Center printing solutions, large format printing, data management services and ICT outsourcing services for corporate customers in the Helsinki metropolitan area. In addition to Finland, Wulff Group operates in Sweden, Norway, and Denmark. Check out our products and services at wulff.fi . 

Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018

Stockholm, Sweden, August 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company’s Interim Report for the period January – June 2018 on Thursday,August 23, 2018 at 08:00 a.m. CET. BioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media on August 23, at 09:30 – 10:30 a.m. CET. Gunilla Osswald, CEO, and Jan Mattsson, CFO, to present BioArctic and comment on the Interim Report for the period January – June 2018 followed by a Q&A-session. To attend, please dial-in at one of the numbers below from:Sweden: + 46 8 566 426 63Denmark: + 45 354 455 75Germany: + 49 692 222 290 46The Netherlands: + 31 207 168 416Switzerland: + 41 225 675 548UK: + 44 203 008 9814US: + 1 855 831 5946 Webcast: https://tv.streamfabriken.com/bioarctic-q2-2018 The webcast will afterwards also be available on demand at BioArctic’s corporate website www.bioarctic.com, Investors, Financial presentations. For more information, please contact:Christina Astrén, IR & Communications DirectorTelephone: + 46 70 835 43 36E-mail: christina.astren@bioarctic.se About BioArcticBioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap(STO: BIOA B). www.bioarctic.com This information was submitted for publication at 08:00 a.m. CET on August 14, 2018.

Gaming Innovation Group reports Q2 2018

Gaming Innovation Group Inc. (GiG) reports EUR 36.9 million in revenues in Q2 2018, a 39% increase over Q2 2017. EBITDA for Q2 2018 was EUR 1.7 million, compared to EUR 1.9 million in Q2 2017. In Q2, GiG entered the largest category in iGaming, sports betting, with a portfolio of products and the launch of the new sportsbook on Rizk.com. The Company’s platform service, GiG Core, was licensed in the regulated US market of New Jersey and operations started through our partnership with Hard Rock International. “GiG has invested significantly to expand across all verticals of iGaming. We are building to become the one stop shop for every company serious about its iGaming business. With the majority of the heavy-lifting behind us and the strongest season ahead of us, we should see growth in both revenues and profits in the coming quarters, while working towards our goal of becoming the largest full service company to the iGaming industry”, says Robin Reed, CEO of GiG. Financial highlights Q2 2018 · Operating revenues of EUR 36.9 million, up by 39% from Q2 2017 · Organic revenue growth of 30% compared to Q2 2017 · EBITDA of EUR 1.7 million, compared to EUR 1.9 million in Q2 2017 · B2B revenues of EUR 15.6 million, up by 84% from Q2 2017 · B2C revenues of EUR 24.2 million, up by 20% from Q2 2017 · Marketing expenses of EUR 13.2 (11.1) million, 36% of total revenues, down from 42% in Q2 2017 Operational highlights · Media Services reached quarterly all-time-high revenues of EUR 8.7 million, 99% growth from Q2 2017 · New Sport Betting Services launched, live on in-house operator Rizk.com, offered to clients from July · GiG Core, part of Platform Services, licensed in New Jersey (US), live with HardRockCasino.com · GiG Comply: new website monitoring compliance tool developed and ready for launch in September, two external customers expected to sign soon · Process for listing at NASDAQ Stockholm proceeding according to plan Outlook · Strategic initiatives expected to improve profitability for Gaming Operators · Expecting to sign new clients with Sport Betting Services and GiG Comply in Q3 · Launching first proprietary game in H2 2018 · Full year 2018 guidance, revenues EUR 155 - 162 million, EBITDA EUR 16 - 20 million Investor presentation and webcast: The Company will present the Q2 2018 financial results on Tuesday 14 August 2018 at 10:00 CEST at Høyres Hus Konferanse & Selskapslokaler, Stortingsgaten 20, 0161 Oslo. The presentation will be given by CEO Robin Reed and it will be transferred via webcast: http://webtv.hegnar.no/presentation.php?webcastId=92025557 For further information, contact: Robin Reed, CEO, +356 9999 0382 (Robin@gig.com) About GIG: Gaming Innovation Group Inc. is a technology company providing products and services throughout the entire value chain in the iGaming industry. Founded in 2012, Gaming Innovation Group's vision is "To open up iGaming and make it fair and fun for all". Through our eco-system of products and services, we are connecting operators, suppliers and users, to create the best iGaming experiences in the world. Gaming Innovation Group operates out of Malta and is listed at the Oslo Stock Exchange under the ticker symbol GIG. For more information about the Company and our services: https://www.gig.com/ https://www.guts.comhttps://www.betspin.comhttps://www.rizk.comhttps://www.thrills.comhttps://www.kaboo.comhttps://www.superlenny.comhttps://www.highroller.com  

ASPIRE GLOBAL’S INTERIM REPORT FOR THE SECOND QUARTER 2018 – CONTINUING TO HIT RECORD LEVELS

SECOND QUARTER (APR-JUNE 2018)• Revenues increased by 43% to €24.7 million (17.3)• B2B Revenues increased by 39% to €12.4 million (8.9)• EBITDA increased by 58% to €5.7 million (3.6)• EBITDA margin amounted to 22.9% (20.8%)• EBIT amounted to €5.2 million (3.3)• Earnings after tax from continued operations amounted to €5.3 million (2.9)• Earnings per share after tax from continued operations amounted to €0.11 (0.06)• First time depositors (FTDs) increased by 34% to 80.8 thousand (60.3) INTERIM PERIOD (JAN-JUNE 2018)• Revenues increased by 29% to €43.1 million (33.4)• B2B Revenues increased by 32% to €22.1 million (16.7)• EBITDA increased by 35% to €8.5 million (6.3)• EBITDA margin amounted to 19.6% (18.9%)• EBIT amounted to €7.6 million (5.7)• Earnings after tax from continued operations amounted to €7.5 million (5.4)• Earnings per share after tax from continued operations amounted to €0.15 (0.12)• First time depositors (FTDs) increased by 32% to 150.0 thousand (114.0) SIGNIFICANT EVENTS DURING AND AFTER THE SECOND QUARTER• April 3rd Aspire Global finalized the issue of a €27.5 million senior secured bond loan under a €80 million framework for M&A purposes. The company applied for a listing of the bond onNasdaq Stockholm and the first trading date was May 15th.• The AGM took place on May 8th electing Aharon Aran as new Board member along with present Board members Carl Klingberg, Fredrik Burvall, Tsachi Maimon and Barak Matalon who were re-elected. The meeting also resolved on a transfer of €3.8 million, or approximately SEK 0.85 per share, to be paid as dividend for the financial year ending December 31st 2017 with therecord date May 11th 2018.• April 17th 2018, Aspire Global signed an agreement on platform services with Aller Media Denmark, a company within Aller Group, a leading publisher of magazines and newspapers in theNordic region. The new iGaming brand Hyggespil.dk was launched on June 19th.• May 1st 2018, Aspire Global’s Danish gaming license was extended until 2023.• August 7th 2018, Aspire Global submitted the application for a Swedish gaming license. KEY FIGURES€ million    SECOND QUARTER        INTERIM PERIOD FULL YEAR 2018 2017 2018 2017 2017Revenues 24.7  17.3  43.1  33.4  71.9 EBITDA 5.7  3.6  8.5  6.3  14.3 EBITDA, % 22.9  20.8  19.6  18.9  19.9 EBIT 5.2  3.3  7.6  5.7  13.0 EBIT, % 21.1  19.1  17.6  17.1  18.1 Earnings per share*, € 0.11  0.06  0.15  0.12  0.23 Company hold, % 55.0  51.2  53.7  51.7  52.7 FTDs (K) 80.8  60.3  150.0  114.0  246.1 * From continued operations A WORD FROM THE CEO I am pleased to present the second quarter. Both revenues and EBITDA hit record levels, reflecting the strong performance of several partner brands including Karamba, combined with a great interest in our sports solution that was launched in the first quarter. The second quarter delivered excellent results with strong contribution from several key partners. Revenues increased by 43% (55% excluding closed markets) while EBITDA improved by 58% compared to the corresponding quarter last year, which also included substantial revenues from the Australian market that was discontinued on September 12th, 2017. The strong performance is mainly driven by two factors; successful partnerships and a stronger offering. Firstly, we have improved our ability to focus our resources on the partners and brands with the highest potential and strongest performance. As for the offering, we continuously improve our solution, both in terms of quality and width of the solution, most recently through the upgrade to a more advanced platform system and the very promising launch of Sportsbook as well as higher efficiency in our data-driven tools. As a result, several B2B-brands are outperforming, along with higher activity for B2C. MAINTAINING STRONG MOMENTUM FOR SPORTSBOOKThe second quarter was the first full quarter to include revenues from the sports vertical which immediately grew to nearly a tenth of the B2C-revenues and boosted the performance for the two partners who were live with Sportsbook, Goliath and Nossa Aposta. The World Cup contributed to the interest in our product and we hope to maintain momentum as the Champions league starts off in the coming month along with European Club football. We look forward to launching Sportsbook with additional partners going forward. We recently signed an agreement with BetRegal, a sports operator that will be migrating to Aspire Global from a competing platform during the fourth quarter of 2018. The migration is strategically important as it confirms the competitive advantage of our sports solution; something that makes me proud. As for Karamba, Sportsbook is attracting a whole new audience to the proprietary brand. In the first six months, we invested in a unique front-end for Sportsbook (including the tool for bet recommendation) as well as marketing around the launch. We also re-organized the team to realize the full potential of the brand, and the effect so far has exceeded our expectations. CONTINUING THE SEARCH FOR INNOVATIVE PARTNERSHIPSAller Media Denmark recently became one of the first Nordic media house to add an iGaming offering to their business through a partnership with Aspire Global. The deal was signed in April, and already in June the new brand Hyggespil.dk went live, offering a wide range of casino games. We look forward to following their progress and we believe that the partnership with Aller Media will be an eye-opener to other companies outside the traditional gaming industry as it demonstrates the potential for companies with significant online traffic to capitalize further on their assets. LOOKING FORWARD TO MEETING WITH YOU“Everything we do, we do to enable our partners achieve their full potential”. In line with our vision, we continue to improve our offering by developing our turnkey platform, exploring additional verticals and expanding our game portfolio including proprietary game development. Furthermore, we continuously evaluate new partnerships as well as potential transactions, focusing on innovative partnerships in regulated markets. We recently submitted the application for a Swedish gaming license in line with this strategy. Being a company with stable growth and high ambitions, we also increase our efforts to communicate with the capital market. On September 13th 2018, we will be hosting our first Capital Markets Day in Stockholm where we are looking forward to meeting with many of our shareholders, analysts and media to present the company and the investment case more closely.Tsachi Maimon, CEO Aspire Global FOR MORE INFORMATION, PLEASE CONTACT:Tsachi Maimon, CEO, Tel: +356-79777898 or email: tsachi@aspireglobal.comMotti Gil, CFO, Tel: +972-73 372 3154 or email: mottigi@aspireglobal.com ABOUT THIS INFORMATIONAspire global discloses the information provided herein pursuant to the EU Market Abuse Regulation(MAR) and the Securities markets Act. The information was submitted for publication by the contact person above at 08:15 am (CET) on August 14th 2018. TELECONFERENCEToday, on August 14th 2018, at 10:00 (CET), the company CEO, Tsachi Maimon, and CFO, Motti Gil, will be presenting the report and answering questions at a teleconference (in English), which will be webcasted live through the following link: https://financialhearings.com/event/10983. The meeting, including the Q&A-session, is also available by calling one of the telephone numbers below.The complete interim report is available at http://www.aspireglobal.com/wp-content/uploads/2018/08/AGQ218-final-report.pdf and the presentation material can be found on the company website.Sweden: +46 8 5664 26 62UK: +44 20 3008 98 08US: +1 855 753 22 35 ABOUT ASPIRE GLOBALFounded in 2005, Aspire Global offers a comprehensive iGaming solution for operators and white labels, including a complete suite of services for casino and sportsbook, multilingual CRM, payments and risk control, support call center, VIP management, acquisition optimization and a robust, market-leading platform. Aspire Global also holds licenses in regulated markets including the UK, Denmark, Belgium, Italy and Malta. Aspire Global is listed on NASDAQ First North Premier under ASPIRE. Certified Advisor: FNCA Sweden AB

Nexam Chemical presents the second quarter 2018 on August 16 at 11:00 CET

In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Anders Spetz, CEO will present and comment the report. The presentation will be held in Swedish via a conference call or audio webcast at https://financialhearings.com/event/10747  If you do not intend to ask questions at the end of the presentation, please both listen and see the presentation via audio webcast for increased quality. Phone number for the conference: Sweden: +46 8 5664 2691 UK: +44 20 3008 9801  No pre-registration is required. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start. In connection with the conference, it will be possible to ask questions directly or via e-mail. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com ___________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com. The company´s Certified Adviser is FNCA Sweden AB.

Veronica Rörsgård new head of AcadeMedia Preschools in Sweden and member of Executive Management

Veronica Rörsgård has recently joined AcadeMedia as head of Preschools in Sweden. Veronica most recently worked at Skanska, where she held the position as HR and IT Director. Before that Veronica Rörsgård was Managing Director of the recruitment company Alumni. Veronica Rörsgård is a part of AcadeMedia’s Executive Management and reports to CEO Marcus Strömberg. - I am very excited to become a part of the largest education company in Sweden. My impression is that AcadeMedia is a company that stands for quality and good education at all levels. It is especially inspiring to work with preschool as this is so important for society. A good preschool is the basis for lifelong learning for all children, says Veronica Rörsgård. Veronica Rörsgård has a solid leadership experience, organisational development and talent management. She was awarded HR Director of the year in Sweden at “Chefsgalan” 2016. - With the experiences and new perspectives that Veronica Rörsgård brings she will become an important part in creating an even better education organisation, says Marcus Strömberg, CEO at AcadeMedia. For more information, please contact:Marcus Strömberg, CEOTelephone: +46 8 794 4200E-mail: marcus.stromberg@academedia.se About AcadeMediaAcadeMedia creates opportunities for people to develop. The 15,800 employees at our 650 preschools, compulsory schools, upper secondary schools and adult education centres share a common focus on quality and development. Our 176,000 children and students are provided with a high quality education, giving them the best conditions to attain both learning objectives and their full potential as individuals. AcadeMedia is Northern Europe ́s largest education company, with locations/facilities/presence in Sweden, Norway and Germany. Our size gives us the capacity to be a robust, long term partner to the communities we serve. More information about AcadeMedia is available on www.academedia.se.

ETTEPLAN Q2 2018: Growth accelerated and profitability close to the target level

Etteplan Oyj Half Year Financial Report August 14, 2018 at 1:00 pm ETTEPLAN Q2 2018: Growth accelerated and profitability close to the target level Review period April-June 2018 · The Group’s revenue grew by 14.2 per cent and was EUR 62.0 million (4-6/2017: EUR 54.3 million). At comparable currencies, growth was 16.2 per cent. · Organic revenue growth was 9.6 per cent. At comparable currencies, organic growth was 11.5 per cent. · EBIT from business operations* improved and amounted to EUR 6.0 (4.7) million or 9.7 (8.6) per cent of revenue. EBIT from business operations included exceptional items with a combined negative effect of EUR 0.3 (0.2) million. · Operating profit (EBIT) was EUR 5.7 (4.2) million or 9.1 (7.8) per cent of revenue. Operating profit included exceptional items with a combined negative effect of EUR 0.1 (0.2) million. · The profit for the review period was EUR 4.4 (3.2) million. · Operating cash flow was EUR 4.5 (5.4) million. · Undiluted earnings per share were EUR 0.18 (0.12). · Etteplan continued to invest in growth by acquiring the software company Eatech Oy. · Etteplan updates its financial guidance: We expect the revenue for the year 2018 to grow clearly and the operating profit for the year 2018 to grow significantly compared to 2017. Review period January-June 2018 · The Group’s revenue grew by 10.9 per cent and was EUR 121.0 million (1-6/2017: EUR 109.1 million). At comparable currencies, growth was 12.5 per cent. · Organic revenue growth was 7.9 per cent. At comparable currencies, organic growth was 9.5 per cent. · EBIT from business operations* improved and amounted to EUR 11.0 (9.0) million or 9.0 (8.2) per cent of revenue. EBIT from business operations included exceptional items with a combined negative effect of EUR 0.5 (0.6) million. · Operating profit (EBIT) was EUR 10.1 (8.0) million or 8.3 (7.4) per cent of revenue. Operating profit included exceptional items with a combined negative effect of EUR 0.3 (0.6) million. · The profit for the review period was EUR 7.6 (6.0) million. · Operating cash flow improved and was EUR 7.7 (7.3) million. · Undiluted earnings per share were EUR 0.31 (0.24). · The number of personnel increased by 11.7 per cent and the Group had 3,051 (2,731) employees at the end of June 2018. * EBIT from business operations is an alternative performance measure that is presented because it reflects the Company’s operational performance better than operating profit (EBIT). EBIT from business operations does not include the amortization of fair value adjustments at acquisitions or premeasurements of contingent considerations. More information on page 17.  Market outlook 2018 The most important factor affecting Etteplan's business is the global development of the machinery and metal industry. Our business environment is currently developing favorably in all market areas. The development of the Central European markets is expected to remain unchanged. The favorable situation in the Swedish market is expected to continue. The market situation in Finland is good. In Asia, the growth of the service market is expected to continue. Financial guidance 2018, updated on August 14, 2018 We expect the revenue for the year 2018 to grow clearly and the operating profit for the year 2018 to grow significantly compared to 2017. Financial guidance 2018, updated on May 3, 2018 We expect the revenue and operating profit for the year 2018 to grow clearly compared to 2017. Key figures (EUR 1,000) 4-6/2018 4-6/2017 1-6/2018 1-6/2017 1-12/2017Revenue 62,031 54,314 120,995 109,116 214,768EBIT from 6,046 4,669 10,917 8,998 17,163businessoperationsEBIT from 9.7 8.6 9.0 8.2 8.0businessoperations, %Operating profit 5,653 4,218 10,068 8,045 15,484(EBIT)EBIT, % 9.1 7.8 8.3 7.4 7.2Basic earnings 0.18 0.12 0.31 0.24 0.47per share, EUREquity ratio, % 38.5 40.1 38.5 40.1 40.7Operating cash 4,469 5,400 7,747 7,305 18,254flowROCE, % 24.4 19.3 22.1 18.6 17.8Personnel at end 3,051 2,731 3,051 2,731 2,802of the period President and CEO Juha Näkki: ‘The market situation remained good in all of our market areas in the second quarter of the year. We accelerated organic growth for example by opening new operations in China and Poland. We also acquired Eatech Oy and significantly strengthened our position in software design and IoT solutions. Our strong operating performance also improved our EBIT from business operations close to our target level of 10 per cent. I am very satisfied with the development of our business and the results we have achieved, and I want to thank our people for a job well done. Development was particularly strong in the Engineering Services service area. Our performance was excellent in all market areas and our operational profitability exceeded our target level of 10 per cent for the first time. The Embedded Systems and IoT service area also developed positively. The Eatech acquisition in May accelerated growth. The measures taken to improve the efficiency of the project business began to show results and the profitability of the business continued to increase. Technical documentation was burdened by further delays in deliveries for a project and challenges in Germany. In general, however, the service area saw positive development and interest in our outsourcing solutions, in particular, remained at a good level. Our revenue has now grown for 16 consecutive quarters and our operating profit has improved for 9 consecutive quarters. While tension related to international trade has increased uncertainty in the markets, we will continue to invest in profitable growth of our business. As our operating profit for the first half of the year exceeded EUR 10 million, we updated our financial guidance regarding operating profit and we now expect that operating profit for the year 2018 will grow significantly compared to 2017.’ Disclosure procedure This stock exchange release is a summary of Etteplan's January-June 2018 Half Year Financial Report. The complete Half Year Financial Report is attached to this stock exchange release in pdf format and is also available on Etteplan's website at www.etteplan.com. Conference call and live webcast today, August 14, 2018 Etteplan’s President and CEO Juha Näkki will present the Company’s results for January-June 2018 in a conference call and a live webcast, held in English language, on August 14, 2018 starting at 2.30 p.m. Finnish time (EEST). To participate in the conference call please dial 5-10 minutes prior to the start of the conference to +358 (0)9 8171 0495 and tell the operator that you wish to join Etteplan conference call. Questions can be asked in Finnish and in English after President and CEO’s presentation only through conference call connection. Juha Näkki’s presentation can be followed as a live webcast on https://www.inderes.fi/videot/etteplan-osavuosikatsaus-h12018-webcast-1482018-1430. The webcast starts at 2.30 p.m. Finnish time (EEST). A recording of the webcast will be available later at www.etteplan.com/Investors. Vantaa, August 14, 2018 Etteplan Oyj Board of Directors

OV predicts drug efficacy in breast cancer patients. New study on cornerstone drug epirubicin published in “Breast Cancer Research and Treatment”

Epirubicin is an anthracycline and like its sister molecule doxorubicin a cornerstone in the treatment of primary and advanced breast cancer. In primary breast cancer epirubicin or doxorubicin are part of the adjuvant therapy given after surgery to prevent later recurrence. In advancer breast cancer usually about 50% will benefit with a reduction in their tumor size. Until now there has been no method to find out who will benefit and who will not. The current study looked at 140 consecutive patients receiving epirubicin to evaluate Oncology Ventures anthracycline Drug Response Predictor (DRP®). The DRP was significantly associated to Time to Progression (TTP). TTP is a measure of the time from start of treatment to progression of the disease. The estimated median time to progression (TTP) for a patient with a DRP value of 25% was 7 months versus 13 months for a patient with a DRP value of 75%. Hazard Ratio was 0.55 for a 50% points difference in DRP score meaning that the patient has a statistically significant and clinically relevant longer benefit (TTP) of the drug at a DRP score of 75 compared to a DRP score of 25. Data from this study substantiates a pool of previous retrospective/prospective DRP data from OV and the presented clinical validation provides a strong tool to be applied in clinical studies of OV’s liposomal doxorubicin – where patients tumor tissue can be measured by the DRP method for likelihood of response ahead of entering a 2X-111 study. Oncology Venture’s 2X-111 is a GSH-liposomal- doxorubicin product for breast and brain cancer. After finalization of manufacturing 2X-111 will be developed in two focused Phase 2 trials in metastatic breast cancer and in Glioblastoma.   “Oncology Ventures proprietary Drug Response Prediction - DRP - technology again provides strong and convincing data on its ability to match patients with effective drugs. I feel confident by these epirubicin results that we will be able to develop 2X-111 as a very effective drug for breast cancer patients. Knowing who will be likely to benefit is of outmost importance and so in knowing who will not – these patients needs a treatment with a different drug”, said Peter Buhl Jensen, M.D., CEO of Oncology Venture. “Epirubicin and doxorubicin are used in many different cancers and the DRP is of value for treatment of several tumor types as lymphoma, multiple myeloma, sarcomas, endometrial cancer and ovarian cancers”, Peter Buhl Jensen further commented.   For further information on Oncology Venture please contact Ulla Hald Buhl, COO and or Peter Buhl Jensen, CEOMobile: +45 21Chief IR & 60 89 22E-mail:CommunicationsMobile: pbj@oncologyventure.com +45 2170 1049E-mail:uhb@oncologyventure.com About 2X-111 – a liposomal doxorubicin 2X-111 is an anthracycline which is able to pass the blood brain barrier and has the potential to treat cancers also in the brain. This is a very unusual opportunity. 2X-111 is enriched by a technology for enhanced delivery of doxorubicin to the brain and to enable better treatment of metastatic cancer types and primary brain tumors. In preclinical studies it has been shown that conjugation of glutathione to liposomes can provide a five-fold increased delivery of doxorubicin to the brain compared to untargeted liposomes. 2X-111 has been studied in a phase 1/2a clinical trial in 10 clinical sites in the United States, the Netherlands, Belgium, and France confirming its tolerable safety profile in 85 patients and showing encouraging signs of anti-tumor activity in metastatic Breast Cancer and Glioblastoma (primary brain tumor). Initial data using the DRP was presented as a poster at the annual ASCO conference 2017. A robust manufacturing procedure is in place, and we look forward to developing this product once contract negotiations on product manufacturing are in place. After finalization of manufacturing 2X-111 will be developed using the DRP technology in two focused Phase 2 trials in metastatic breast cancer and in glioblastoma. About the Drug Response Predictor - DRP® Companion Diagnostic  Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene DRP® to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. The goal is developing the drug for the right patients, and by screening patients before treatment the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. DRP® is based on messenger RNA from the patient’s biopsies.  The DRP® platform, i.e. the DRP® and the PRP™ tools, can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US. The PRP® is used by MPI for Personalized Medicine. The DRP® is used by Oncology Venture for drug development.  DRP® is a registered trademark of Medical Prognosis Institute A/S. About Oncology Venture AB  Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly-owned Danish subsidiary, Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP® –to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.    The current product portfolio includes: LiPlaCis® for breast cancer in collaboration with Cadila Pharmaceuticals; irofulven for prostate cancer; and APO010, an immuno-oncology product for multiple myeloma.  Oncology Venture has spun out two companies as Special Purpose Vehicles: Oncology Venture U.S. Inc. (previously 2X Oncology Inc.), a US-based precision medicine company focusing developing two promising phase 2 product candidates, and OV-SPV 2, a Danish company that will test and potentially develop a Phase 2 oral Tyrosine Kinase inhibitor.  On the May 30, 2018, MPI and Oncology Ventures respective general assemblies decided to merge . Trading in the Oncology Venture share continues the next couple of months and all OV shares will - when the merger is finalized - give 1,8524 MPI shares. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

PowerCell signs MOU with Siemens regarding development of marine systems based on fuel cells

The English version is an in house-translation. In case of any discrepancy, the Swedish text will prevail. Siemens AG is a world leading manufacturer of integrated propulsion and power generating systems for marine applications and has developed a complete system that is being marketed and sold under the name of SISHIP BlueDrive. PowerCell and Siemens will jointly develop a fuel cell-based system that can be integrated into ships such as ferries, yachts and cruise ships. Commercial shipping is affecting the environment through emissions of both carbon dioxide and particle matters. The International Maritime Organization, IMO, has set a target to reduce the emissions from commercial shipping with 50 percent by 2050, which will require a substantial decrease in the use of fossil fuels. In June a power generating system based on PowerCell’s fuel cell stacks and developed by PowerCell’s Norwegian joint venture Hyon, got the first ever approval in principle for a fuel cell-based power generating system for marine vessels. Great potential“In large segments of the marine industry a rapid transition has already started, with increased electrification and decreased use of fossil fuels as strong trends”, Per Wassén, CEO of PowerCell said. “If commercial shipping is to meet the IMO target, and seriously take on the challenge that the climate change poses, large sections of it has to convert to much more sustainable solutions. Fuel cells are a very promising alternative and Siemens and PowerCell see a great potential for the cooperation we are now entering into.” For further information, please contact: Per Wassén CEO, PowerCell Sweden AB (publ) Phone: +46 (0) 31 720 36 20 Email: per.wassen@powercell.se About PowerCell Sweden AB (publ)  PowerCell Sweden AB (publ) develops and produces fuel cell stacks and systems for stationary and mobile applications with a world class energy density. The fuel cells are powered by hydrogen, pure or reformed, and produce electricity and heat with no emissions other than water. As the stacks and systems are compact, modular and scalable, they are easily adjusted to any customer need. PowerCell  was founded in 2008 as an industrial spinout from the Volvo Group. The share (PCELL) is since 2014 subject to trade at Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.

Interim report, 1 January–30 June 2018

· Total incomeQ2: SEK 227.0 (211.1) millionHY1: SEK 426.6 (436.0) million · EBITDAQ2: SEK –9.3 (10.0) millionHY1: SEK –2.3 (39.3) million · Result before taxQ2: SEK –57.0 (–43.9) millionHY1: SEK –95.7 (–85.1) million · Result per share after taxQ2: SEK –1.19 (–0.92) millionHY1: SEK –2.01 (–1.78) million Events in the second quarter ·  Another quarter without any Lost Time Injuries ·  Three suezmax vessels chartered in (50% share) ·  Two MR (ECO) vessels chartered in (50% share)  Events after the end of the quarter ·  Another One suezmax vessel chartered in (50% share) ·  Stena Paris chartered out for 12 months  Key ratios  · Total income, SEK million 426.6 (436.0) · EBITDA, SEK million –2.3 (39.3) · EBITDA, USD million –0.3 (4.4) · Operating result, SEK million –91.9 (–69.9) · Result excluding impairment and tax, SEK million –95.7 (–85.1) · Result before tax, SEK million –95.7 (–85.1) · Result after tax, SEK million –95.7 (–85.1) · Equity ratio, % 41 (49) · Return on equity, % –54 (–3) · Available liquid funds, including unutilised credit facilities, SEK million 185.0 (281.0) · Result per share after tax, SEK –2.01 (–1.78) · Equity per share, SEK 25.94 (38.29) · Lost-time injuries 0 (0) Distribution  For environmental reasons, we are only publishing our interim reports digitally. Concordia Maritime’s interim reports and additional financial information about the Company can be read or downloaded from our website www.concordiamaritime.com/en/investor-relations  The information in this report is information that Concordia Maritime is required to disclose in accordance with the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was made public on 14 August 2018, at 2.00 p.m. 

Australian Cannabis Researcher and Producer Invests in Heliospectra’s Innovative LED Lighting Solutions

Heliospectra’s fully adjustable ELIXIA LED grow light solution will be installed in the company’s new state-of-the-art Conviron cannabis grow rooms, to be used for cannabis-related research at the company’s research and development facility. This allows the researchers to control all aspects of the grow; including light, nutrients, airflow, temperature, humidity, and carbon dioxide. The aim of the research is to obtain greater yield per square meter, resulting in more cost-effective cannabinoid pharmaceuticals. “For cannabis cultivation, production of highest-quality crops and the ability to control compounds is of utmost importance as facilities scale. This includes the ability to influence terpenes and control THC and CBD levels,” said Ali Ahmadian, CEO of Heliospectra. “Utilizing our ELIXIA light with controllability of spectrum helps our research customers and commercial growers to reach their production objectives and I look forward to seeing their future result.” Heliospectra's ELIXIA creates clear business benefits for cultivation teams and researchers around the world. The fully adjustable LED lighting solution is compatible with Heliospectra's HelioCORE™ light control software, enabling growers to improve the quality of plants and accelerate harvest and production cycles while providing consistent and standardized returns. Delivery will take place and be visible in the accounts during the fourth quarter of 2018.

Nomination Committee convened ahead of 2019 Annual General Meeting

In accordance with the resolution of the 2018 Annual General Meeting  of MTG shareholders, a Nomination Committee has been convened to prepare proposals for the 2019 Annual General Meeting. The Nomination Committee comprises John Hernander, appointed by Nordea Funds; Jimmy Bengtsson, appointed by Skandia Liv; and Joachim Spetz, appointed by Swedbank Robur. The members of the Nomination Committee will appoint a Committee Chairman at their first meeting. Please see this page  for information about the work of the Nomination Committee. Shareholders wishing to propose candidates for election to the MTG Board of Directors should submit their proposals in writing to agm@mtg.com or to The Company Secretary, Modern Times Group MTG AB, Box 2094, SE-103 13, Stockholm, Sweden. **** NOTES TO EDITORS MTG (Modern Times Group MTG AB (publ.)) is a leading international digital entertainment group and we are shaping the future of entertainment by connecting consumers with the content that they love in as many ways as possible. Our brands span TV, radio and next generation entertainment experiences in esports, digital video content and online gaming. Born in Sweden, our shares are listed on Nasdaq Stockholm (‘MTGA’ and ‘MTGB’).  Contact us:press@mtg.com (or Tobias Gyhlénius, Head of Public Relations; +46 73 699 27 09)investors@mtg.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14)Download high-resolution photos: Flickr Follow us:mtg.com  / Facebook  / Twitter  / LinkedIn  / Instagram  / YouTube  To read MTG’s privacy policy, click here 

StarVR Unveils the World’s Most Advanced Virtual Reality Headset with Integrated Eye Tracking

With advanced optics, integrated eye tracking, industry-leading field-of-view, state-of-the-art rendering technology, and open integration to the VR hardware and software ecosystem, the industry leader raises the bar for premium VR experiences for the enterprise – the VR ‘Final Frontier’. SIGGRAPH 2018 –VANCOUVER, B.C., Aug. 14, 2018 –StarVR ®, the leader in premium virtual reality for the enterprise, today unveiled its next-generation VR headset specifically architected to support the most optimal life-like VR experience to date to meet commercial and enterprise needs and requirements. Launched today at SIGGRAPH 2018 , StarVR One is a one-of-its-kind VR head mounted display that provides nearly 100-percent human viewing angle. StarVR One features key technology innovations critical to redefine what’s possible in virtual reality. Featuring the most advanced optics, VR-optimized displays, integrated eye tracking, and vendor-agnostic tracking architecture, StarVR One is built from the ground up to support the most demanding use cases for both commercial and enterprise sectors. “StarVR continues its legacy of innovation that pushes past the barriers standing in the way of enterprise-grade VR experiences,” said Emmanuel Marquez, CTO of StarVR Corporation. “StarVR is blazing new trails to deliver break-through technology for a new world of realism to support real business decisioning and value creation. With our StarVR One headset we are conquering the VR final frontier – the enterprise.” StarVR One features an extensive 210-degree horizontal and 130-degree vertical field-of-view. This breakthrough architecture covers nearly 100 percent of natural human vision. The unparalleled field-of-view supports a new, more expansive user experience, approximating natural human peripheral vision; this opens up what is now possible with StarVR One, including support for rigorous and exacting VR experiences such as driving and flight simulations, and the ability to identify design issues in engineering applications, for example.  StarVR’s custom AMOLED displays serve up 16 million sub-pixels at a refresh rate of 90 framesper second to bring every detail to the eyes. The proprietary displays are designed specifically for VR with a unique full RGB per pixel arrangement to provide a professional-grade color spectrum for real-life color. Coupled with StarVR’s custom-crafted Fresnel lenses, the result is a crystal-clear visual experience within the entire field-of-view. The state-of-the-art lens design and precision manufacturing ensures exceptional contrast and true clean colors in every VR experience. StarVR One seamlessly integrates Tobii’s industry-leading eye tracking technology. Along with the eye tracking, StarVR One automatically measures Interpupillary Distance (IPD) and instantlyprovides the best image adjusted for every user. Integrated eye tracking empowers dynamic foveated rendering, a break-through rendering technology which concentrates high-quality rendering only where the eyes are focused. As a result, the highest quality imagery is pushed to the eye focus area while maintaining the right amount of peripheral imagery detail. StarVR One eye tracking unleashes a new world of commercial possibilities to leverage user intent data for content gaze analysis and improved interactivity, including heat maps.  StarVR enables a wide variety of use case scenarios. Two product variants are available with two different integrated tracking systems. The StarVR One is out-of-the-box ready for the SteamVR 2.0 tracking solution. Alternatively, the StarVR One XT is embedded with active optical markers for compatibility with optical tracking systems for the most demanding use cases. It is further enhanced with ready-to-use plugins for a variety of tracking systems and provides the additional tools for customization. The ergonomic headset design supports comfortable wearability. The headset weighs only 450g and the headband evenly distributes the weight to ensure comfort even during extended sessions andlonger use. StarVR features exceptional extensibility for ease-of-integration with a wide array of components, systems and environments. The StarVR software development kit (SDK) makes developingnew content or upgrading existing VR experience to StarVR’s premium wide-field of view platform seamless. Developers also have the option of leveraging the StarVR One dual-input VR SLI mode, maximizing the rendering performance to deliver the best image quality. The StarVR SDK API is designed to be familiar to developers working with existing industry standards and empowers them with feature sets beyond other platforms. The development effort that has culminated in the launch of StarVR One has involved extensive collaboration from StarVR’s industry-leading technology partners, including Intel, NVIDIA and Epic Games.  “We are excited to partner with StarVR to combine Intel’s computing performance with StarVR’s advanced commercial VR technology to create incredibly true-to-life virtual experiences that are bound only by one’s imagination,” said Kumar Kaushik, GM, AR/VR , Intel. “VR is destined to transform industries of all kinds, and Intel and StarVR are on the forefront of this wave.” “StarVR and NVIDIA have collaborated to deliver an innovative, best-in-class solution with the StarVR One platform,” said David Weinstein, NVIDIA’s director of Enterprise VR. “StarVR One is tightly integrated with NVIDIA’s Quadro GPU, leveraging VRWorks and foveated rendering to support the most demanding VR use cases in the commercial and enterprise markets.” “Unreal Engine is renowned for its ability to render visuals that are unparalleled in quality for immersive VR experiences, many of which are mission-critical and business-priority use cases,” said Simon Jones, director of Unreal Engine Enterprise at Epic Games. “StarVR’s native Unreal plugin gives developers quicker access to premier hardware features, enabling them to manifest their vision of creativity, form and function, and to create business value.” ”Epic is fully invested in advancing the OpenXR standard for cross-platform XR applications, and we're working with StarVR to combine Unreal Engine 4's OpenXR application support with StarVR's preliminary OpenXR runtime and hardware, alongside their existing UE4 plugin. We're excited to empower developers to build content in a platform-agnostic way, and this is a huge first step towards that," said Nick Whiting, technical director of VR and AR, Epic Games.

StarVR Unveils Advanced Virtual Reality Headset with Integrated Tobii Eye Tracking

Today, at the annual Siggraph Conference, StarVR unveiled its upcoming StarVR® One virtual reality headset, featuring advanced optics, integrated eye tracking, industry-leading field of view, and sophisticated rendering technology. “Over the last few years, Tobii has shown that integrated eye tracking is a foundational technology for next generation VR devices,” said Henrik Eskilsson, CEO of Tobii. “The StarVR One headset represents an important proof point for the many ways that eye tracking fundamentally leads to enhanced experiences.” In September of 2015, Tobii and Starbreeze announced  a VR development collaboration. Due to that successful collaboration, the StarVR One headset will include seamless and industry-leading eye-tracking technology, enhancing the device with capabilities to support dynamic foveated rendering, and automatic interpupillary distance (IPD) measurement. In addition to enhancing the device, eye tracking will create better user experiences by enabling interactions in virtual reality that streamline the user interface, emulate true hand-eye coordination, and allow expressive eye contact. For more information on how eye tracking creates better devices and better experiences, visit the Tobii website . Tobii’s scope of delivery for the StarVR One headset includes the Tobii EyeChip and licenses for Tobii’s system design, IP and software. Information about product availability, pricing, and order volume commitment is not yet available. Additional information and specifications for the new StarVR One headset can be found on the company’s web page www.starvr.com. This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on August 14, 2018, at 8:45 p.m. CET. 

THQ Nordic AB (publ) publishes Q2 2018: EBIT INCREASED 73% TO SEK 52.5 MILLION

SECOND QUARTER 2018 · Net sales increased by 878% to SEK 837.4 m (85.6). · EBITDA increased by 421% to SEK 206.9 m (39.7), corresponding to an EBITDA margin of 24.7%. · EBIT increased by 73% to SEK 52.5 m (30.3), corresponding to an EBIT margin of 6%. · Cash flow from operating activities amounted to SEK 164.5 m (21.6). · Earnings per share were SEK 0.42 (0.32). · 4 owned titles and 6 publishing titles were released in the second quarter. · The company completed a directed new share issue and received proceeds of approximately SEK 1,448 million before transaction costs. · The company’s change of the financial year to end March 31 was confirmed by authorities. INTERIM PERIOD JANUARY-JUNE 2018 · Net sales increased by 778% to SEK 1 470,4 m (167.5). · EBITDA increased by 430% to SEK 432.8 m (81.6), corresponding to an EBITDA margin of 29.4%. · EBIT increased by 157% to SEK 159.8 m (62.2), corresponding to an EBIT margin of 11%. · Cash flow from operating activities amounted to SEK 864.3 m (51.3). · Earnings per share were SEK 1.44 (0.65). · As of 30 June 2018, cash and cash equivalents were SEK 1,513.7 m. Available liquidity including credit facilities was SEK 2,686.4 m. For additional information, please contact:Lars Wingefors, Founder and CEOTel: +46 708 471 978E-mail: lwingefors@thqnordic.com About THQ NordicTHQ Nordic acquires, develops and publishes PC and console games for the global games market. The company has an extensive catalogue of over 100 owned franchises, such as Saints Row, Dead Island, Homefront, Darksiders, Metro (exclusive license), Titan Quest, MX vs ATV, Red Faction, Delta Force, Destroy All Humans, ELEX, Biomutant, Jagged Alliance, SpellForce, The Guild amongst others. THQ Nordic has a global publishing reach within marketing, sales and distribution, both online and offline. The company has a global presence, with its group head office located in Karlstad, Sweden and with operational offices in Vienna, Austria and Munich, Germany. The group has eleven internal game development studios based in Germany, UK, USA and Sweden and engages almost 1,750 people. THQ Nordic’s shares are publicly listed on Nasdaq First North Stockholm under the ticker THQNB:SS with FNCA Sweden AB as its Certified Adviser. For more information, please visit: http://www.thqnordic-investors.com This Interim Report is information that is mandatory for THQ Nordic to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 06:30 CET on 15 August 2018.

THQ Nordic acquires Timesplitters

Timesplitters was largely considered as one of the most influential console games of the early 2000’s. The three game series earned a large and passionate fan base thanks to its unique humour, art style and pop culture references while encouraging customization and modification to give each person their own individual experience.  Timesplitters was originally created by the development studio Free Radical Design that later become Deep Silver Dambuster, part of the THQ Nordic group.  In addition to Timesplitters, the IP and the rights to science fiction action-adventure game Second Sight were acquired. Both acquisitions were made through THQ Nordic’s fully owned subsidiary Koch Media GmbH. For additional information, please contact:Lars Wingefors, Founder and CEOTel: +46 708 471 978E-mail: lwingefors@thqnordic.com About THQ NordicTHQ Nordic acquires, develops and publishes PC and console games for the global games market. The company has an extensive catalogue of over 100 owned franchises, such as Saints Row, Dead Island, Homefront, Darksiders, Metro (exclusive license), Titan Quest, MX vs ATV, Red Faction, Delta Force, Destroy All Humans, ELEX, Biomutant, Jagged Alliance, SpellForce, The Guild amongst others. THQ Nordic has a global publishing reach within marketing, sales and distribution, both online and offline. The company has a global presence, with its group head office located in Karlstad, Sweden and with operational offices in Vienna, Austria and Munich, Germany. The group has eleven internal game development studios based in Germany, UK, USA and Sweden and engages almost 1,750 people. THQ Nordic’s shares are publicly listed on Nasdaq First North Stockholm under the ticker THQNB:SS with FNCA Sweden AB as its Certified Adviser. For more information, please visit: http://www.thqnordic-investors.com

Asetek – Q2 2018: Record quarterly revenue

Asetek reported revenue of $19.5 million in the second quarter of 2018, a 75% increase from the second quarter of 2017. First-half 2018 revenue amounted to $33.4 million, representing growth of 48% compared with the first half of 2017. The change from prior year reflects an increase in desktop revenue driven by shipments in the do-it-yourself (DIY) market. “The growing popularity of PC gaming and eSports fueled growth in DYI sales for our desktop segment and led to record quarter and first-half revenues. While the long-term outlook is strong for the desktop business, we expect a more modest development in the second half of the year”, said Andre Sloth Eriksen, CEO and founder of Asetek. “For our data center business, we continue to execute on our strategy of adding new OEM partnerships while increasing end-user adoption with existing ones. Adoption of new technology takes time, and performance will continue to fluctuate as our emerging data center business is maturing”, said Sloth Eriksen. EBITDA adjusted for share-based compensation expense was $2.9 million in the second quarter of 2018, compared with EBITDA adjusted of $1.1 million in the second quarter of 2017. First-half 2018 EBITDA adjusted was $3.8 million, compared to $1.8 million for the first-half of 2017. Desktop revenue was $18.3 million in the second quarter, an increase of 80% from the same period of 2017. First half revenue was $31.5 million, an increase of 49% from 2017. Operating profit from the desktop segment was $5.9 million for the second quarter and $9.9 million for the first half, both reflecting improvement over the respective periods of 2017, due to growth in DIY sales. During the quarter Asetek announced that ASUS, a premium brand for gaming systems, is expanding its Republic of Gamers (ROG) ecosystem utilizing Asetek solutions. The new ASUS ROG all-in-one coolers, Ryujin and Ryuo, are based on Asetek’s latest Generation 6 liquid cooling solution and include custom lighting and other features. Data center revenue was $1.2 million in the second quarter, an increase of 25% from the same period of 2017. Revenue in the first half of 2018 totaled $1.9 million, an increase of 35% from the same period of 2017. Operating loss from the data center segment was $2.1 million for the second quarter and $4.3 million for the first half of 2018. This compares with losses of $1.6 million and $3.4 million in 2017, respectively. Continued variability of data center operating results is expected while the company secures new OEM partners and growth of end-user adoption through existing OEM partners. Through partnerships with data center OEMs, the company is growing its end-user adoption with technology deployed to new HPC installations. In the second quarter, Asetek announced it will provide data center liquid cooling to a new OEM, Quanta Computer, for an HPC cluster at the National Center for High-Performance Computing in Hsinchu, Taiwan. The new HPC installation will focus on artificial intelligence, and will be the largest supercomputer in Taiwan at the time of commission. During the quarter Asetek received orders for RackCDU™ liquid cooling solutions from two established data center OEMs. Penguin submitted a follow-on order for further build-out of an undisclosed U.S. Department of Energy HPC installation, and Fujitsu will utilize 1,300 Asetek Direct-to-Chip (D2C) coolers for a new HPC system installation in Japan. On June 15, Asetek raised its full year 2018 desktop revenue expectation to a range of 15% to 25% growth over 2017. Desktop revenue variability by quarter is expected to continue, partly due to when new key hardware components such as GPUs and CPUs are made available to the market. As one such major product launch has experienced delays, Asetek’s full-year revenue growth may shift towards the lower-end of the guided range. The outlook for the data center business is unchanged, with revenue expected to be level compared with 2017. Conference call and webcast today Wednesday, 15 August at 9:00 AM CEST: CEO André Sloth Eriksen and CFO Peter Dam Madsen will host a presentation at 9:00 AM CEST. Asetek invites investors, analysts and media to join the presentation. The presentation is expected to last up to one hour, including Q&A, and can be followed through live webcast or by conference call. Webcast – audio and slide presentation: Please join the Q2 2018 Results webcast by clicking here . Conference call – audio only: Please dial in 5-10 minutes prior using the phone numbers and confirmation code below: +--------------------------------------+-----------------------+|Copenhagen, Denmark: |+45 3515 8049   |+--------------------------------------+-----------------------+|Oslo, Norway: |+47 2100 2610 |+--------------------------------------+-----------------------+|London, United Kingdom: |+44 (0) 330 336 9125   |+--------------------------------------+-----------------------+|Paris, France: |+33 (0)1 70 72 25 50 |+--------------------------------------+-----------------------+|New York, United States of America:   |+1 929 477 0324 |+--------------------------------------+-----------------------+|Confirmation code: 7079537 |+--------------------------------------+-----------------------+ Material: The second quarter report and presentation will also be made available on www.asetek.com  and www.newsweb.no, as well as through news agencies. A recorded version of the presentation will be made available on www.asetek.com  approximately two hours after the broadcast has concluded. For questions or further information, please contact:CEO and Founder André S. Eriksen, +45 2125 7076, email: ceo@astek.comCFO Peter Dam Madsen, +45 2080 7200, email: investor.relations@asetek.com About Asetek: Asetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK.OL).

PROGRESS IN FOCUS AREA MOBILE

SECOND QUARTER  · Net sales for the remaining operation totaled SEK 18.7 (20.1) million. · The operating profit/loss for the remaining operation for the quarter totaled SEK -3.3 (0.5) million. · The profit/loss for the period for the remaining operation totaled SEK -4.1 (0.2) million. · Earnings per share for the remaining operation totaled SEK -0.01 (0.00). · Earnings per share for the total operation totaled SEK -0.01 (0.00). · Cash flow from total operating activities totaled SEK -8.6 (-1.3) million. INTERIM PERIOD  · Net sales for the remaining operation totaled SEK 36.9 (36.8) million. · The operating profit/loss for the remaining operation for the interim period totaled SEK -5.3 (-2.2) million. · The profit/loss for the period for the remaining operation totaled SEK -6.6 (-3.2) million. · Earnings per share for the remaining operation totaled SEK -0.02 (-0.01). · Earnings per share for the total operation totaled SEK -0.02 (-0.01). · Cash flow from total operating activities totaled SEK -16.8 (15.8) million. · Cash and cash equivalents were SEK 93.6 (115.0) million at the end of the period. SIGNIFICANT EVENTS DURING THE QUARTER  · Huawei Honor 10 was launched, in which Precise BioMatch Mobile has been implemented with a Qualcomm ultrasound sensor beneath the glass. · Deepened collaboration with NXP and Kona-i, two prominent actors in the field of smart cards who supply payment cards to banks. · Introduced Precise BioMatch Card, a powerful algorithm solution for fingerprint recognition in smart cards. SIGNIFICANT EVENTS SINCE THE END OF THE QUARTER  · Stefan K Persson took over as new CEO as of August 1. FINANCIAL DATA AND KEY INDICATORS As a result of the Mobile Smart Card Solutions business area having been disposed of as of January 1, 2018, previously reported figures have been restated in order to improve comparability. The business area has been reported as a business held for sale starting in the interim report for the second quarter of 2017. In order to obtain comparable historical data, previously reported figures have only been adjusted for the expenses relating directly to the discontinued business area, which will no longer affect the company’s remaining operation. The discontinued operation’s impact on the financial position has not been reported separately, as the company does not consider it possible to report the discontinued operation’s impact on cash flow. Cash flow is instead reported for the total operation. Unless otherwise specified, reported figures in the interim report relate to the remaining operation.  KEY INDICATORS  +------------------------+-------+--------+--------+--------+----------+--------+|Amounts in SEK thousand | 2018 | 2017 | 2018 | 2017 | 2017 |Rolling ||unless otherwise stated | | | | | | |+------------------------+-------+--------+--------+--------+----------+--------+|   | Q2 | Q2 | Q1-Q2 | Q1-Q2 |Full year | 12 mon.|+------------------------+-------+--------+--------+--------+----------+--------+|Net sales  |18,728 | 20,160 | 36,880 | 36,777 | 61,039 | 61,142 |+------------------------+-------+--------+--------+--------+----------+--------+|Net sales growth, %  | -7.1% | 6.5% | 0.3% | -7.0% | -26.7% | -24.1% |+------------------------+-------+--------+--------+--------+----------+--------+|Gross margin, %  | 82.8% | 95.0% | 87.4% | 94.7% | 93.3% | 88.9% |+------------------------+-------+--------+--------+--------+----------+--------+|Operating profit/loss  |-3,296 | 482 | -5,329 | -2,179 | -13,936 |-17,086 |+------------------------+-------+--------+--------+--------+----------+--------+|Operating margin, %  |-17.6% | 2.4% | -14.5% | -5.9% | -22.8% | -27.9% |+------------------------+-------+--------+--------+--------+----------+--------+|Cash flow from operating|-8,609 | -1,314 |-16,835 | 15,808 | 22,788 | -9,855 ||activities  | | | | | | |+------------------------+-------+--------+--------+--------+----------+--------+|Cash and cash |93,580 |115,006 | 93,580 |115,006 | 116,955 | 93,580 ||equivalents, total | | | | | | ||operation  | | | | | | |+------------------------+-------+--------+--------+--------+----------+--------+ PRESENTATION OF THE INTERIM REPORTIn connection with today’s interim report, we issue an invitation to an informational event today at 10:00 AM. Please see the last page of the interim report for further information about participation. THE CHAIRMAN’S COMMENTSFingerprint sensors with optics or ultrasound that are placed beneath the glass are gaining more and more ground in the high-end mobile segment. Interest in these sensors is being driven by new design, in which the screen covers the entire front of the mobile phone. Several mobile phones have been launched this year with optical or ultrasound sensors. One of these phones is the Huawei Honor 10, in which our Precise BioMatch Mobile software is integrated with an ultrasound sensor from Qualcomm. The device has been a sales success and has sold more than three million units in less than three months. To further strengthen our position and win new business, we are continuing our close collaboration with several customers that are focusing on optical and ultrasound sensors. There are long lead times in this segment and it takes time from the start of a project until it generates royalty revenues. The prices of capacitive fingerprint sensors are continuing to fall, which enables more mobile phones in the low-price segment to get such sensors. Our software is included in a number of phones in this segment that were launched recently, from suppliers including Nokia, TCL and Lenovo.  New pilot projects with biometric payment cards have been launched, and at the same time the evaluations from the first pilot projects in countries including the USA and Japan have generated overwhelmingly positive responses. The major benefits highlighted in these evaluations are that biometric payment cards provide a smooth user experience and that fingerprints are perceived to be a more secure authentication method than PIN codes.The major suppliers of payment solutions are working to confirm the specifications for biometric payment cards, which is a precondition for the cards to be able to enter into commercial use. The first specification from MasterCard is expected to come before the end of the year, which means that biometric cards for payments could be used commercially and provide us with royalty revenues in the latter part of 2019.  We have deepened our collaboration with NXP and Kona-i, two prominent actors in the field of smart cards. These partnerships strengthen our position as the leading supplier of fingerprint software for smart cards.  The use of biometrics in new areas of application is on the increase, and the technology is moving into more and more areas. A number of new products with fingerprint technology were launched during the quarter, including USB keys and crypto wallets with fingerprint readers, which increases security for the user.  On August 1, Stefan K Persson started as CEO of Precise Biometrics. The Board looks forward to working with Stefan in continuing to develop our business in our focus areas and to broaden the use of biometrics in new areas of application.  Work to generate profitable growth continues, and our financial position provides us with opportunities to continue to invest in the focus areas we have identified.  This information is information that Precise Biometrics AB is obligated to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 AM on August 15, 2018.

Stora Enso invests in building a Competence Centre and diversifying the raw material base for biocomposites

In order to meet increasing customer demand, Stora Enso will broaden its biocomposites raw material base at the Hylte Mill, Sweden to provide more choice in technical properties and selection of fibres. The investment covers a new Biocomposites Competence Centre and the installation of new machinery for the milling of large fibres for the DuraSense™ by Stora Enso biocomposite material. “As we see an increasing demand for the innovative DuraSense™ biocomposite, the diversification of the raw material base and the new Biocomposites Competence Centre will provide Stora Enso with faster access to the market for replacing fossil-based plastics with renewable ones,” says Jari Suominen, Executive Vice President, Stora Enso’s Wood Products division. “With our fully integrated process and excellent fibre knowledge we can enhance our growth in this market.”“With the new equipment in place, Stora Enso will be able to provide more choice to DuraSense™ users in the technical properties and selection of fibres for the biocomposites, and also offer an attractive price position compared to traditional plastics. This will make it easier for customers to switch from existing material solutions to those based on biocomposites,” says Patricia Oddshammar, Head of Biocomposites in Stora Enso.Production of large fibres is scheduled to start by the end of 2019.The Biocomposites Competence Centre will be built in one of the existing buildings at Hylte Mill. The competence centre will house a laboratory and piloting facilities, performance testing capabilities and a show room. The building project for the competence centre is estimated to start in the 2018 and be completed during 2019.“At the new Biocomposites Competence Centre we will be able to share our knowledge with our customers as well as assist them with test runs and product testing, step by step,” Oddshammar says.The investment of EUR 7 million will further strengthen Stora Enso’s position as a renewable materials company. The biocomposite mill in Hylte started up earlier this year. Its annual production capacity is 15 000 tonnes, making it the largest wood fibre-based biocomposite plant in Europe. Although the new investment will not have significant impact on the production capacity, it will diversify the raw material base.As previously communicated, once fully ramped up, the biocomposite business will increase Stora Enso’s Wood Products sales by approximately EUR 25 million and will exceed the division’s profitability target, operational return on operating capital (ROOC) of 20%.For further information, please contact:Ulrika Lilja, EVP, Communications, tel. +46 72 221 9228 Investor enquiries:Ulla Paajanen-Sainio, SVP, Investor Relations, tel. +358 40 763 8767 Part of the bioeconomy, Stora Enso is a leading global provider of renewable solutions in packaging, biomaterials, wooden constructions and paper. We believe that everything that is made from fossil-based materials today can be made from a tree tomorrow. Stora Enso has some 26 000 employees in over 30 countries. Our sales in 2017 were EUR 10 billion. Stora Enso shares are listed on Nasdaq Helsinki (STEAV, STERV) and Nasdaq Stockholm (STE A, STE R). In addition, the shares are traded in the USA as ADRs (SEOAY). storaenso.com  STORA ENSO OYJ 

Double Bond Pharmaceutical manufactures first GMP batch of SI053

Double Bond Pharmaceuticals contract manufacturer of SI053 reports that they have successfully manufactured the first GMP batch. The batch is to be used among other things for the stability study for SI053. “There is a lot of work behind this batch and we are very pleased to be able to start the stability study according to plan” says Charlotte Karlsson, Quality Assurance Manager and coordinator of the manufacturing projects. “Getting a material for future clinical trials is an important milestone in the drug development process” commented Igor Lokot, CEO of Double Bond Pharmaceutical. More about SI-053: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. The product has a working name SI-053 in DBP pipeline.  More about our products: www.doublebp.com This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15 of August 2018. ____________________________________________________________________  Full Company Name:   Double Bond Pharmaceutical International AB (publ) Corporate identity:       556991-6082 Stock short name:       DBP B Share ISIN code:         SE0007185525 For more info, contact Igor Lokot, CEO Homepage: http://www.doublebp.com/ E-mail: info@doublebp.com Blog: http://blog.doublebp.com Follow us on LinkedIn and Twitter ! _______________________________________________________________________________ Information on Double Bond Pharmaceutical International AB DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline. 

Study of depression and efficacy of treatment published with promising results and in line with the National Board of Health and Welfare guidelines

The study is an important part of the development that SensoDetect works with for both tests for initial assessment of mental ill-health and for the choice of medication and control of its effect.  "Depression and anxiety disorders belong to the major public diseases and affect people of all ages. The risk of developing depression is approximately 36% for women and 23% for men [7]. Approximately 25% of the population is estimated to suffer from an anxiety disorder, and in adults it is two to three times as common in women compared to men. Among children before puberty, anxiety disorders occur in about 10% and are as common in boys as in girls. Many of those affected by depression or anxiety are of working age. Diagnoses in the Depression and anxiety area (including adaptation disorder and response to severe stress) are responsible for approximately 90% of all sick leave due to mental illness in Sweden [8]. In both depression and anxiety disorders, there are varying severities, but even in the case of less seriousness, the condition often means that the person has a loss of quality of life and difficulties in coping with everyday life and work. The lives of relatives can also be influenced to a large extent. It is therefore important to have adequate and early treatment to prevent, as far as possible, disabilities, risk of long-term disease and återinsjuknande.", the Swedish Social Welfare Board's guidelines for Depression and anxiety, 20171204 This is also a stated goal for the Swedish National Board of Health and Welfare in Sweden when there is a clear problem with, among other things, increased drug prescription. The importance of being able to follow up and respond to the desired effect is difficult within a very large group of patients especially in psychiatry and therefore it is important to be able to follow up quickly so that the impact on both the patient, the environment and society's costs are minimized. The National Board of Health and Welfare evaluation also identified a number of areas for improvement, "• Develop procedures for early detection and treatment of bodily diseases in people with mental illness • Develop routines for Suicide risk assessment • Increase access to evidence-based psychological treatment • Develop routines for early detection and diagnostics of mental ill-health • Increase follow-up of treatment", from the Swedish Social Welfare Board's guidelines for Depression and anxiety, 20171204 In the study made they identified that markers have been found to clearly identify depression in line with "early detection and support for the diagnosis of mental ill-health". It is also noted that it is very quickly possible to see the effect of the treatment which also coincides very well with the National Board of Health and Welfare list, "increasing the follow-up of treatment". "An electro-physiological marker for depression has been identified by this study. It separates depressive individuals from healthy with high statistical significance. By combining ABR results from several complex stimuli, a second marker was constructed that enabled detection of effects of treatment with Citalopram after only one week. The study is a starting point for further development that is commented on in the discussion. The ultimate goal is to achieve a method of diagnosis and treatment control. An objective contribution for these purposes in psychiatry would be of great benefit.", quote from ACTA PSYCHOPATHOLOGICA ISSN 2469-6676, Depressive State and Auditory Brainstem Response a Tentative Future Method for Diagnosis and Pharmacological Control of Depression by Jens Holmberg, Johan source Strand and Sören Nielzén, 20180705. Link to the article   ACTA PSYCHOPATHOLOGICA ISSN 2469-6676, Depressive State and Auditory Brainstem Response a Tentative Future Method for Diagnosis and Pharmacological Control of Depression av Jens Holmberg, Johan Källstrand och Sören Nielzén, 20180705; http://psychopathology.imedpub.com/depressive-state-and-auditory-brainstem-response-a-tentative-future-method-for-diagnosis-and-pharmacological-control-of-depression.pdf "If one can avoid" trial-and-error "methods of medication of patients, it saves not only money, the environment and suffering also is likely to save life. Unfortunately it is not obvious which medication or treatment is always best, but it becomes a bit of an experience guess and to try out for both doctors and patients. We can read almost daily that after years of treatment it has been discovered that a patient has been taking wrong medication and been suffering both from medications as well as from not getting treated. This not least in psychiatry with ADHD and Depression at the top of that list. That is why I see this as very interesting possibility and we will continue the development towards creating conditions not only for tests that help in the assessment of an individual disease but also on the effects. It is important for all parties and since it is very difficult in any other way to test this, I see it as obvious that we should now help with this as soon as we can. It will as always with medical technology take a while before we can launch it since all medical technology needs to have more studies and we will also need to get help from doctors and patients to test and evaluate it. But it will absolutely be part of our future activities as I see it. "says CEO Johan Olson, SensoDetect AB (publ.)

Bambuser AB (publ) publishes H1 2018

CEO Maryam Ghahremani comments: After assuming the position as Interim CEO of Bambuser March, 2018, with the mission to review the product and increase the short term revenues, I started working with the organization to form a clear and measurable strategy for 2018. We introduced a new Go-to-Market strategy in early April, which we have started to launch in August. In the new strategy, we have reviewed and changed a great deal of our brand profile. We have shut down the Iris product brand and reverted to Bambuser. Doing this, we clarify our message and focus our marketing and communication around a brand that is well established in our target groups. The entire website has been redesigned, focusing on the digital conversion of visitors to customers. Here we have also added transparent pricing and the ability to subscribe directly on the website. In addition, there is an online calculator that helps our customers choose the right subscription plan. The website design is optimized to drive digital purchases and to make it easy to convert trial users to new customers. Another important change in the new brand platform is the review of our previous offering, which has prompted us to sell Bambuser as a single platform rather than as separate products. The focus and watchwords throughout this process have been to make it easy to understand the product and to make the purchase of our services as easy as possible. I consider the first half of this year a restart for Bambuser. Our work to transition the company has gone according to plan and we are now in a favourable position to drive revenue through our new strategy. During the second half we will focus on optimizing our digital sales funnel and we expect to be able to show growth in customers as well as revenues in the latter part of 2018. We have recruited a new COO/CPO from Spotify, who will head our new data-driven strategy. With Jesper Funck on board, it is our vision to gain market share at a rapid pace. Early in the fall, I have a planned parental leave. During that time, Jesper Funck will take over the operational responsibility. The groundwork to capitalize on our new strategy is in place and I look forward to doing so together with all of our talented employees. This information is information that Bambuser AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out below, on August 15, 2018, 08.30 CEST.

New Australian patent approval for Episurf Medical

The Australian patent office IP Australia has announced that Episurf Medical (NASDAQ: EPIS B) has obtained another granted patent in Australia. The patent, entitled “Design method of a rig”, is within the area of individualised surgical instruments with a focus on the drill guide for the Episealer® Femoral Twin implant. "I’m happy to see how the Episealer® Femoral Twin technology is getting backed up by a strong patent coverage globally”, comments Pål Ryfors, CEO, Episurf Medical. For more  information, please contact: Pål Ryfors, CEO, Episurf Medical Tel:+46 (0) 709 62 36 69 Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 15 August 2018.

Interim report January – June 2018

Highlights from Q2 2018 report · Subscriber base up 47% Y/Y to 621 200, on track to reach 800 000 in 2018 · Streaming sales up 43% Y/Y to 239 MSEK, on track to reach 1 000 MSEK in 2018 · International streaming sales now 47% of total, on track to surpass 50% in 2018 · Storytel launched in the UAE, Turkey and Italy · E-book reading device (Storytel Reader) launched at the end of June · Announced preparation to move to Nasdaq First North before end of 2018 Key numbers for  Streaming and Print Publishing Currency:                                      Q3 2018thousand SEK  Q2  Q3  Q4  Q1  Q2 2017 2017 2017 2018 2018 Forecast1Streaming            TotalRevenue 167 008 197 881 209 225 222 133 239 139 275 500Contribution 27 847 27 784 30 277 24 079 25 045Profit2Contribution 16,7% 14,0% 14,5% 10,8% 10,5%MarginPaying 423 200 503 900 533 400 577 900 621 200 725 000SubscribersARPU3 132 131 131 128 128 127(SEK/Month) StreamingSwedenRevenue 101 365 113 709 118 038 122 046 125 759 135 000Contribution 31 257 32 872 38 501 43 067 35 763ProfitContribution 30,8% 28,9% 32,6% 35,3% 28,4%MarginPaying 255 800 282 300 292 700 305 100 314 700 339 000SubscribersARPU 132 134 134 133 133 133(SEK/Month) StreamingInternational4Revenue 65 643 84 172 91 187 100 087 113 380 140 500Contribution -3 410 -5 088 -8 224 -18 988 -10 718ProfitContribution -5,2% -6,0% -9,0% -19,0% -9,5%MarginPaying 167 400 221 600 240 700 272 800 306 500 386 000SubscribersARPU 131 127 126 122 123 121(SEK/Month) PrintPublishing5Revenue 111 969 132 619 173 832 106 312 115 898Contribution 37 840 47 905 66 854 39 223 41 889Profit6Contribution 33,8% 36,1% 38,5% 36,9% 36,1%Margin 1 Forecast is an approximation based on information available at time of reporting. 2 Contribution Profit is defined as streaming revenue minus costs for content (licensed content and in-house productions) and marketing. Storytel Reader is not included in Streaming. 3 ARPU = Average Revenue Per User (Subscriber) per month 4 Storytel Norway included in figures @ 100%. In the consolidated group accounts Norway is reported according to the principle of proportional consolidation. 5 Print Publishing refers to physical books. Internal transactions have been redacted. Barnens bokklubb not included in table. 6 Contribution Profit is defined as revenue minus cost per sold unit, distribution costs, and sales and marketing costs. The interim report for January - September will be released on November 15, 2018 This information is such information that Storytel AB (publ) is obliged to make public in accordance with EU:s market regulation (marknadsmissbruksförordning). The information was made public by above contact person on August 15th, 2018, 8.30 CET. For more information, please contact: Jonas Tellander, CEO: +46 70 261 61 36 Sofie Zettergren, CFO: +46 70 509 98 08 About Storytel The Storytel group is comprised of two divisions, Streaming and Publishing. The Streaming division currently offers a subscription service for audio books and e-books under the brand names Storytel and Mofibo in Sweden, Norway, Denmark, Finland, Iceland, The Netherlands, Poland, Russia, Spain, India, the United Arab Emirates, Turkey and Italy. The Streaming division also publishes audio books and Storytel Originals, mainly through the audio-book publisher Storyside. The Publishing division is comprised of the publishers Norstedts, Massolit, Kontentan, Telegram, the Danish People’s Press, Storytel Publishing, Rabén & Sjögren and B. Wahlströms, as well as Norstedts Kartor.

Journal of Clinical Oncology publishes that IMMray™ PanCan-d serum biomarker test detects early pancreatic cancer with 96% accuracy

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year survival of <10% because of diffuse symptoms leading to late-stage diagnosis. It is widely accepted that that survival could increase significantly if localized tumors could be detected early to enable surgical intervention. IMMray™ PanCan-d incorporates a novel 29 biomarker signature of early-stage PDAC derived from a large Danish patient cohort, including patients with well-defined early-stage (I and II) PDAC. The JCO paper reports on how this signature has now been validated in both Danish and US cohorts with a receiver operating characteristic area (ROC) under the curve value (AUC) of 0.96. Senior author, Professor Carl Borrebaeck, CREATE Health Cancer Center, Lund University, commented: “JCO is a very prestigious journal with a clinical focus, and we are very pleased that the largest study on early detection of PDAC will be published there. Protein-based approaches, such as IMMray™ PanCan-d, have the best possibilities for early detection of pancreatic cancer because of its high sensitivity and requirement of only microliter sample volumes. The next step is now a well-designed prospective validation study, which Immunovia has already initiated in the form of the multi-center trial called PanFAM-1 .” Mats Grahn, CEO Immunovia said: “We are delighted to see the publication of this study in JCO, which confirms that IMMray™ PanCan-d can detect pancreatic cancer in the earliest stages with an accuracy as high as 96%, in two completely different patient cohorts collected independently on different continents. “ Link to the article in JCO: Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer . For more information, please contact: Mats Grahn Chief Executive Officer, CEO, Immunovia Tel.: +46-70-5320230 Email: mats.grahn@immunovia.com About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Hi3G selects Ericsson to develop transport network for 5G in Denmark

Ericsson (NASDAQ: ERIC) has been selected by Hi3G, operating as 3 in Denmark, to modernize its transport network with 5G-ready routers over the next three years. The new IP Mobile Backhaul transformation project will see the implementation of Router 6000  hardware, software and customer support (part of Ericsson Radio System). This will prepare Hi3G’s network for future 5G requirements, and support the significant increase in the number of connected devices on the network. The rollout will start during the fall of 2018 and expands Ericsson’s partnership with Hi3G . The Scandinavian communications service provider already has a long experience with Ericsson’s MINI-LINK product portfolio, which shares a common management system with Router 6000 series. This makes the management and deployment of Router 6000 easy and efficient. Kim Christensen, Network Director, 3 Denmark, says: “We are looking forward to continuing our good partnership and relationship with Ericsson with state of the art transmission equipment. This is the next step into the 5G era.” Arun Bansal, Senior Vice President and Head of Ericsson in Europe & Latin America, says: “Hi3G is establishing itself as one of the 5G leaders in the region and we are committed to helping them on this journey by building the highest quality network that provides an outstanding user experience. The network is at the heart of 5G and our portfolio – the most complete in the industry – will enable service providers today to evolve smoothly to the next generation of networks.” Ericsson’s 5G Business Potential report , found that operators can add a revenue of USD 204 to 619 billion (12 to 36 percent) to their forecast service revenues of USD 1.7 trillion in 2026 by targeting the digital transformation of other industries, such as automotive and manufacturing, using 5G-IoT technology. The Router 6000 series is a game changer because it responds directly to operators' challenges of exponentially growing data traffic volumes and significant increase in the number of connected devices. It not only addresses operators’ needs for scalability, but also for security and higher operational efficiency. NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericsson www.facebook.com/ericssonwww.linkedin.com/company/ericssonwww.youtube.com/ericsson Subscribe to Ericsson press releases here . MORE INFORMATION AT: News Center  media.relations@ericsson.com (+46 10 719 69 92) investor.relations@ericsson.com (+46 10 719 00 00) ABOUT ERICSSON Ericsson enables communications service providers to capture the full value of connectivity. The company’s portfolio spans Networks, Digital Services, Managed Services, and Emerging Business and is designed to help our customers go digital, increase efficiency and find new revenue streams. Ericsson’s investments in innovation have delivered the benefits of telephony and mobile broadband to billions of people around the world. The Ericsson stock is listed on Nasdaq Stockholm and on Nasdaq New York. www.ericsson.com ABOUT Hi3G Hi3G is owned by CK Hutchison Holdings (60 percent) and Investor AB (40 percent). The service provider has a 3G license in Denmark and Sweden where it provides mobile voice and broadband services.

Electrolux invests in and partners with food waste startup Karma

The new partnership with Karma will explore new innovative solutions within the future of food and help to scale up the fight against food waste. The partnership will combine Electrolux expertise within appliances and food preservation with Karma’s digital platform and expertise within sharing economy. ”We are committed to drive a positive change and we know that the best way to do this is by working together with others who share our ambition. Electrolux is continuously exploring solutions that drives a better and more sustainable living and we’re excited to support Karma”, said Jonas Samuelson, President and CEO of Electrolux. Reducing food waste is an important target in Electrolux sustainability framework with the goal to inspire better food consumption among consumers and professionals. For more info about Electrolux sustainability framework, please visit: https://www.electroluxgroup.com/en/category/sustainability/ “As a world leader in appliances, Electrolux is working closely with Karma to help alleviate the global problem of food waste. We’re impressed with Karma’s innovative digital business model particularly as everyone wins: both the food seller and buyer but importantly also the environment”, said Marty Carroll, Vice President Digital Marketing at Electrolux. The USD 12 million round announced today was led by the Swedish investment firm Kinnevik. It also includes Bessemer, a U.S. venture capital firm, as well as other existing investors in Karma including the global venture capital firm e.ventures.   About Karma Karma is a marketplace that allows restaurants and grocery stores to reduce food waste by selling unsold food at a discount direct to consumers, who pick up the food on location. Since its launch in November 2016, Karma has expanded to help over 1500 restaurants, grocery stores, hotels, cafes and bakeries reduce food waste by selling their surplus to 350000 Karma users. Karma will use the new funding to continue to develop their product range, especially within supermarkets, and to expand to new markets, starting with Europe. For more info about Karma, please visit: www.karma.life

Acando Norway acquires September BI – a company specialized in Analytics solutions for retail

September BI (www.septemberbi.no) is one of Norway's leading companies within Business Intelligence (BI) for Retail and Supply Chain Management. September BI has a proprietary solution, Retail Operational Intelligence, that controls and optimizes flows and provides customer insights. September BI’s has several significant customers including XXL, Intersport, G-Sport, Nille and Vita.  September BI employs approximately 20 senior consultants with deep expertise within relevant technologies and in developing ERP, BI and POS solutions for the retail industry. September BI is led by Øyvind Stige. - The retail industry is in the middle of an extensive transformation. Modern technology makes the digital customer experience in the physical store a reality. Customers have higher demands, and the desire for an individual and customized customer experience is increasing. Through the acquisition of September BI our ability to deliver retail solutions is strengthened, and our range of digital solutions, IoT and Analytics can be combined in innovative solutions for our customers, says Sven Ivar Mørch, CEO Acando Norway. Acando has long experience in working with advanced retail solutions with major clients in Northern Europe. Every day, over 350 Acando consultants work with retail companies and Acando has helped large organizations to carry out extensive transformation projects and to implement innovative solutions. The acquisition of September BI strengthens the ability to realize data-driven processes creating increased customer satisfaction and efficiency.

HUOLETI ACCELERATES TOWARDS U.S. AND EUROPEAN MARKETS AT VERTICAL ACCELERATOR GROWTH TRACK

Huoleti is focused on excellence and growth, leveraging the Growth Track at Finland’s leading health and wellness accelerator, operated by Vertical and Helsinki area Regional Council in the beginning of August. The purpose of the project is to boost promising startups to the next level. During the program, Huoleti will focus on building a sustainable model for service discovery and user engagement in Finland. At the same time, Huoleti is preparing for entry in the U.S. and European markets. Huoleti’s go-getting attitude convinced Vertical We are continuously monitoring for potential startups to be our partners. The Huoleti team has a really dynamic can-do-spirit that impressed us. They have an excellent team that makes things happen, their business idea is strong and the company has been growing rapidly during its first year, says Eero Toppinen, Venture Analyst, from Vertical. Huoleti’s mentoring will be focused on service discovery and pricing analysis with different target groups, as well as messaging the benefits of the service to the customers and users. Developing the service discovery is the top priority, it is critical to understand how people with a severe illness or any psychosocial challenge find the service and its benefits in their life situations. It is also valuable to know which paths lead them to become users, and what motivates them to become regular users of the service. Huoleti is sailing on Blue Oceans Even though there are plenty of existing services that include health technology and communities, Toppinen sees a niche for Huoleti. Competition is a sign that the industry is potentially profitable in the first place. The number of competitors is still small, which gives Huoleti versatile and scalable service a major advantage, Toppinen points out. The potential market for Huoleti is huge, since there is no existing service that combines information about illnesses from reliable sources, as well as the mutual help and support of communities within the same app. When we are healthy, we don’t always understand how the world is changing for the ill, and how hard it is to ask for and offer help, reminds Carita Savin, CEO of Huoleti.’ Join us in continuing to create Huoleti’s success story Huoleti Ltd has opened a digital crowdfunding campaign on the Invesdor platform . The funding round will help the company to expand its product development, accelerate sales in Finland and accelerate its growth in the U.S. Huoleti is an early mover in the growing market for modern patient communities and care team support, which includes both the patient and their loved ones as end users. With the addition of offering safe and secure volunteering through the platform, Huoleti has all the potential to become the most inclusive and diverse service of targeted support for patients. It has the impact of truly improving lives and strengthening bonds within communities. Huoleti Ltd. in a nutshell · Huoleti’s main customers are private sector healthcare providers, insurance companies and patient associations. · Huoleti is one step ahead in combining social apps and online health care:  there are currently no other products that have all the features included. · The market for Huoleti is huge. Cancer patients and survivors, alone amount to tens of millions of attainable target users in Europe, and hundreds of millions globally. · Huoleti signed a contract with Roche in June 2017 · First US pilot negotiations are ongoing with Cleveland Clinic, Jefferson University Hospital and Visiting Nurse Association. Prizes and nominations · November 2016: Huoleti was one of the three winners of Kertomalla paranee innovation challenge. · February 2017: Huoleti got on board in the Vertical Accelerator along with 12 other companies, out of 270 applicants from 50 countries. · May 2017: Huoleti was one of the three winners of the OP Smart Health Innovation Challenge. The competition had 200 participants from several countries. · May 2017 Huoleti was nominated as the fourth most promising startup at the Digital Health Finland convention. · April 2018 Huoleti was chosen to pitch in Chicago in MedCity Invest conference. www.huoleti.com

MTG and NENT Group secure SEK 4 billion credit facility

Modern Times Group MTG AB (publ) and its subsidiary Nordic Entertainment Group AB (NENT Group) have jointly agreed a SEK 4 billion five year revolving credit facility with a group of six Nordic banks. The facility replaces MTG’s existing SEK 4 billion facility, which matures in December 2018, and will provide back-up funding for MTG’s SEK 3 billion commercial paper program and other short-term financing. The facility will serve as an initial source of funding for NENT Group when the company is listed separately on Nasdaq Stockholm prior to the intended issue of new commercial paper and bonds. The facility has been arranged by Nordea and SEB and is based on the same terms and conditions, including financial covenants, as the existing facility. **** NOTES TO EDITORS MTG (Modern Times Group MTG AB (publ.)) is a leading international digital entertainment group and we are shaping the future of entertainment by connecting consumers with the content that they love in as many ways as possible. Our brands span TV, radio and next generation entertainment experiences in esports, digital video content and online gaming. Born in Sweden, our shares are listed on Nasdaq Stockholm (‘MTGA’ and ‘MTGB’).  Contact us:press@mtg.com (or Tobias Gyhlénius, Head of Public Relations; +46 73 699 27 09)investors@mtg.com (or Stefan Lycke, Head of Investor Relations; +46 73 699 27 14)Download high-resolution photos: Flickr Follow us:mtg.com  / Facebook  / Twitter  / LinkedIn  / Instagram  / YouTube  To read MTG’s privacy policy, click here 

Autoliv Declares Quarterly Dividend

The dividend will be payable on Thursday, December 6, 2018 to Autoliv shareholders of record on the close of business on Wednesday, November 21. The ex-date will be Tuesday, November 20, for holders of common stock listed on the New York Stock Exchange (NYSE) as well as for holders of Swedish Depository Receipts (SDRs) listed on Nasdaq Stockholm. Inquiries:Corporate Communications: Stina Thorman, Tel +46 (0)8 587 206 50Investors & Analysts: Anders Trapp, Investor Relations, Tel +46 (0)8 587 206 71Investors & Analysts: Henrik Kaar, Investor Relations, Tel +46 (0)8 587 206 14  This information is information that Autoliv, Inc. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out above, at 14.30 CET on August 15, 2018.   About AutolivAutoliv, Inc. is the worldwide leader in automotive safety systems, and through its subsidiaries develops and manufactures automotive safety systems for all major automotive manufacturers in the world. Together with its joint ventures, Autoliv has more than 66,000 employees in 27 countries. In addition, the Company has 12 technical centers around the world, with 19 test tracks. The Company’s shares are listed on the New York Stock Exchange (NYSE: ALV) and its Swedish Depository Receipts on Nasdaq Stockholm (ALIVsdb). For more information about Autoliv, please visit our company website at www.autoliv.com. Safe Harbor StatementThis report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Pilängen Logistik divests XXL’s logistics centre in Örebro to Aberdeen Standard Investments

Pilängen Logistik AB (publ) (“Pilängen”), a company established and managed byPareto, has today divested XXL’s logistics centre located in Örebro, Sweden,to Aberdeen Standard Investments for around SEK 400 million.The logistics centre, which comprises approximately 43,000 square metres, isfully let to the leading Norwegian sports retailer XXL with over 10 yearsremaining lease period.XXL has two logistics centres in the Nordics, one in Örebro (inside the EU)and one at Gardermoen, Norway (outside the EU). The logistics centre inÖrebro, which is the largest site among the two, serves Sweden, Finland,Denmark and Austria.Sven I Hegstad, Pilängen CEO comments:-         We are pleased to have completed a good transaction for our investors and areconfident that Aberdeen Standard Investments will continue to support XXL’sgrowth within e-commerce. Aberdeen Standard Investments has acquired all shares in Pilängen, whichthrough its subsidiary is the sole owner of the property.Pilängen was represented by Pangea Property Partners as sell-side adviser andMAQS acted legal adviser. Aberdeen Standard Life was advised by NCAP as buyside adviser and Linklaters acted as legal adviser.For more information, please contact:Sven I Hegstad, CEO Pilängen Logistik AB (publ) (+47 22 01 58 80)About Pilängen Logistik AB (publ)Pilängen Logistik AB (“Pilängen”) was established by Pareto Securities AB inconnection with the acquisition of the XXL property in 2015. The XXL propertyis Pilängen’s only asset and the company has, since the acquisition of theproperty, been managed by Pareto Business Management AB. 

Proposed Placing in Oncopeptides AB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. PRESS RELEASE 15 August 2018 Accelerated bookbuild offering of up to 1,200,000 existing shares in Oncopeptides Stiftelsen Industrifonden ("Industrifonden") announces the launch of an accelerated bookbuild offering to institutional investors (the "Transaction") of up to 1,200,000 existing shares in Oncopeptides AB (publ) (the "Company" or "Oncopeptides"), equivalent to up to approximately 2.73% of the existing share capital and voting rights in the Company. Jefferies International Limited, (the "Manager") is acting as Sole Bookrunner in the Transaction. The bookbuilding period commences today, 15 August 2018, with immediate effect and may close at any time on short notice. A further announcement will be made following completion of the bookbuilding and pricing of the Transaction. Subject to customary exceptions or obtaining consent from the Manager, Industrifonden will not make additional sales of shares in Oncopeptides for 90 days. Assuming all the shares available in the Transaction are sold, Industrifonden's holding of shares in Oncopeptides will be reduced to 10,420,805 shares corresponding to approximately 23.67% of the existing share capital and voting rights in the Company. Oncopeptides will not receive any proceeds from the Transaction. IMPORTANT NOTICE THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA.  THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES.  THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION.  NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES OR INVESTMENTS FOR SALE OR A SOLICITATION OF AN OFFER TO BUY SECURITIES OR INVESTMENTS IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO ACTION HAS BEEN TAKEN THAT WOULD PERMIT AN OFFERING OF THE SECURITIES OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") WHICH HAVE IMPLEMENTED THE PROSPECTUS DIRECTIVE (EACH, A "RELEVANT MEMBER STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED EXCLUSIVELY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE PROSPECTUS DIRECTIVE ("QUALIFIED INVESTORS"). FOR THESE PURPOSES, THE EXPRESSION "PROSPECTUS DIRECTIVE" MEANS DIRECTIVE 2003/71/EC (AND AMENDMENTS THERETO, INCLUDING THE 2010 PD AMENDING DIRECTIVE, TO THE EXTENT IMPLEMENTED IN A RELEVANT MEMBER STATE), AND INCLUDES ANY RELEVANT IMPLEMENTING MEASURE IN THE RELEVANT MEMBER STATE AND THE EXPRESSION "2010 PD AMENDING DIRECTIVE" MEANS DIRECTIVE 2010/73/EU. IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED. IN CONNECTION WITH THE TRANSACTION, THE MANAGER AND ANY OF ITS AFFILIATES ACTING AS AN INVESTOR FOR THEIR OWN ACCOUNT MAY TAKE UP AS A PRINCIPAL POSITION ANY SHARES AND IN THAT CAPACITY MAY RETAIN, PURCHASE OR SELL FOR THEIR OWN ACCOUNT SUCH SHARES. IN ADDITION THE MANAGER OR ITS AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS AND SWAPS WITH INVESTORS IN CONNECTION WITH WHICH THE MANAGER (OR ITS AFFILIATES) MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SHARES. THE MANAGER DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATION TO DO SO. NO GUARANTEE CAN BE MADE THAT ANY SECURITIES WILL BE SOLD PURSUANT TO THE TRANSACTION. THE MANAGER IS ACTING ON BEHALF OF THE SELLERS AND NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANY OTHER PERSON FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF THE MANAGER OR FOR PROVIDING ADVICE IN RELATION TO THE TRANSACTION. This press release was submitted for publication on 15 august 2018 at 17.31 (CEST). This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Pihlajalinna Half Year Financial Report 1 January–30 June 2018 (6 months)

Pihlajalinna Plc     Half Year Financial Report     16 August 2018 at 8.00 a.m. Pihlajalinna Half Year Financial Report 1 January–30 June 2018 (6 months) Pihlajalinna’s result weighed down by expansion and structural reforms Brief look at April–June: • Revenue amounted to EUR 125.3 (106.7) million – an increase of 17.5 per cent • EBITDA amounted to EUR 5.6 (7.1) million • Adjusted EBITDA was EUR 6.6 (7.4) million • Operating profit (EBIT) was EUR 0.8 (3.7) million • Adjusted operating profit (EBIT) was EUR 1.9 (4.0) million • IFRS 3 costs and amortisation related to M&A transactions had a negative effect of EUR 1.8 (1.2) million on operating profit • Earnings per share (EPS) was EUR 0.00 (0.10) Brief look at January–June: • Revenue amounted to EUR 244.5 (216.7) million – an increase of 12.8 per cent • EBITDA amounted to EUR 9.9 (16.0) million • Adjusted EBITDA was EUR 10.5 (16.5) million • Operating profit (EBIT) was EUR 0.9 (9.1) million • Adjusted operating profit (EBIT) was EUR 1.6 (9.7) million • IFRS 3 costs and amortisation related to M&A transactions had a negative effect of EUR 4.0 (2.3) million on operating profit • The number of personnel at the end of the review period was 5,918 (4,898) • Earnings per share (EPS) was EUR -0.06 (0.25) Pihlajalinna’s outlook for 2018 Revised outlook for 2018 (published on 20 June 2018): Pihlajalinna’s consolidated revenue is expected to increase clearly from 2017 level especially due to M&A transactions. Adjusted EBIT is expected to remain below 2017 level. Previous outlook for 2018 (published on 13 February 2018): Pihlajalinna’s consolidated revenue is expected to increase clearly from 2017 level especially due to M&A transactions. Adjusted EBIT is expected to improve compared to 2017. In the financial year 2017, revenue was EUR 424.0 million and the adjusted EBIT was EUR 20.0 million. KEY FIGURES AND RATIOS  4–6/2018 4–6/2017 1–6/2018 1–6/2017 2017 3 months  6 months  6 months  12 months  3 months  INCOME STATEMENT    Revenue, EUR million  125.3  106.7  244.5  216.7  424.0 EBITDA, EUR million  5.6  7.1  9.9  16.0  33.3 EBITDA, %  4.4  6.7  4.0  7.4  7.9 Adjusted EBITDA, EUR 6.6  7.4  10.5  16.5  34.1 million* Adjusted EBITDA, %*  5.3  6.9  4.3  7.6  8.0 Operating profit (EBIT), 0.8  3.7  0.9  9.1  19.1 EUR million Operating profit, %  0.6  3.5  0.4  4.2  4.5 Adjusted operating 1.9  4.0  1.6  9.7  20.0 profit (EBIT), EURmillion* Adjusted operating 1.5  3.7  0.6  4.5  4.7 profit, %* Profit before tax (EBT), 0.2  3.3  -0.4  8.3  17.4 EUR million  SHARE-RELATEDINFORMATION Earnings per share 0.00  0.10  -0.06  0.25  0.46 (EPS), EUR Equity per share, EUR  5.18  4.84  4.87  OTHER INFORMATION Return on capital 5.1  10.6  11.8 employed (ROCE), % Return on equity (ROE), 5.9  11.8  13.6 Equity ratio, %  36.9  44.7  41.8 Gearing, %  78.8  32.4  32.3 Interest-bearing net 97.4  33.5  34.2 debt, EUR million Net debt/adjusted 3.5  1.1  1.0 EBITDA, 12 months* Gross investments, EUR 6.3  3.1  85.6  7.8  30.4 million** Cash flow from operating 0.5  0.8  3.0  14.3  34.9 activities, EUR million Cash flow after -5.0  -1.5  -42.7  8.0  16.4 investments, EURmillion Average number of 4,320  3,812  3,879 personnel (FTE) Personnel at the end of 5,918  4,898  4,753 the period (NOE)  * Significant transactions that are not part of the normal course of business, infrequently occurring events or valuation items that do not affect cash flow are treated as adjustment items affecting comparability between review periods. According to Pihlajalinna’s definition, such items include, for example, restructuring measures, impairment of assets and the remeasurement of previous assets held by subsidiaries, the costs of closing down businesses and business locations, gains and losses on the sale of businesses, costs arising from operational restructuring and the integration of acquired businesses, costs related to the termination of employment relationships, as well as fines and corresponding compensation payments. Pihlajalinna does not recognise as adjustments affecting comparability acquisition-related transfer taxes and expert fees (IFRS 3 costs) or purchase price allocation (PPA) amortisation.   EBITDA adjustments totalled EUR 1.1 (0.2) million for the quarter and EUR 0.7 (0.5) million for the review period. Adjustments to operating profit totalled EUR 1.1 (0.3) million for the quarter and EUR 0.7 (0.6) million for the review period.  ** Finance leases are not included in the gross investments  Joni Aaltonen, CEO of Pihlajalinna: "The Group’s revenue in the second quarter increased in line with expectations, but profitability declined compared to the previous year. EBITDA and the operating result continued to be weighed down by the start-up of new units, the lower profitability of occupational health services and the lower volume of reception centre services and surgical operations. While the result for the second quarter was better than the result for the first quarter, it was not at the level we aim to achieve. We have taken measures to improve profitability and the result for the second quarter represents a step in the right direction. The implementation of the planned measures will continue. As we announced in June, putting into practice the structural reforms we initiated early in the year has taken more time than we expected. While the first half of the year has been weak, we remain confident that our planned measures, reforms and new services will improve our profitability in the second half of the year. However, as we previously announced, they will not be sufficient to elevate our adjusted operating profit to last year’s level or above it. In June, Pihlajalinna increased its holdings in Pihlajalinna group companies that are jointly owned with municipalities. Pihlajalinna now owns 81 per cent of the share capital of Mäntänvuoren Terveys Oy and Kolmostien Terveys Oy as well as 90 per cent of the share capital of Jokilaakson Terveys Oy. In addition, the company signed a conditional agreement with the Kuusiokunnat municipalities according to which it will increase its holding in Kuusiolinna Terveys Oy to 97 per cent by the end of the year. Service provision contracts and the shareholders’ agreements of the companies remain unchanged. In July, Pihlajalinna announced its withdrawal from the freedom of choice experiment in Jyväskylä. As the capitation payment set by the City of Jyväskylä does not cover the costs, the experiment has been unprofitable. The freedom of choice experiments currently underway in different locations across Finland use different capitation criteria, and there are also differences between the services included in the experiments. Pihlajalinna is continuing its involvement in the freedom of choice experiments in Tampere and Hämeenlinna. The parliamentary Constitutional Law Committee issued a statement on the legislation package related to the reform of healthcare, social services and regional government at the beginning of June. The government amended the schedule of the healthcare and social welfare reform after the statement of the Constitutional Law Committee. The aim is to have parliament decide on all legislation pertaining to the reform of Finland’s regional government, healthcare and social services in autumn 2018, and for the responsibility for organising healthcare and social services to be transferred to the counties on 1 January 2021. County elections are planned for spring 2019. Pihlajalinna’s view is that there is still a strong need for health and social services reform and that the reform is worth implementing in spite of the drawbacks of the proposed model. In any case, the model must be reviewed and developed as more experience is accumulated. We are preparing for health and social services reform particularly by engaging in geographical expansion, but our strategy and growth are not dependent on the planned reforms. In our view, the health and social services reform would provide faster access to basic-level care while also improving service quality. Achieving the financial goals would largely depend on the counties’ capacity and willingness to take advantage of the opportunities presented to them, such as fixed compensation, a performance-based share and incentives. In our view, freedom of choice should be developed in such a way as to give the service providers of health and social services centres the obligation and the opportunity to take more extensive responsibility for customers, excluding demanding specialised care services. This could be achieved by introducing services from various specialised branches of medicine to the health and social service centres. This would allow customers to obtain care from a single location and avoid the fragmentation of the care path, unnecessary chains of referrals and needless bureaucracy." Pihlajalinna’s financial reporting in 2018 Interim Report January–September: Thursday, 1 November 2018 Briefing Pihlajalinna Plc will hold a briefing for analysts and the media on Thursday, 16 August 2018 at 10:00 a.m. in the Paavo Nurmi room at Hotel Kämp, Pohjoisesplanadi 29, 00100 Helsinki, Finland. Helsinki, 15 August 2018 Pihlajalinna Plc’s Board of Directors

ICA Gruppen interim report second quarter 2018

Second quarter 2018 in summary · Consolidated net sales amounted to SEK 29,258 million (27,940), an increase of 4.7% · Operating profit excluding items affecting comparability was SEK 1,041 million (1,094) · Operating profit excluding items affecting comparability includes costs of SEK 17 million (16) for the previously planned integration of IKI in Lithuania · Profit for the period was SEK 935 million (1,021). Profit includes capital gains on sales of non-current assets and impairment losses of SEK -90 million net (165) · Earnings per share were SEK 4.62 (5.06) · Positive tax effect of SEK 202 million from remeasurement of deferred tax liabilities and deferred tax assets due to the forthcoming reduction of the Swedish corporate tax rate · Cash flow from operating activities amounted to SEK 2,755 million (2,001). Excluding ICA Bank, cash flow was SEK 2,188 million (1,836) · Agreement signed with the British company Ocado on new e-commerce solution in Sweden After the end of the quarter · No significant events have taken place after the end of the quarter Comment from the CEO of ICA Gruppen, Per Strömberg: “The trends from the first quarter of the year continued into the second quarter - good sales growth, good momentum in e-commerce, strong cash flow and favourable earnings performance for several of the Group’s operations. At the same time, ICA Sweden showed weak earnings, where the favourable sales performance was not reflected in operating profit. Targeted measures are on-going to restore profitability.” For further information, please contact: Frans Benson, Head of Investor Relations tel. +46 8-561 500 20 ICA Gruppen press service Tel +46 10 422 52 52 Press and analyst meeting ICA Gruppen is arranging a press and analyst meeting on Thursday August 16 at 10.00 CET at IVA Grev Turegatan 16 in Stockholm. CEO Per Strömberg and CFO Sven Lindskog will present the interim report. The conference can also be followed at www.icagruppen.se/investerare. To call in, please dial:    SE +46856642695 UK +442030089809 Calendar 25 October 2018                   Q3 interim report 13 December 2018               Capital Markets Day 7 February 2019                   2018 year-end report This information is such that ICA Gruppen AB is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at time 07.00 CET on Thursday August 16, 2018.

Interim Report Q2, 2018

“In June, we successfully raised SEK 650m in conjunction with our listing on Nasdaq Stockholm to secure the funding necessary to initiate our pivotal Phase 3 study of our lead project Nefecon, for the treatment of the severe and under-treated disease IgA nephropathy (IgAN). We have worked diligently to prepare for the study, and we are now in a good position to launch it.” Summary of Q2 April 1 - June 30, 2018 · Net sales for the period was SEK - (-) million. · Net income (loss) for the period was SEK -18.2 (-16.1) million. · Earnings and diluted earnings per share was SEK -1.08 (-1.10). · At June 30, 2018, cash and cash equivalents amounted to SEK 17.0 (35.7) million. Significant events during the period April 1 – June 30, 2018 in summary · Calliditas Therapeutics was listed on Nasdaq Stockholm on June 29 in the Mid Cap segment and shares worth a value of SEK 650 million were subscribed for. · In connection with the listing, outstanding bridge loans of SEK 95.2 million were converted, including accrued interest, to new shares. · During the second quarter, 2018, the Company filed a new patent application. The application covers method of use for treatment of autoimmune diseases. Significant events after the end of reporting period · The liquidity from the rights issue of 650 MSEK, before deduction of issue costs, in connection with the listing was received in early July. · In July, the over-allotment option issued in connection with the listing was utilized, which resulted in the Company receiving an additional SEK 88.7 million, before deduction of issue costs. Key figures +-----------------+----------+----------++----------+----------++----------+| | Apr-Jun || Jan-Jun || Jan-Dec |+-----------------+----------+----------++----------+----------++----------+|Amounts in SEK | 2018| 2017|| 2018| 2017|| 2017||000s | | || | || |+-----------------+----------+----------++----------+----------++----------+| | | || | || |+-----------------+----------+----------++----------+----------++----------+|Expenses | (10,000)| (9,517)|| (41,531)| (16,756)|| (51,686)||relating to | | || | || ||research and | | || | || ||development | | || | || |+-----------------+----------+----------++----------+----------++----------+|Expenses | 54%| 62%|| 73%| 63%|| 61%||relating to | | || | || ||research and | | || | || ||development/opera| | || | || ||ting expenses, % | | || | || |+-----------------+----------+----------++----------+----------++----------+|Operating profit | (18,207)| (15,487)|| (56,464)| (26,496)|| (84,509)||(loss) | | || | || |+-----------------+----------+----------++----------+----------++----------+|Earnings per | (1.08)| (1.10)|| (3.37)| (1.99)|| (5.81)||share before and | | || | || ||after dilution, | | || | || ||SEK | | || | || |+-----------------+----------+----------++----------+----------++----------+|Total registered |33,232,347|14,775,000||33,232,347|14,775,000||16,673,000||shares at the | | || | || ||end of period | | || | || |+-----------------+----------+----------++----------+----------++----------+|Equity at the | 7,332| (10,066)|| 7,332| (10,066)|| 33,176||end of the | | || | || ||period | | || | || |+-----------------+----------+----------++----------+----------++----------+|Equity ratio at | 11%| neg|| 11%| neg|| 53%||the end of the | | || | || ||period % | | || | || |+-----------------+----------+----------++----------+----------++----------+|Cash and cash | 17,023| 35,670|| 17,023| 57,352|| 57,352||equivalents at | | || | || ||the | | || | || ||end of the | | || | || ||period | | || | || |+-----------------+----------+----------++----------+----------++----------+ Investor presentation August 16, 10:00 CEST Audio cast with teleconference, Q2, 2018, August 16, 2018, 10:00 (Europe/Stockholm) Webcast: https://tv.streamfabriken.com/calliditas-therapeutics-q2-2018 Teleconference: Dial-in number UK: +442030089811 SE: +46850556453 Financial calendar Interim report for the period 1 January – 30 September 2018, 1 November 2018 Year-end report for the period 1 January – 31 December 2018, 7 February 2019 For further information, please contact: Renée Aguiar-Lucander, CEO at Calliditas Email: renee.lucander@calliditas.com  Telephone: +46 722 52 10 06 Mikael Widell, Head of Communications at Calliditas Email: mikael.widell@calliditas.com Telephone: +46 703 11 99 60 The information in the press release is such that Calliditas Therapeutics AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07:00 CEST on August 16, 2018. About Calliditas Therapeutics Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. Visit www.calliditas.com for further information.

Stockmann Group's Half year financial report 1 January - 30 June 2018

STOCKMANN plc, Stock Exchange Release 16.8.2018 at 8:00 EET  April-June 2018, continuing operations:- Consolidated revenue was EUR 279.4 million (281.3).- Gross margin was 58.2% (56.1).- Adjusted operating result was EUR 23.8 million (14.6).- Reported operating result was EUR 29.6 million (14.6), including a capital gain of EUR 7.0 million from the divestment of the Book House property in Helsinki. January-June 2018, continuing operations:- Consolidated revenue was EUR 481.8 million (498.1).- Gross margin was 56.9% (54.9).- Adjusted operating result was EUR -1.0 million (-10.5).- Reported operating result was EUR 2.7 million (-10.5).- Adjusted earnings per share were EUR -0.37 and reported earnings per share were EUR -0.35(-0.42). Guidance for 2018 remains unchanged:Stockmann expects the Group’s revenue for 2018 to be on a par with the previous year. Adjusted operating profit is expected to improve in 2018. CEO Lauri Veijalainen:Our second quarter was a good quarter for the Group. The Group’s performance improved and the adjusted operating profit was up by nearly EUR 10 million. The gross margin continued to improve due to healthy inventory levels and reduced clearance sales. Lindex showed solid sales growth thanks to strong, renewed spring and summer collections which led to increased sales in all markets and channels. The tough but needed cost savings are also starting to bear fruit. The gross margin improved and subsequently the adjusted operating result increased by EUR 8 million. In Stockmann Retail, the Crazy Days campaign in April was a success, but sales were slower towards the end of the quarter. We aim to compensate the decline in revenue with an improved gross margin and cost savings throughout 2018, and thus to catch up with Retail’s performance improvement schedule targets. However, Stockmann Retail is not expected to reach a positive operating result for the full year. Digital projects aiming at increasing sales are also under way. Real Estate’s performance continued as planned. Based on customer feedback, we introduced several new restaurants and cafés in our department stores during the quarter. The divestment of the Book House in Helsinki was completed. Investigations into the possible divestment of the Nevsky Centre in St Petersburg are being actively pursued. In the autumn, we will continue to speed up our strategic projects, particularly digital acceleration, in order to reach the growth targets and improve our profitability. Due to seasonality, the most important months are ahead of us, in the second half of 2018. KEY FIGURES Continuing operations 4-6/ 4-6/ 1-6/ 1-6/ 1-12/ 2018 2017 2018 2017 2017Revenue, EUR mill. 279.4 281.3 481.8 498.1 1 055.9Gross margin, % 58.2 56.1 56.9 54.9 55.8EBITDA, EUR mill. 43.5 29.5 30.8 19.4 67.6Adjusted EBITDA, EUR mill. 37.7 29.5 27.1 19.4 73.2Operating result (EBIT), EUR 29.6 14.6 2.7 -10.5 -148.4mill.Adjusted operating result (EBIT), 23.8 14.6 -1.0 -10.5 12.3EUR mill.Net financial items, EUR mill.* -8.8 -10.8 -17.5 -15.4 -31.1Result before tax, EUR mill. 20.8 3.8 -14.8 -25.9 -179.5Result for the period, EUR mill. 8.0 -1.1 -22.9 -28.0 -198.1Earnings per share, 0.09 -0.03 -0.35 -0.42 -2.82undiluted and diluted, EURPersonnel, average 7214 7224 7144 7217 7 360 Continuing and discontinued 4-6/ 4-6/ 1-6/ 1-6/ 1-12/operations** 2018 2017 2018 2017 2017Net earnings per share, 0.09 -0.09 -0.35 -0.52 -2.98undiluted and diluted, EURCash flow from operating 79.7 48.2 17.9 -29.9 25.9activities, EUR mill.Capital expenditure, EUR mill. 7.4 7.9 15.1 15.7 34.7Equity per share, EUR 11.92 14.32 12.29Net gearing, % 72.7 76.5 83.8Equity ratio, % 45.7 46.9 43.0Number of shares, undiluted and 72 049 72 049 72 049diluted, weighted average, 1 000pcReturn on capital employed, -8.3 1.3 -9.1rolling 12 months, % * Includes a write-off of EUR 3.8 million related to Stockmann’s investment in Tuko Logistics Cooperative (Q2 2017), EUR 2.0 million related to Seppälä (Q3 2017), and EUR 1.5 million related to Hobby Hall (Q4 2017).** Discontinued operations include Stockmann Delicatessen food operations in Finland (2017). Items affecting comparability EUR million 4-6/ 4-6/ 1-6/ 1-6/ 1-12/ 2018 2017 2018 2017 2017Adjusted EBITDA 37.7 29.5 27.1 19.4 73.2Adjustments to EBITDARestructuring arrangements -1.2 -3.3 -9.6Fair value gains and losses on 4.0investment propertiesGain on sale of properties 7.0 7.0Adjustments total 5.7 3.7 -5.6EBITDA 43.5 29.5 30.8 19.4 67.6 EUR million 4-6/ 4-6/ 1-6/ 1-6/ 1-12/ 2018 2017 2018 2017 2017Adjusted operating result (EBIT) 23.8 14.6 -1.0 -10.5 12.3Adjustments to EBITLindex goodwill impairment -150.0Restructuring arrangements -1.2 -3.3 -14.6Fair value gains and losses on 4.0investment propertiesGain on sale of properties 7.0 7.0Adjustments total 5.7 3.7 -160.6Operating result (EBIT) 29.6 14.6 2.7 -10.5 -148.4 Stockmann uses Alternative Performance Measures according to the guidelines of the European Securities and Market Authority (ESMA) to better reflect the operational business performance and to facilitate comparisons between financial periods. Gross profit is calculated by deducting the costs of goods sold from the revenue, and gross margin is calculated by dividing gross profit by the revenue as a percentage. EBITDA is calculated from the operating result excluding depreciation, amortisation and impairment losses. Adjusted EBITDA and adjusted operating result (EBIT) are measures which exclude non-recurring items and other adjustments affecting comparability from the reported EBITDA and the reported operating result (EBIT). OUTLOOK FOR 2018 In the Stockmann Group’s largest operating countries, Finland and Sweden, the general economic situations have improved and according to forecasts by the national central banks, the GDP growth is expected to continue in 2018. Consumer confidence is also estimated to continue its positive development. However, purchasing behaviour is changing due to digitalisation and increasing competition. This is reflected in the outlook for the fashion market, which according to Stockmann’s management estimate is not developing as well as the economy in general. In the Baltic countries, the outlook for the retail trade is, according to the management estimate, expected to be better than that for the Stockmann Group’s other market areas. Stockmann will continue to improve the Group’s long-term competitiveness and profitability. The efficiency measures launched at Lindex at the end of 2017, and at Stockmann at the beginning of 2018, have mostly been implemented and they will be fully visible in the 2019 operating costs. Capital expenditure for 2018 is estimated to be approximately EUR 40-45 million, which is less than the estimated depreciation for the year. GUIDANCE FOR 2018 Stockmann expects the Group’s revenue for 2018 to be on a par with the previous year. Adjusted operating profit is expected to improve in 2018. Half year financial reportThis company announcement is a summary of the Stockmann's Half year finacial report for 1 January – 30 June 2018 and includes the most relevant information of the report. The complete report is attached to this release as a pdf file and is also available on the company's website at stockmanngroup.com . Press and analyst briefing and webcastA press and analyst briefing will be held today, on 16 August 2018 at 10:00 a.m. EET in the Fazer À la Carte restaurant on the 8th floor of Stockmann’s Helsinki city centre department store, Aleksanterinkatu 52 B. The event can be followed as a live webcast by this link  or on the address stockmanngroup.com.  To participate in the webcast, please dial one of the numbers below 5–10 minutes before the webcast begins. The recording and presentation material are available on the company's website after the event. Finland: +358 (0)9 7479 0360Sweden: +46 (0)8 5033 6573United Kingdom: +44 (0)330 336 9104United States of America: +1 323 974 2095 Confirmation code: 424569 Further information:Lauri Veijalainen, CEO, tel. +358 9 121 5062Kai Laitinen, CFO, tel. +358 9 121 5800 www.stockmanngroup.com STOCKMANN plc Lauri VeijalainenCEO Distribution:Nasdaq HelsinkiPrincipal media

Interim report January–June 2018

SECOND QUARTER• Group revenue increased by 41 percent to MSEK 753 (536), with organic revenue growth amounting to 39 percent (37).• Profitability improved, and EBITDA increased by 78 percent to MSEK 165 (93) and the EBITDA margin was 22 percent (17).• Profit for the period amounted to MSEK 91 (15).• Earnings per share before and after dilution amounted to SEK 0.77 (0.03) and SEK 0.76 (0.03) respectively.• The Board of Directors appointed Gunnar Lind as Acting CEO.• Cherry has completed the acquisition of 44 percent of the shares in the affiliate company, Game Lounge, with Cherry now holding 95 percent of shares outstanding. The purchase consideration amounted to MEUR 9.8 and 1,554,017 newly issued shares in Cherry AB.• A further 7.5 percent of the shares in the online gaming company Almor Holding were acquired, with Cherry now holding 90 percent of the shares outstanding. The purchase consideration amounted to MEUR 2.2 and 299,504 newly issued shares in Cherry AB. SIX MONTHS• Group revenue increased by 33 percent to MSEK 1,434 (1,077), with organic revenue growth amounting to 32 percent (40).• Profitability improved, and EBITDA increased by 103 percent to MSEK 357 (176) and the EBITDA margin was 25 percent (16).• Profit for the period amounted to MSEK 180 (51).• Following new share issues, the number of shares has increased to 4,988,000 Class A shares and 100,680,026 Class B shares, as of 30 June 2018, totalling 105,668,026 shares.• Earnings per share before and after dilution amounted to SEK 1.56 (0.27) and SEK 1.55 (0.26) respectively. EVENTS AFTER THE END OF THE PERIOD• On 3 July, Cherry was granted a sports betting license in Poland.• On 7 August Cherry exercised its option to acquire an additional 7.8 percent of the shares in the gaming specialist Highlight Games. Cherry also acquired shares corresponding to 15.1 percent in the company and now holds of 60.4 percent of the shares outstanding in Highlight Games.• On 9 August Game Lounge acquired two premium domains in North America, BetNJ.com for sports betting and casino in New Jersey, and the Mexican domain OnlineCasino.mx. Comments by the CEO“Strong and broad operations”  With a revenue increase of 41 percent, of which organic growth amounted to 39 percent, the quarter was characterized by expansion and investment. Investments during the quarter were made primarily in the marketing of existing and new brands, and of games developed in-house by Yggdrasil and Highlight Games. Cherry has strong and broad operations meeting the market’s demand for quality in everything we deliver, and it is gratifying to note that July demonstrated that our investments have generated returns in line with our expectations. The second quarter of 2018 was characterized by a focus on growth, in the short term as well as long term. Investments in marketing were significant and effective. Online Gaming is expanding and strengthening its position in key markets, while the business area’s new brands are also rapidly building awareness and establishing a good customer base. Game Development and Online Marketing have also acted proactively through increased investment in game development, acquisitions and a clearer presence in Sweden. To me, as acting CEO, this is a secure situation providing opportunities to continue strengthening Cherry in its core markets and, in parallel, to assess complementary growth alternatives. Over the quarter, the Group’s revenues increased from MSEK 536 to MSEK 753 and EBITDA increased by 78 percent, from MSEK 93 to MSEK 165. The foremost individual explanation for this trend is continued favourable development within the Online Gaming business area. The gaming operator holds a strong market position and has launched new brands meeting the market’s wishes. Beyond this, company management, now with permanent CEO Lahcene Merzoug at the helm, is continuing to optimize the cost base. Cherry’s subsidiary Almor, including the German brands Sunmaker and Sunnyplayer Casino, experienced one of its strongest quarters, thereby strengthening Cherry’s market position in the regulated Schleswig-Holstein market (Germany). Game developer Yggdrasil had an active quarter that included the launch of five new games, including “Sonya Blackjack”, the first game in the new “Table Games” product vertical. During the quarter, Yggdrasil signed distribution agreements with 13 operators. The number of employees (FTE) of Yggdrasil at the end of the period was 243 (134). Following the end of the period, a global distribution agreement was reached with 888 Holdings, one of the world’s most popular gaming operators. An agreement was also reached with Intralot, which has a strong position in Italy, complementing Yggdrasil’s existing collaboration with Lottomatica. In April, Northern Lights became the first independent game studio to use Yggdrasil’s partner program, YGS Masters, and we make the assessment that this will be an excellent way to collaborate with companies in early phases of development. Following the end of the quarter, Yggdrasil was also certified for the fast-growing Spanish market – an important milestone in Yggdrasil’s strategy to grow in regulated markets. At the beginning of the year, Highlight Games launched its virtual soccer game, SOCCERBET, in selected African markets, while the company also prepared for its introduction in Italy. During the third quarter, Highlight Games, alongside Eurobet and other leading Italian operators, will launch the game in Italy, where the virtual gaming market is expected to generate sales of some EUR 2 billion in 2018, as assessed by the independent data specialist H2 Gambling Capital. Highlight Games has favourable prospects of capturing significant market share, thus Cherry has acquired additional shares in the company and Cherry’s holdings in August totalled 60.4 percent and, accordingly, consolidated as a subsidiary effective from August 2018. The Group’s affiliate company, Game Lounge, is developing according to plan. The company has established a new office in Stockholm and has a total of 60 employees. During the quarter, Game Lounge acquired assets, including some 1,500 websites, various search engine optimization (SEO) tools and services, and a team of ten employees with unique SEO expertise to aid the expansion of the company into new verticals. In August, Game Lounge acquired two premium domains in North America, which will be important bridgeheads in New Jersey and Mexico.In June, we were able to complete the acquisitions of additional shares in subsidiaries Game Lounge and Almor Holding. The payment for the additional 44 percent and 7.5 percent respectively consisted in part of new shares in Cherry AB, now bringing the total number of shares in the company to 105,668,026. Both companies are experiencing a positive development trend, and with Cherry’s support, we perceive good opportunities for them to develop at a higher pace and with a broader offering. During the quarter, the Board took the decision to terminate Anders Holmgren’s employment as the President and CEO of Cherry. At the same time, the Board resolved to appoint the undersigned as CEO until a permanent CEO has been appointed. With my previous experience as CEO of Cherry and as a Board member in the company, I was able to get started relatively quickly. The recruitment of a permanent President and CEO has been initiated and includes both internal and external candidates. I am sure the Board of Directors is doing a thorough job and, as its work progresses, I am focusing on developing the Group in accordance with the established strategy, supported well by all employees. Gunnar LindActing President and CEO MARKET OUTLOOKThe gaming market is currently growing strongly and Cherry estimates that demand in the Group’s largest geographic markets will continue to develop favourably. The Group continuously studies conditions for new business within the related business areas and geographic markets in and outside Europe. The Group’s focus is on generating shareholder value by being an active participant in the development of new and existing companies in the gaming, media and entertainment sector. The objective is for the companies to become market leaders in their respective areas by building their core values of entrepreneurship, responsibility and commitment. These are important prerequisites for the Group to be able to achieve its financial targets and to continue its successful profitable growth, through both organic growth and acquisitions, in existing and new verticals and geographic markets. PRESENTATION OF THE INTERIM REPORTThe company’s Executive Chairman, Morten Klein, Acting President and CEO, Gunnar Lind, and CFO Christine Rankin, will present and comment on the report at a telephone conference at 10:00 a.m. CET on 16 August 2018. The presentation materials will be available approximately one hour earlier at www.cherry.se. The presentation can be followed via www.cherry.se and/or www.financialhearings.com. To participate by phone, call +46 8-566 426 97 (SE) or +44 203 008 9807 (UK). For further information, please contact: Christine Rankin, CFO, Telephone: +46 76 539 94 92, christine.rankin@cherry.se  Anders Antonsson,  IR & Communications, Telephone: +46 709 994 970, anders.antonsson@cherry.se (carolina.stromlid@cherry.se)  CHERRY IN BRIEF Cherry is an innovative and fast-growing gaming company with operations in gaming, entertainment and media. The company was founded in 1963 and today, Cherry operates through five diversified business areas: Online Gaming, Game Development, Online Marketing, Gaming Technology and Restaurant Casino. The objective is to grow organically in combination with strategic acquisitions of fast-growing companies. Cherry employs some 1,400 people and has about 9,250 shareholders. The company’s class B-share has been listed on the Nasdaq Stockholm exchange, Mid Cap segment since 18 October 2017.

MIPS INTERIM REPORT JANUARY - JUNE 2018

CEO’S COMMENTS STRONG DEVELOPMENT IN THE QUARTERWith a growth of over 50% and an almost doubled operating profit during the quarter, I am pleased that MIPS continues to develop in line with its long-term plan. Net sales, adjusted for currency effects, increased during the quarter by 53% to SEK 55.6m. During the first six months, net sales, adjusted for currency effects, increased by 42% to SEK 79.1m. The sales increase is driven by the fact that more and more helmet models from leading brands are now being marketed with MIPS BPS. After a soft start at the beginning of the year in the snow category, sales for this category increased during the second quarter, while the important bicycle and motorcycle categories continued to grow strongly. Growth and our scalable business model contributed to improve our adjusted operating profit to SEK 21.7m (11.5) with an adjusted operating margin of 39.0% (31.5) during the second quarter. For the first half of the year, adjusted operating profit improved to SEK 23.4m (13.1) and the adjusted operating margin increased to 29.6% (22.7). INCREASED PENETRATION WITH OUR KEY CUSTOMERSSeveral world leading helmet brands have expanded their range of models with MIPS BPS during the year. Through close development cooperation and sales support training, we have succeeded in ensuring that several brands now offer product lines where MIPS BPS is largely implemented in all models. MIPS BPS VALIDATED BY EXTERNAL TESTSIn United States, Virginia Tech University has developed a rating method for bicycle helmets that includes testing of rotational motion and its impact. The rating method is based on research and considers the forces that arise in an oblique fall. In the tests carried out, all top-rated helmets (5 stars) were equipped with MIPS BPS. Virginia Tech's rating system is similar to the car industry's Euro NCAP and will help guide consumers at the time of purchase. We have previously seen similar tests and results in Swedish tests conducted by Swedish insurance companies and other test institutes. It is positive to see that testing helmets for rotational motion is now also conducted internationally and that MIPS’ technology has once again been confirmed as having a positive impact. INCREASED INTEREST IN SEVERAL AREASAt Eurobike in Germany, the world's largest bicycle fair, MIPS’ successful progress continued. More helmets than ever, equipped with MIPS BPS were exhibited and the major helmet manufacturers presented MIPS BPS in their product ranges in a more prominent way than previously. It is apparent that professional users are also increasingly concerned about their personal safety; half of all the cyclists in the two major bike races “Tour de France” and “Giro d’Italia” were using MIPS BPS helmets. We are proud to help ensure that so many more athletes have improved protection. LEADING POSITION AND EXCITING FUTUREDuring the first half of the year we have successfully protected our intellectual property rights and concluded legal processes. We will defend and strengthen our intellectual property rights. MIPS research is conducted in collaboration with the Royal Institute of Technology and together with our own ongoing product development activities, it gives us a unique position in the industry. We are a team that represents an unbeatable base of knowledge and experience that is highly appreciated by our partners. We are constantly working to provide an even better preventive protection for active people. I am pleased with the company’s and our customers' development. With MIPS ability to translate research results into commercially successful products, we have a strong foundation to achieve our 2020 goals. Johan ThielPresident and CEO FOR FURTHER INFORMATION, PLEASE CONTACT: Johan Thiel, President and CEOJohan.Thiel@Mipsprotection.comphone +46 73 399 65 88 Max Strandwitz, CFOMax.Strandwitz@Mipsprotection.comphone +46 70 961 17 54 This information is such that MIPS AB (publ) is obliged to disclose in accordance with the EU’s Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 16 August 2018 at 7.30 a.m. CET. MIPS will present the Interim report at a teleconference on 16 August 2018 at 10.00 a.m. CET. To participate, please register at: http://emea.directeventreg.com/registration/6066408 ABOUT MIPSMIPS is a world-leader in helmet-based safety and the protection of the brain. Based on an ingredient brand business-model, MIPS Brain Protection System (“BPS”) is sold to the global helmet industry. The BPS solution, which is patented in all relevant markets, is based on 20 years of research and development together with the Royal Institute of Technology and the Karolinska Institute, both located in Stockholm, Sweden. MIPS headquarter with 26 employees engaged in research and development, sales and administration is in Stockholm, where its product and technology test facility is also located. Production and manufacturing operations take place at sub-contractor facilities. MIPS is traded on the Nasdaq Stockholm stock exchange. For more information, visit www.mipscorp.com.

Nexam Chemical Holding AB (publ) Interim Report 1 January – 30 June 2018

Second quarter at a glance Operational: ·NEXAMITE® qualified in commercial standard product. ·Organization strengthened with additional key resources. ·Increased extruder capacity in Hungary. ·Purchasing project initiated to reduce material cost. ·High utilization of capacity in St Andrews leads to increased outsourcing of intermediary products. Financials: ·Net sales for the second quarter totaled SEK 27,623,000 (4,577,000). ·The operating loss before depreciation (EBITDA) for the quarter SEK -471,000 (-5,209,000). ·In comparison to the beginning of the year, cash and cash equivalents amounted to SEK 68,973,000 (86,407,000). ·Cash flow from operating activities during quarter was SEK -2,257,000 (-4,762,000). ·Result per share after dilution for the quarter was SEK -0.04 (-0.09). Lomma 16 August 2018 The Board of Directors These financial statements have not been reviewed by the Company´s auditor. Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Anders Spetz, CEO, +46-703 47 97 00, anders.spetz@nexamchemical.com This information is information that Nexam Chemical Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on August 16, 2018. ___________________________________________________________________________ About Nexam Chemical Nexam Chemical develops technology and products that make it possible to significantly improve the production process and properties of most types of plastics in a cost-effective manner and with retained production technology. The improved properties include strength, toughness, temperature and chemical resistance as well as service life. The improvements in properties that can be achieved by using Nexam Chemical's technology make it possible to replace metals and other heavier or more expensive materials with plastics in a number of applications. In applications where plastic is already used, Nexam Chemicals products can improve the manufacturing process, reducing material use and enable more environmental friendly alternatives. Example of commercial applications: pipe manufacturing, foam production and high-performance plastics. More information about the business will be found on www.nexamchemical.com. The company´s Certified Adviser is FNCA Sweden AB.

Management changes in AB Electrolux

· Kenneth L. Ng, currently Head of Major Appliances APAC and Executive Vice President of AB Electrolux, has decided to retire from the company. · The major appliances organization in Middle East and Africa (MEA), which is currently part of Major Appliances Europe, Middle East and Africa (EMEA), will be included in Major Appliances Asia Pacific (APAC). Dan Arler, currently Head of Major Appliances Europe, Middle East and Africa (EMEA) and Executive Vice President of AB Electrolux, has been appointed Head of Major Appliances APAC & MEA and Executive Vice President of AB Electrolux.   · Anna Ohlsson-Leijon, currently Chief Financial Officer (CFO) of AB Electrolux, has been appointed Head of Major Appliances Europe and Executive Vice President of AB Electrolux.  · Therese Friberg, currently CFO of Major Appliances EMEA, has been appointed new CFO of AB Electrolux.   · The management changes are effective as from October 1, 2018 and the change in the business area organizational structure from January 1, 2019.   “Ken has made significant contributions to our company since he joined Electrolux in 2015. Under his leadership, Electrolux has successfully strengthened its position in Southeast Asia and Australia, and created a new foundation for growth in China. I wish him all the best for the future,” said Jonas Samuelson, President and CEO of Electrolux. “I am very pleased that Electrolux through structured succession planning have three strong leaders in Dan, Anna and Therese to take on their new and important roles within the Group Management team. Merging the two organizations within APAC and MEA, which are regions with similar market dynamics, will position Electrolux well to drive future growth.” Dan Arler has been Head of Major Appliances EMEA since January 2016. He previously held the position as Senior Vice President of the Kitchen product line within the same business area. He has been with Electrolux since 2002, with previous responsibilities including heading the Laundry product line in Asia-Pacific, General Manager of Electrolux Japan and heading the Electrolux brand’s business activities in EMEA. Anna Ohlsson-Leijon has been Group CFO since February 2016. She held the position as CFO of Major Appliances EMEA from 2013-2016. Anna joined Electrolux in 2001 as Director of Project Management. She has since held senior management positions including Head of the Group’s internal audit function, Group Treasurer and Head of Corporate Control & Services. Therese Friberg was appointed CFO of Major Appliances EMEA in 2016. Therese joined the company in 1999 and has held several positions within the company, including Head of Group Business Control, Sector Controller Home Care & SDA, Pricing Manager EMEA and Product Line Kitchen Controller EMEA. She is a Swedish citizen and holds a Bachelor of Science degree in Business Administration from Stockholm University, Sweden. Electrolux plans to publish restated financial information for earlier periods for the business areas Major Appliances Europe and Major Appliances APAC & MEA in connection with the release of the Q4 interim report on February 1, 2019.

INTERIM REPORT, January–June 2018

Second quarter of 2018 · Consolidated net sales increased by 22 percent to SEK 736 m (603), of which organic growth amounted to 2 percent. Acquisitions contributed by 16 percent and currency by 4 percent · Net sales in Products & Solutions amounted to SEK 565 m (430) and Installation Services to SEK 201 m (207) · EBITDA before items affecting comparability increased by 21 percent to SEK 96 m (79) · Operating profit (EBIT) before items affecting comparability increased by 10 percent to SEK 79 m (72) · Operating profit (EBIT) amounted to SEK 76 m (65) · ROCE before items affecting comparability on rolling 12 months basis was 15.2 percent (16.9) · Operating cash flow amounted to SEK 41 m (-12) · Earnings per share before and after dilution were SEK 2.43 (2.13) · A dividend of SEK 3.75 (3.75) per share was paid January–June 2018 · Consolidated net sales increased by 23 percent to SEK 1,210 m (983), of which organic growth amounted to 2 percent. Acquisitions contributed by 18 percent and currency by 3 percent · Net sales in Products & Solutions amounted to SEK 932 m (729) and Installation Services to SEK 320 m (303) · EBITDA before items affecting comparability increased by 24 percent to SEK 117 m (94) · Operating profit (EBIT) before items affecting comparability increased by 6 percent to SEK 85 m (80) · Operating profit (EBIT) amounted to SEK 79 m (69) · Operating cash flow amounted to SEK -20 m (-29) · Earnings per share before and after dilution were SEK 2.30 (2.07) Message from the CEOStrong second quarter with earnings growthConsolidated net sales for the second quarter rose by 22 percent compared with last year, from SEK 603 m to SEK 736 m. Acquisitions contributed 16 percent, organic growth was 2 percent and currency exchange rate effects was 4 percent.At SEK 79 m, EBIT before items affecting comparability was above last year’s profit of SEK 72 m, an increase of 10 percent. At the same time, EBITDA increased 21 percent to SEK 96 m compared with SEK 79 m in the corresponding period in the preceeding year.Veg Tech, our third acquisition this year, was completed after the reporting period in the beginning of July, in line with our commitment to develop our business towards sustainable and environmentally efficient solutions. The Swedish company Veg Tech, a leading specialist in green roofs and multifunctional vege-tation systems, has annual sales of SEK 125 m within a segment benefiting from growing demand.The consolidated net sales growth of 22 percent in the second quarter was driven by the strong roofing and infrastructure markets in Sweden and Denmark but also the prefabricated elements business in both Denmark and Norway. While our Products & Solutions operating segment reported a sales increase of 31 percent, our Installation Services operating segment decreased 3 percent as a deliberate and direct consequence of our more selective project approach and efforts to increase profitability in the Finnish installation services business.Within our Products & Solutions segment, Denmark continued to see a favorable demand trend and Sweden showed returning growth following the long and cold winter during the first quarter. We are implementing a second sales price increase for our bitumen based products with effect from the end of the third quarter, to adress recent further bitumen price increases.In both Denmark and Norway, the prefabricated elements business continue to develop very well and enjoys strong order intake.The profit improvement program within our flat roof installation services business in Finland is developing according to plan within the larger unit in Finland, and our efforts, including a more selective approach towards roofing projects and the execution of the projects, are starting to show positive financial effects are visible as of mid-2018. Our Danish franchise companies continued to perform well during the second quarter, with strong order books and an EBIT contribution in line with the preceding year.The continued strength in the Danish market has led to some capacity constraints in terms of finding and hiring skilled and qualified roofers. In September, we are therefore starting up a co-operation and a trainee program together with the Vejen municipality and roofing companies throughout Denmark. The program aims to educate, increase the interest and prepare young adults to be able and willing to pursue a future career within roofing, as we foresee a continued lack of skilled roofers in the coming years.As of the beginning of July, after the reporting period, I am pleased to welcome Veg Tech and our new colleagues to our Group. Veg Tech's solid position in vegetation technology and green roofs is a perfect complement to our existing offering of high-quality waterproofing solutions. Through the acquisition of Veg Tech, we demonstrate and enhance our commitment towards sustainable and environmentally efficient solutions for the building industry. Veg Tech is operated as a separate business unit within the Products & Solutions segment, and Bengt-Erik Karlberg, Head of Veg Tech, is as of today a new member of the Group Management of Nordic Waterproofing.Vejen, 16 August 2018Martin Ellis,President and CEO   Conference callA conference call for investors, analysts and media will be held today, 16 August 2018, at 10:00 a.m. CEST and can be joined online at www.nordicwaterproofing.com . Presentation materials for the call will be available on the website one hour before the call.  To participate, please dial: From the United Kingdom: +44 20 3008 9806From Denmark: +45 35 44 55 75From Sweden: +46 8 566 193 53   Further information can be obtained from Martin Ellis, President and CEO tel: +45 31 21 36 69Jonas Olin, CFO & Investor Relations tel: +46 708 29 14 54   This information is information that Nordic Waterproofing Holding A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 16 August 2018, 08:00 a.m. CEST.

Results of Placing in Oncopeptides AB

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA.  PRESS RELEASE 16 August 2018 Sale of 1,200,000 existing shares in Oncopeptides by Industrifonden Further to the announcement by Stiftelsen Industrifonden ("Industrifonden"), on 15 August 2018, Industrifondenannounces it has sold 1,200,000 existing shares in Oncopeptides AB (publ) ("Oncopeptides" or the "Company"), equivalent to approximately 2.73% of the existing share capital and voting rights in Oncopeptides, to institutional investors pursuant to an accelerated bookbuild offering at a price of SEK 148.00 per share (the "Transaction").Jefferies International Limited, (the "Manager") acted as Sole Bookrunner on the Transaction.  Following settlement of the Transaction, Industrifonden's holding of shares in Oncopeptides will be reduced to 10,420,805 shares corresponding to approximately 23.67% of the existing share capital and voting rights in the Company. Subject to customary exceptions or obtaining consent from the Manager, Industrifonden will not make additional sales of shares in Oncopeptides for a period of 90 days. Oncopeptides will not receive any proceeds from the Transaction.     IMPORTANT NOTICE  THIS ANNOUNCEMENT IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA.  THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE INTO THE UNITED STATES.  THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN APPLICABLE EXEMPTION FROM REGISTRATION.  NO PUBLIC OFFERING OF SECURITIES IS BEING MADE IN THE UNITED STATES.  THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES OR INVESTMENTS FOR SALE OR A SOLICITATION OF AN OFFER TO BUY SECURITIES OR INVESTMENTS IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO ACTION HAS BEEN TAKEN THAT WOULD PERMIT AN OFFERING OF THE SECURITIES OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.  IN MEMBER STATES OF THE EUROPEAN ECONOMIC AREA ("EEA") WHICH HAVE IMPLEMENTED THE PROSPECTUS DIRECTIVE (EACH, A "RELEVANT MEMBER STATE"), THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED EXCLUSIVELY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE PROSPECTUS DIRECTIVE ("QUALIFIED INVESTORS"). FOR THESE PURPOSES, THE EXPRESSION "PROSPECTUS DIRECTIVE" MEANS DIRECTIVE 2003/71/EC (AND AMENDMENTS THERETO, INCLUDING THE 2010 PD AMENDING DIRECTIVE, TO THE EXTENT IMPLEMENTED IN A RELEVANT MEMBER STATE), AND INCLUDES ANY RELEVANT IMPLEMENTING MEASURE IN THE RELEVANT MEMBER STATE AND THE EXPRESSION "2010 PD AMENDING DIRECTIVE" MEANS DIRECTIVE 2010/73/EU.  IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS (I) WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER") OR (II) WHO FALL WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, AND (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED.  IN CONNECTION WITH THE TRANSACTION, THE MANAGER AND ANY OF ITS AFFILIATES ACTING AS AN INVESTOR FOR THEIR OWN ACCOUNT MAY TAKE UP AS A PRINCIPAL POSITION ANY SHARES AND IN THAT CAPACITY MAY RETAIN, PURCHASE OR SELL FOR THEIR OWN ACCOUNT SUCH SHARES. IN ADDITION THE MANAGER OR ITS AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS AND SWAPS WITH INVESTORS IN CONNECTION WITH WHICH THE MANAGER (OR ITS AFFILIATES) MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SHARES. THE MANAGER DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATION TO DO SO.  NO GUARANTEE CAN BE MADE THAT ANY SECURITIES WILL BE SOLD PURSUANT TO THE TRANSACTION.  THE MANAGER IS ACTING ON BEHALF OF THE SELLERS AND NO ONE ELSE IN CONNECTION WITH THE TRANSACTION AND WILL NOT BE RESPONSIBLE TO ANY OTHER PERSON FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF THE MANAGER OR FOR PROVIDING ADVICE IN RELATION TO THE TRANSACTION.  This press release was submitted for publication on 16 August 2018 at 08:00 (CEST).  This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

YIT and Telia Finland agree on leasing the Tripla offices

YIT and Telia Finland have signed a long-term lease agreement on the Tripla Workery East offices under construction in Pasila, Helsinki, Finland. The agreement covers approximately 21,000 square metres in the easternmost quarter of Tripla above the new Pasila station. With the agreement, the occupancy rate of the Tripla Workery East offices will be approximately 80 per cent. The construction of the offices started in the beginning of 2018, and Telia Finland plans to move in during March 2020. Tripla is a three-block complex in Central Pasila to be completed in phases in 2019–2020 with the Mall of Tripla shopping centre, a parking garage, a public transportation hub, apartments, a hotel and offices. The offices cover totally approximately 50,000 square metres. “We investigated several possible locations for our new office and found the Tripla Centre in Pasila to best meet our requirements. Tripla’s location as a transport hub is an unbeatable advantage, and its services will also be extremely extensive. Our new head office will become a great meeting place for our customers and ecosystem partners, an inspiring working environment for our employees as a flexible space that can meet the future needs of the New Generation Telco”, says Stein-Erik Vellan, CEO, Telia Finland. The agreement includes the sale of Telia Finland’s current head office buildings in Vallila, Helsinki, to YIT. Additionally, YIT and Telia Finland are negotiating on the possibility of establishing a real estate development joint venture. The buildings to be bought cover approximately 50,000 square metres, and the plan is to develop there versatile modern office spaces to cover various end-uses.   ”We are happy to be able to offer Telia Finland new offices in the future Tripla centre. Additionally, we look forward to the opportunity to develop the entire Central Pasila area as a whole, combining comfortable living, modern multi-use offices as well as extensive services and traffic connections,” says Esa Neuvonen, Executive Vice President, Business premises segment, YIT Corporation.  For further information, please contact: Hanna Jaakkola, Vice President, Investor Relations, YIT Corporation, tel. +358 40 5666 070, hanna.jaakkola@yit.fi   Esa Neuvonen, Executive Vice President, Business premises and Partnership properties segments, YIT Corporation, tel. +358 40 500 1003, esa.neuvonen@yit.fi YIT Corporation Hanna Jaakkola Vice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com  YIT is the biggest construction company in Finland and a major player in Northern Europe. We construct and develop apartments, business premises and entire residential areas. Furthermore, we are specialists in infrastructure construction and paving. Together with our customers, our 10,000 professionals create increasingly functional, appealing and sustainable cities and living environments. We have operations in 11 countries: Finland, Russia, Scandinavian and Baltic countries, the Czech Republic, Slovakia and Poland. The new YIT was created by the merger of YIT Corporation and Lemminkäinen Corporation, both over 100 years old, on February 1, 2018. In 2017, our pro forma revenue amounted to over EUR 3.8 billion. YIT Corporation’s share is listed on Nasdaq Helsinki. www.yitgroup.com 

Kleresca® receives CE mark approval for the next generation biophotonic system in dermatology

For Kleresca®, the CE mark approval is the foundation for future expansion in both Europe, US, Canada and Australia. It confirms that the product meets the requirements of the European Medical Device Directive. “The CE mark approval is a significant accomplishment for Kleresca® as it is based on a quality management system that we have tailored to our business from scratch securing a high degree of flexibility and agility in our day to day work while still being compliant. This degree of flexibility is important for us to be able to continue growing in a rapidly changing market”, said Mr. Mikkel Schoedt, General Manager of Kleresca®. Until end of June this year, Kleresca® operated under the CE mark of one of its founding fathers, LEO Pharma.   Today’s CE mark approval enables Kleresca® to consolidate its business on the European market as an independent company and paves the way for future market activities in the US, Australia and Canada as the company expects to apply the Medical Device Single Audit Program (MDSAP) on top of the CE Mark before the end of this year. At the same time, the company has also been successfully certified towards ISO 13485:2016. To date, Kleresca® has built a strong partner structure counting more than 250 skin clinics in key markets leveraging gentle, non-invasive skin treatments with high efficacy and safety currently indicated for therapeutic (acne) and aesthetic (skin rejuvenation) purposes. With the new CE-mark, the technology has furthermore been secured for treatment of rosacea as well as a pre-post treatment as an add on treatment to other dermatological procedures like IPL and laser treatments. The Kleresca® biophotonic system uses fluorescent light energy to stimulate the skin’s own biological processes and repair mechanisms. It has been available on the market since 2014.  

ANNOUNCEMENT RELATING TO THE DECISION MADE BY THE STOCK EXCHANGE APPEALS COMMITTEE

The Board of Directors (the “Board”) of EMAS Offshore Limited (the “Company” and together with its subsidiaries, the “Group”) refers to the announcement released by the Company on 15 February 2018, 19 February 2018 and the announcement released by the Oslo Stock Exchange (“OSE”) on 15 August 2018 (“OSE Announcement”) (please see Appendix A). As stated in the OSE Announcement, the Financial Supervisory Authority of Norway (“FSA”) has on 15 August 2018 resolved to impose the OSE to delist the shares of the Company pursuant to section 25(3) of the Norway Stock Exchange Act (the “Decision”). The OSE has in accordance with the imposition from FSA further announced that the shares of the Company will be delisted from trading on Oslo Børs and the last listing date for the Company's shares will be 28 September 2018. The Company has further been informed by the FSA that the Company has three weeks from 15 August 2018 to appeal the Decision. The Company is seeking legal advice and will provide further updates when there are material developments. Shareholders and potential investors should consult their financial, tax or other advisors when in doubt as to what action they should take. This announcement is subject to disclosure in accordance with section 5-12 of the Norwegian Securities Trading Act. By Order of the Board Lee Kian Soo Director 16 August 2018 Appendix A 

AVTECH Sweden AB and the Met Office (UK) signs 3-year contract for unique 10KM Resolution Weather

Under the new contract AVTECH has an exclusive access to the jointly developed Access Protocol (API), which allows the most detailed and accurate forecasts to be commercially available, through AVTECH’s products, for the Aviation market. “We are extremely pleased to continue our already established cooperation with Met Office,” says AVTECH CEO Christer Fehrling. “AVTECH has performed an extensive study of Aviation forecast accuracy, involving more than 50 000 flights, and have established that Met Office’s 10KM grid resolution forecast, when comparing to the aviation standard of 140KM grids, reduces wind and temperature errors by more than 50%. The 10KM forecast simply represents the most realistic and accurate forecasts available in the market. Thanks to our exclusive API access directly with Met Office’s 10KM weather model, AVTECH and Met Office can now continue to bring unique solutions to the aviation community, giving our customers a possibility to improve efficiency and safety,” he continues. Emma Connett, Transport Business Manager at the Met Office, said, “We are delighted to continue and develop our work with AVTECH. We look forward to working together to continually improve and bring further developments to Aviation weather forecasting. As we see the Aviation industry seek further efficiency gains and operational improvements, we see an increased need for our high resolution weather data to be delivered in a timely manner, available direct to the cockpit".   AVTECH is currently utilizing Met Office’s 10KM Resolution forecast in their Aventus products NowCast™ and SIGMA, which is primarily focusing on airline use. Besides the current offerings, additional services are under development which in the future will broaden the use of 10KM resolution forecasts further. For more information, please contact Sören Skog, Marketing Director, +46 (0) 8 544 104 80Christer Fehrling, Managing Director, +46 (0) 8 544 104 80 This information is information that Avtech Sweden AB (publ) is obliged to make public pursuant to the Swedish securities market act. The information was submitted for publication, through the agency of the contact persons set out above, August 16, 2018 at 11.45 AM CET.About AVTECH Sweden AB www.avtech.aero AVTECH develops products and services for digital Air Traffic Management (ATM). Its customers include the global aviation industry; e.g. airlines, airports, aviation authorities, technology companies and airline manufacturers. By using AVTECH’s products and services, each individual flight as well as the entire airline operation can be optimized in terms of cost, noise and emission, efficiency, punctuality and safety. AVTECH Sweden AB is listed on NASDAQ OMX First North and has appointed Redeye AB, tel: +46 8 545 013 30, as Certified Adviser.

Bone Index Ltd. Announces Medicare Reimbursement Coverage for Bindex Osteoporosis Measurement

Bone Index Ltd., a medical device company with a game changer point-of-care technology (Bindex®) in osteoporosis diagnostics, announces that U.S. Centers for Medicare & Medicaid Services (CMS) has approved coverage for Bindex® measurement in the Ambulatory Surgical Center (ASC) setting, when provided integral to a surgical procedure on ASC list*. In addition, the coverage includes the outpatient hospital settings*. “This significant reimbursement coverage is a remarkable milestone for Bindex measurement. In addition, this is a great example how CMS wants to improve the healthcare in US. Bindex is a new and unique medical device which provides significant improvement in osteoporosis screening and diagnostics in US. Now large number of healthcare operators are able to provide highly needed osteoporosis examinations. However, we continue our hard work to broaden the coverage landscape to physician offices” says Bone Index's CEO, Dr. Ossi Riekkinen. Bindex® point-of-care device measures the cortical bone thickness of the tibia and the algorithm calculates the Density Index, a parameter which estimates bone mineral density at the hip as measured with DXA. Bindex detects osteoporosis with 90% sensitivity and specificity and will significantly help physicians with diagnosis. Undiagnosed osteoporosis is a worldwide challenge. In the US alone osteoporosis is responsible for two million broken bones every year, costing over 19 billion dollars. Experts forecast that by 2025, the costs will rise to 25.3 billion dollars. One of the biggest challenges is the limited availability of osteoporosis diagnostics since bone density scans are mostly performed in hospitals with large DXA X-ray machines that entail high costs. "The overall aim is to prevent osteoporotic fractures, improve surgical outcomes and improve the quality of life for families in the US," says Dr. Riekkinen. For more information:Bone Index Ltd., Dr. Ossi Riekkinen, CEO, Dallas, TXossi.riekkinen@boneindex.fi , M: 469.805.5419 , www.bindex.fi/en/ *https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/11_Addenda_Updates.html HCPCS Code, 0508T: Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia. About Bone Index:Founded in 2011 in Kuopio, Bone Index Finland Ltd. specializes in the development of measuring devices for osteoporosis screening and diagnostics.

Attana receives final approval for the EU project NanoMile

The EU project NanoClassifier (www.nanoclassifier.eu) took part between 2013 and 2017 and was funded by the EU's Seventh Framework Program for Research and Development. In the project Attana and UCD were participating partners. Proteins and other biomolecules in the body interact with the surface of nanoparticles. These interactions create a corona on the surface of the nanoparticles, and the coating affects the behavior of nanoparticles in the body. Attana's technique was used in the project to characterize the interactions of coronal-coated nanoparticles with biomolecules. The information from such experiments is valuable for optimizing therapeutic nanoparticles and predicting their function in the body. The project has developed several experimental methods based on Attana's technology, and some of these have previously been published in the journal Nanoscale . Further results will be presented at the CLINAM "11th European and Global Summit for Clinical Nanomedicine, Targeted Delivery and Precision Medicine - The Building Blocks to Personalized Medicine" in September. The final report of the project was completed last year and is now approved. Attana has been granted a total of just over SEK 2.8 million for its part of the project and now receives SEK 1.8 M. Of these, SEK 400k has been included in previous year's income statements, but the remaining SEK 1.4M and the entire amount will have a positive effect on earnings and cash flow in Q3.

Marne Martin appointed as President of IFS’s Service Management Business Unit and CEO of WorkWave

The IFS Service Management business unit established under Marne will encompass the global IFS service management organization as well as WorkWave, acquired by IFS in September 2017 , and have dedicated engineering, sales and marketing resources to address the unique needs of service management customers globally. Marne’s experience leading high-growth and expansion phases in both publicly and privately held companies will provide the leadership required to propel both brands into their next stages of growth and market expansion. As both President of IFS Service Management and CEO of WorkWave, Marne and her leadership team will continue to elevate the strategic importance of service management to the success of the overall IFS business. Marne will focus on ensuring the entire portfolio of IFS’s service management solutions provide customers with the business value they expect from a global industry leader in field service management  (FSM). “I am thrilled to be leading such a great organization and to be part of the overall IFS senior leadership team as we begin a new chapter in our company’s growth,” said Marne. “WorkWave continues to be an important asset to the overarching value proposition of IFS Service Management, and I look forward to working with the talented IFS and WorkWave teams to make sure IFS’s service management portfolio becomes even more customer-focused.” With Marne’s appointment to its senior leadership team, IFS will be able to draw on her broad experience and proven track record to further increase the significance of the service business and grow its global market share. IFS CEO Darren Roos said, “Marne’s domain experience will enable us to further develop the service management capability across the entire portfolio to deliver even more value to our customers. We remain completely focused on delivering solutions together with our partners that have an impact on the way our customers serve their customers.” Prior to IFS, Marne served as CEO and led the executive leadership team at ServicePower Plc., a field service management software company, where she transformed its go-to-market strategy and shifted its focus to SaaS and managed services revenue, increasing pipeline every year during her tenure. Prior to that, she served as CFO of Norcon, Plc., a UK-based telecom and defense consulting firm, where she grew the company from a business largely dominant in only the Middle East to one diversified across the US, Europe, the Middle East and Asia Pacific. Martin is a winner of a number of awards including 2016 CEO Gamechanger of the Year (FSM) from ACQ 5 Global Awards and 2015 Field Service CEO of the Year from Executive Awards. Read more about Marne and IFS’s executive management team here: https://www.ifsworld.com/corp/company/governance/executive-management/.

Retrospective study results for IMMray™ PanCan-d conclude Immunovia needs to do further optimizations to meet the expected performance

The retrospective study analyzed more than 1000 blood samples from five different clinical collaborators, covering all the stages of pancreatic cancers combined with samples from the patients presenting early symptoms suggestive of pancreatic cancer and from healthy controls. The study was performed as part of the preparation for the certification and accreditation of Immunovia´s commercial version of IMMrayTMPanCan-d. The combination of retrospective samples from different biobanks, with varying sample collection procedures, introduced unforeseen variability in the test algorithm performance. To eliminate the distorting effect caused by the variability in blood sampling, a further optimization of the algorithms will be completed by Q1 2019. The successful optimization of the algorithms is followed by the compulsory verification and validation studies resulting in a delay of the launch of IMMrayTMPanCan-d until the later part of 2019. This study and other studies performed during the accreditation and certification preparations as well as the peer reviewed article in Journal of Clinical Oncology released Tuesday Aug 14th, 2018 , continues to demonstrate solid evidence of the IMMrayTM platform robustness and functionality, including low technical platform variabilities and low laboratory process variations. The financial targets adopted by the Immunovia Board in March 2018 remains, with a corresponding delay in time. The Company’s goal is to reach SEK 250-300 million in turnover in 2022 based on “self-pay”-sales and a turnover of SEK 800-1,000 million in 2024 including self-pay and reimbursements in Europe and the US. These financial targets do not include the pipeline products in other cancers and autoimmunity. All other product pipeline studies are moving forward as planned. “We are confident that the further optimizations of the algorithms will be the final adjustments we need to do before our commercial launch. I would like to point out that this variability in blood sampling process only affects the current study used for the algorithm development and verification phase at Immunovia. To eliminate any future blood sampling variability for the commercial version of IMMrayTM PanCan-d we are standardizing the blood sampling procedure, conforming to current de facto standards of blood sampling,” commented Mats Grahn, CEO, Immunovia. A telephone conference is scheduled on Friday August 17th, 2018, 08:00 am CET to answer questions and further describe the results and the plans. Participant dial in numbers: CH: +41225675548DK: +4582333178FR: +33170750725UK: +442030089804NE +31207168416NO: +4723500253SE: +46856642663US: +16465025116PIN Code for Belgium & Germany: 55734942#BE: +3224017014DE: +496922224998 On the Immunova website under Investors/Audio Gallery there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call.   For further information, please contact: Mats Grahn   Chief Executive Officer, CEO, Immunovia Tel.: +46-70-5320230 Email: mats.grahn@immunovia.com This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.35 CET on August 16, 2018. About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

Catena Media resolves to implement directed new share issue as part of second earn-out payment for assets acquired in December 2016

On 14 December 2016 , the Company announced that it had acquired websites and other affiliate related assets in the US, and that part of the additional purchase consideration for the assets can be paid in the form of newly issued shares in Catena Media. On 28 November 2017 , the Company announced that it had approved a directed new issue of 117,805 shares as payment of part of the first additional purchase consideration for the assets acquired in the US in December 2016. Additionally, on 28 February 2018 , the Company announced certain amended terms regarding the earn-out structure. This meant that the total amount for the two remaining earn-out payments was reduced from a total of USD 34.5 million to a total of USD 17.0 million and that as much as 50 percent of the remaining earn-out payments could still be paid in the form of newly-issued shares in Catena Media.  In light of the foregoing, the Company's Board of Directors has, under the authorization granted by the Company's Articles of Association, approved a directed issue of 77,209 shares to the sellers of the assets in part payment of the second additional purchase consideration, corresponding to a total amount of approximately USD 1,046,791. The shares are subject to a lock-up period of six months. The subscription price for the share issue has been set at SEK 117.38 per share, corresponding to the volume-weighted average price for Catena Media’s share on the Nasdaq Stockholm exchange during a period of 30 trading days up to and including 27 April 2018. Through the share issue, the number of ordinary shares in Catena Media will increase by 77,209 shares, and the share capital will increase by EUR 115.81. For further information, please contact:    Per Hellberg, CEO, Catena Media plcPhone: +46 709 10 74 10, e-mail: per.hellberg@catenamedia.com Åsa Hillsten, Head of IR & Communications, Catena Media plc Phone : +46 700 81 81 17, e-mail : asa.hillsten@catenamedia.com The information was submitted for publication, through the agency of the contact persons set out above, on 16 August 2018 at 17:45 CET. About Catena Media  Catena Media provides companies with high quality online lead generation. Through strong organic growth and strategic acquisitions, Catena Media has since 2012 established a leading market position with approximately 350 employees in the US, Australia, Japan, Serbia, UK, Sweden, Italy and Malta (HQ). Total sales in 2017 reached EUR 67.6 million. The company is listed on Nasdaq Stockholm Mid Cap. Further information is available at www.catenamedia.com 

BJÖRN BORG AB INTERIM REPORT JANUARY – JUNE 2018

1 APRIL – 30 JUNE, 2018       · The Group’s net sales increased 4.1 percent to SEK 140.3 million (134.8). Excluding currency effects sales rose 1.2 percent. · Net sales for own e-com and e-tailers amounted to 28,6 MSEK (23,2), an increase of 23 percent. · The gross profit margin was 59.9 percent (52.1). · Operating profit amounted to SEK 2.9 million (–0.3). · Profit after tax amounted to SEK 1.5 million (–3.3). · Earnings per share before and after dilution amounted to SEK 0.06 (–0.11). 1 JANUARY – 30 JUNE, 2018 · The Group’s net sales fell 3.4 percent to SEK 309.5 million (320.5). Excluding currency effects sales fell 5.6 percent. · Net sales for own e-com and e-tailers amounted to 61,0 MSEK (48,2), an increase of 26 percent. · The gross profit margin was 58.3 percent (50.3). · Operating profit amounted to SEK 18.0 million (6.5). · Profit after tax amounted to SEK 16.3 million (1.7). · Earnings per share before and after dilution amounted to SEK 0.66 (0.07). QUOTE FROM THE CEO “In the second quarter we again saw that anything is possible, and at the same time that the Swedish national football squad showed that the team is stronger than the individual, our Swedish stores increased their revenues by 15 percent compared with the previous year. It had been some time since we had such strong growth for comparable stores. We also set a new record: Our gross margin has never been higher at nearly 60 percent,” said CEO Henrik Bunge.  For further information, please contact:Henrik Bunge, CEO, telephone +46 8 506 33 700Daniel Grohman, CFO, telephone +46 8 506 33 700This information is information that Björn Borg AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above on August 17, 2018 at 7:30 am (CET).

BioGaia AB - Interim report January 1 – June 30, 2018

Comments from the Managing Director: “Our second quarter performance was very strong, with growth of 29% (26%, after foreign exchange effects) compared to the same quarter of last year. Thanks to solid growth in both the Pediatrics and Adult Health segments, we achieved sales of over SEK 200 million for the first time ever. Geographically, growth was strong across all three regions, EMEA, Asia Pacific and the Americas. At the same time, we would like to communicate that we foresee significantly lower royalty revenues from Nestlé as a consequence of the ongoing negotiations of our royalty agreement which terminates at the end of the year” says Sebastian Schröder, Acting Managing Director of BioGaia.  Second quarter 2018(Figures in parentheses and comparative figures in the text refer to the corresponding period of last year. The comparative figures in the balance sheet refer to December 31, 2017). · Net sales amounted to SEK 200.9 million (156.0), an increase of 29% (excluding foreign exchange effects, 26%). · Net sales in the Pediatrics segment reached SEK 168.5 million (132.1), an increase of 28%. · Net sales in the Adult Health segment amounted to SEK 32.1 million (23.0), an increase of 39%. · Operating profit, excluding revaluation of the former associate shareholding in MetaboGen, was SEK 72.9 million (61.2), an increase of 19%. The company has changed an accounting standard as of 1 January 2018, which means that foreign exchange gains/losses attributable to forward contracts are recognized in operating profit or loss (previously in financial items). These amounted to SEK -4.6 million (+1.5). With an unchanged standard, operating profit would have increased by 30%. · Profit after tax was SEK 62.8 million (47.2), an increase of 33%. Excluding revaluation of the former associate shareholding in MetaboGen, profit after tax was up by 18%. · Earnings per share totaled SEK 3.62 (2.72). No dilutive effects arose. · The period’s cash flow was SEK -133.9 million (-117.3). Cash flow includes dividends of SEK 156.0 million (130.0). Key events in the second quarter of 2018 · BioGaia invests further in MetaboGen and increases its holding to 62%. (See also “Key events after the end of the second quarter”.) · Axel Sjöblad, former Managing Director, leaves his post. Isabelle Ducellier will be the new Managing Director with effect from 5 November 2018. · A study showing that Lactobacillus reuteri reduces bone loss in older women is published in the highly reputed Journal of Internal Medicine .   January 1 – June 30, 2018  · Net sales amounted to SEK 357.5 million (297.2), an increase of 20% (no material dilutive effects arose). · Net sales in the Pediatrics segment reached SEK 300.2 million (242.8), an increase of 24%. · Net sales in the Adult Health segment amounted to SEK 56.5 million (49.5), an increase of 14%. · Operating profit, excluding revaluation of the former associate shareholding in MetaboGen, was SEK 129.1 million (117.3), an increase of 10%. The company has changed an accounting standard as of 1 January 2018, which means that foreign exchange gains/losses attributable to forward contracts are recognized in operating profit or loss (previously in financial items). These amounted to SEK -13.6 million (+1.8). With an unchanged standard, operating profit would have increased by 24%. · Profit after tax was SEK 105.9 million (90.1), an increase of 18%. Excluding revaluation of the former associate shareholding in MetaboGen, profit after tax was up by 10%. · Earnings per share totaled SEK 6.14 (5.20). No dilutive effects arose. · The period’s cash flow was SEK -94.1 million (-39.8). Cash and cash equivalents at June 30, 2018, amounted to 215.5 million (305.9). Key events after the end of the second quarter · BioGaia´s royalty agreement with Nestlé, from the sales of growing up milk with Lactobacillus reuteri for children over one year, will be terminated at the end of the year. Nestlé has communicated that they wish to limit the scope of the agreement, which then would result in significantly lower royalty revenue. · BioGaia invests an additional 30% in MetaboGen for SEK 27.8 million. The shareholding in MetaboGen now amounts to 92%.  Teleconference: Investors, analysts and the media are invited to take part in a teleconference on the interim report that will be held today, August 17, 2018, at 9:30 a.m. with Acting Managing Director Sebastian Schröder. To participate in the teleconference, please see https://www.biogaia.com/investors/financial-calendar/ for telephone numbers. The teleconference can also be followed at: https://tv.streamfabriken.com/biogaia-q2-2018  This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the acting Managing Director, at 17 August 2018, 8:00 CET. This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording shall prevail.

High level of orders received and improved operating profit

April – June 2018 ·  Net sales SEK 13,453 million (12,791) ·  Operating profit SEK 677 million (631) ·  Operating margin 5.0 percent (4.9) ·  Pre-tax profit SEK 673 million (617) ·  Earnings per share SEK 1.94 (1.78) ·  Orders received SEK 16,257 million (12,880) ·  Cash flow before financing SEK -704 million (-1,105) January – June 2018 ·  Net sales SEK 24,943 million (23,896) ·  Operating profit SEK 967 million (951) ·  Operating margin 3.9 percent (4.0) ·  Pre-tax profit SEK 929 million (928) ·  Earnings per share SEK 2.68 (2.72) ·  Orders received SEK 29,163 million (25,309) ·  Order backlog SEK 47,453 million (39,470) ·  Cash flow before financing SEK -1,094 million (683) ·  Net debt SEK 3,592 million (2,707) ·  Equity/assets ratio 29.2 percent (29.3) “The outlook for Peab is positive with a solid order backlog, a good project mix, a well-dimensioned development rights portfolio and a strong financial position. The market situation continues to be good with a stable demand in Sweden, Norway and Finland. Thanks to the wide range of our business we can handle a downturn in some product areas with an upturn in others”, says Jesper Göransson, CEO Peab. This information is information that Peab AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at August 17, 2018, at 8.00 a.m. CET. For further information, please contact: Jesper Göransson, CEO +46 431 89338 Charlotte Hagö, CIO +46 725 334545

Idogen extends the project portfolio to projects in autoimmune diseases

Idogen´s technology is designed for the development of tolerogenic cell therapy in a variety of areas, especially treatment of anti-drug antibodies, autoimmune diseases and organ rejection after transplantation. Until now, Idogen's project portfolio consisted of the two product candidates IDO 8 and IDO T. IDO 8 is aimed at patients with severe haemophilia A affected by inhibitory antibodies against their vital treatment with coagulation factor VIII. An initial clinical trial of IDO 8 is scheduled to start in early 2020. IDO T is a treatment method aimed at preventing organ rejection in transplantation, primarily in renal transplantation. Preclinical proof of concept data for IDO T is expected to be presented within three to six months. Idogen has now decided to expand the project portfolio with a third therapeutic area; autoimmune diseases. Patients with autoimmune diseases are often treated for prolonged periods with drugs that strongly suppress the immune system. However, the effect on the underlying disease is rarely optimal and treatment can lead to unwanted side effects. The medical need for improved therapies is therefore large. The purpose of Idogen's tolerogenic cell therapy is to dramatically reduce the need for immunosuppressive drugs by a short treatment with improvements for the patient as a result. Proof of principle data from a preclinical trial model relevant to a rare autoimmune disease is expected to be presented within three to six months. “We are very excited about the opportunity to evaluate the potential of Idogen's technology platform in the field of autoimmune diseases. Today, there is a major unmet medical need in patients with current standard treatments, where we believe that Idogen's tolerogenic cell therapy can play an important role. Our focus will be on one or several rare diseases, which allows for the grant of orphan drug designation that can reduce both development costs and time until market approval, as well as extended market exclusivity”, CEO Lars Hedbys comments.  For additional information, please contact:Lars Hedbys, CEO Idogen ABTel: +46 (0)46-275 63 30E-mail: lars.hedbys@idogen.com This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply. This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on August 17 2018. Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. The treatment is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit www.idogen.com 

Panion in FDA pre-submission conference

Panion Animal Health AB develops a unique new gene therapy treatment for dogs with drug-resistant epilepsy and the primary targeted market is the USA. The company has just been assigned to a pre-submission conference for this product with staff and experts from the FDA’s Center for Veterinary Medicine to take place in October in FDA-CVM’s office, Maryland, USA. At the meeting, the product will be introduced, the development plan will be discussed, and comments from the experts will be sought for a faster and smoother access to approval and marketing. The FDA has already received a documentation package about the product, which was included when the request was sent earlier this year, and the FDA experts normally arrive prepared and briefed. Participants from Panion will be CEO and veterinarian Anja Holm, Director of Business Development Carlos N. Velez, and FDA regulatory expert Dave M. Petrick, plus our scientific experts on a tele-link. “We are eager to hear the views from the FDA experts, because this will give us a better understanding of the investigations and documentation that are necessary for the approval of our deve-lopment product” says CEO Anja Holm. “The plan is also to use the trip to US for other meetings with central persons involved in Panion’s business, so we can maximize the outcome.”Anja Holm, CEO, Panion Animal Health AB New address:Panion has changed address on the 10.th of August 2018:Panion Animal Health ABNorra Kringelvägen 13SE-281 41 Hässleholm, Sweden

Evolution live with first USA Live Casino studio, Atlantic City, New Jersey

The new purpose-built Live Casino production studio for the US market is Evolution’s tenth Live Casino studio worldwide. The news follows recent announcements by Evolution that 888casino, Resorts Casino Hotel, Hard Rock Hotel & Casino Atlantic City, PlaySugarHouse.com operated by Rush Street Interactive and Ocean Resort Casino Atlantic City will all use the new Evolution US studio to launch Live Casino services for players in New Jersey. The New Jersey studio launch is another significant milestone in Evolution’s growing North American presence, which already includes a dedicated Live Casino studio for Canada — opened in Vancouver in January 2018 — as well as a number of Evolution Dual Play (on-premise and online) Roulette tables for the Atlantic City gaming floors of Resorts Casino Hotel, Ocean Resort Casino and Hard Rock Hotel & Casino Atlantic City. The studio and supporting infrastructure provide a state-of-the-art B2B Live Casino solution for multiple operators wishing to offer world-class Live Casino gaming to online players on desktop, tablet and smartphone. Initially the studio offers 10 online live tables and a wide range of Evolution game variants: American (Double Zero) Roulette, Blackjack with side bets and Bet Behind, Baccarat, Three Card Poker and Ultimate Texas Hold’em Poker, plus Slingshot Roulette. Further game launches and additional tables, including dedicated tables that can be used by operators for live sporting event promotions and to cross-promote land-based casino attractions, for example, all form part of the studio’s expansion plans. So far, employment opportunities have been created for 50-plus people. Recruitment continues, and further jobs will be created as studio operations expand. Evolution CEO Martin Carlesund commented: “Our entry into the US market has been a carefully considered long-term project. Back in 2013 Evolution became the first Live Casino provider to gain New Jersey Preliminary Waiver approval. Having closely monitored US market developments over the past few years, while reinforcing our position as Live Casino market leaders in Europe, we believe that now is the right time to launch with a full-fledged studio facility for the US.” Carlesund added: “Now we have a fantastic Live Casino studio in New Jersey — with a wide choice of live games from day one, and ample room for expansion and the rapid ramping up of services to meet our new US licensees’ needs. We are now extremely well placed to support our licensees as they acquire and grow market share in the exciting new US Live Casino market.”

TargetEveryone appoints Torkel Johannessen as new Chief Executive Officer

The board of directors has reached an agreement with Torkel Johannessen to become the new CEO of TargetEveryone. Johannessen has been a board member of TargetEveryone since 2016 and will enter his new position starting October 1st this year. Johannessen comes from the role as Head of Sales and Omnichannel at VITA, the largest Cosmetics retailer in Norway. Johannessen has more than 15 years of experience within the digital space from the US, the UK and the Nordic region. He has previously worked for companies such as Match.com, Yahoo! and Egmont. Johannessen´s position as a board member will be replaced as soon as possible. Björn Forslund will remain a key member of the management group focusing on business- and product development. “We are pleased to present Torkel Johannessen as new CEO for TargetEveryone AB” says TargetEveryone’s Chairman Fredric Forsman. “Torkel’ s extensive international expertise from the MARTECH space, coupled with the ability to grow businesses from early-phase to a considerable size, gives us an important reinforcement of the management function. I am convinced that he will successfully take TargetEveryone into its next phase of expanding globally”. Björn Forslund says, “Torkel´s knowledge and support as our board member during the last years have been highly appreciated, and I believe he is the perfect candidate for the position. Now I can focus much more on business development in TargetEveryone, which has always been my great passion”.  “I am extremely excited about joining TargetEveryone as their new CEO” says Torkel Johannessen. “My entire career has been spent at the junction between marketing and technology development, with deep industry experience from media and retail sectors. TargetEveryone is a pioneer within the rapidly growing Marketing Technology area, which is currently transforming the vast majority of consumer-facing businesses worldwide. I am very much looking forward to joining such a talented and committed group of professionals, and I’m honored to be a part of a leadership team that carries such a sharp focus and commitment for delivering on the high expectations of its clients.” Torkel is a resident of Oslo, Norway, 41 years old and father of four. He holds a Master’s degree in International Business from Macquarie University and a Bachelor’s degree in International Marketing from BI.

ExpreS2ion appoints CBO and IR partner

The appointment of Bent U. Frandsen as CBO follows the strengthening of the Company’s offer to provide complete services in vaccine development and GMP production to early clinical trials based on its ExpreS2-platform. The platform is currently used in several projects, including developing treatments for infectious diseases such as malaria and Ebola. “We have recently added key technical and marketing personnel that has boosted the capacity in our core service segment significantly. Now, we also have a clearer company structure with Bent in overall charge of our sales, marketing and business development efforts,” says ExpreS2ion’s CEO Dr. Steen Klysner. In addition to Bent U. Frandsen’s appointment, the Company announces the appointment of Honeybadger as the Company’s non-exclusive IR partner on the Swedish market. Honeybadger undertakes to assist ExpreS2ion in strategic communication as well as production of press releases, reports and non-regulatory market communication in Swedish and English. ExpreS2ion’s relationship with Sedermera Fondkommission, the Company’s Financial and Certified Advisor, is not affected by this and will continue to the same extent as before. “With the capital received from the rights issue in the early spring, we have initiated a significant growth in operations. This has also increased the need for high-quality and transparent communication with our shareholders and the market. To meet this demand while keeping focus on our core activities, we have appointed Honeybadger, whom we have collaborated successfully with since the end of 2017, as our IR partner,” says ExpreS2ion’s CEO Dr. Steen Klysner. About Honeybadger Honeybadger AB is an IR communication agency based in Gothenburg, Sweden, that enables listed companies to communicate with shareholders, potential investors, media and other parties of interest in an efficient, qualitative and transparent way. The company focuses on clients that have the potential to improve the living conditions of humans, animals and nature through scientific and technological advances. Honeybadger is based on 15 years of experience in communication for listed companies and corporations in the financial sector. Certified Adviser  Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

ExpreS2ion’s platform (ExpreS2) featured in npj Vaccines article on malaria vaccine candidate production

The article describes the production of the University of Oxford’s leading blood-stage malaria vaccine candidate RH5.1 in accordance with GMP using the ExpreS2 platform. The product met all criteria for sterility, purity and identity and the vaccine formulation was judged suitable for use in humans. RH5.1 is currently evaluated in a phase 1/2a clinical trial. “This publication adds to the evidence that our ExpreS2 system is an excellent platform for vaccine development and GMP production for clinical trials. We are excited to work with the University of Oxford and their promising RH5.1 malaria vaccine candidate and will of course inform the market when results from this study becomes public”, says ExpreS2ion’s CEO Dr. Steen Klysner. Summary of the npj Vaccines articleA leading malaria blood-stage vaccine candidate (PfRH5) called “RH5.1” was produced as a soluble product under GMP using the ExpreS2 platform. The QC testing showed that the master cell bank and the RH5.1 product met all specified acceptance criteria including those for sterility, purity and identity. The vaccine formulation was judged suitable for use in humans and is currently in a Phase 1/2a clinical trial. The data support the future use of the ExpreS2 platform for GMP-compliant biomanufacturing of other novel vaccines. The article can be accessed via the following link:https://doi.org/10.1038/s41541-018-0071-7  Malaria Malaria is a major global health problem with 3.2 billion people living at risk of malaria infection. In 2015, malaria was thought to have caused 429,000 deaths, most of which (70%) occurred in children under five years old (WHO, 2016, http://www.who.int/malaria/media/world-malaria-report-2016/en/). In a malaria market assessment study by the Boston Consulting Group sponsored by the Malaria Vaccine Initiative, the malaria vaccine demand was estimated to be translated into a global market value of up to $400M per year. Certified Adviser  Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

Nordea has received permission for continued use of existing internal models from the ECB

As part of the planned re-domiciliation to Finland, Nordea Bank Abp (“Nordea”) reached another milestone in the transition from the Swedish FSA (“SFSA”) regulatory framework to the banking union regulatory framework by being granted temporary use of internal models for calculation of risk exposure amounts (“REA”) from the European Central Bank (“ECB”). The decision, as expected, implies a migration of Pillar 2 capital add-ons into Pillar 1 REA and an unchanged nominal capitalisation level. As previously communicated, Nordea has voluntarily committed to comply with the SFSA 2018 Supervisory College Joint Decision as of 1 October 2018 until the ECB has issued a decision establishing prudential requirements prepared in accordance with the 2019 Supervisory Review and Evaluation Process (“SREP”) expected late 2019. During this transition, the ECB decision, including the already announced implementation of the Swedish residential real estate risk-weight floor, reduces the forecasted Common Equity Tier 1 (“CET1”) ratio for the fourth quarter of 2018 to approximately 15.5 per cent and similarly reduces the associated transitional CET1 capital requirement[1] to approximately 13.7 per cent (of which 3 per cent relates to Pillar 2)[2]. Thus, the management buffer in nominal terms is expected to remain largely unchanged. Nordea expects to communicate the final capital requirements after 1 October 2018 following the SFSA 2018 Joint Capital Decision.   Nordea remains equally strongly capitalised and Nordea’s capital and dividend policy will remain unchanged. The decision does not change Nordea’s business model or risk profile and Nordea is committed to maintain its AA rating after the change of domicile. As part of the decision for temporary use of internal models, Nordea has committed to a model improvement development plan with applications expected no later than 2020. For further information:Rodney Alfvén, Head of Investor Relations, +46 722 350 515Afroditi Kellberg, Chief Press Officer, Sweden, +46 73 350 5599  [1] For clarity the transitional CET1 capital requirement is set by the SFSA 2018 joint capital decision and applies from 1 October 2018 to when the ECB issues their 2019 Joint Capital Decision expected late 2019.[2] This can be compared to the current forecasted CET1 ratio, for the fourth quarter in 2018, under the Swedish regulatory capital framework, including the announced implementation of the Swedish residential real estate risk-weight floor, of approximately 18.5 per cent and similarly a forecasted CET1 requirement of approximately 16.5 per cent. Nordea’s reported CET1 as of Q2 was 19.9 per cent with a requirement of 17.6 per cent.

Kindred partners with Hard Rock Hotel & Casino Atlantic City in New Jersey

Kindred Group (previously Unibet Group) has agreed with Hard Rock Hotel & Casino Atlantic City to pursue a Casino Service Industry Enterprise License in New Jersey. The agreement allows Kindred to take its first important step towards offering US customers online sports betting and gaming services. Hard Rock Hotel & Casino Atlantic City opened the doors to its casino in Atlantic City in June 2018 with ambition to become the market leader and to offer customers a first-class casino and sports betting experience. Kindred Group shares the same aspirations. The collaboration between two strong international brands, will combine Hard Rock’s first-class lifestyle and entertainment experience with Kindred’s state-of-the-art digital innovation and data analysis, creating a strong offering in the New Jersey market. “Hard Rock is proud to partner with one of the fastest growing operators in the industry. We are hopeful that Kindred’s international experience and commitment to innovation will translate to a significant success in New Jersey,” said Kresimir Spajic, SVP Online Gaming at Hard Rock International. “This is a very exciting moment for Kindred as we have been working hard to take this first important step into what will most likely become the largest betting market in the world. I’m also delighted that we have been able to team up with a true lifestyle and entertainment brand and I am confident that Kindred and Hard Rock Hotel & Casino Atlantic City will give New Jersey customers an absolutely great sports betting and gaming experience”, says Manuel Stan, SVP Kindred US. Kindred has been preparing to take this step for a long time and intensified its efforts when the US Supreme Court ruled against PASPA in May this year. The agreement is part of Kindred’s ongoing process to secure regulatory approval.

Tobii Dynavox acquires UK-based Smartbox Assistive Technology

Tobii’s largest business unit Tobii Dynavox  has entered into an agreement to acquire 100% of the shares in UK-based Smartbox  Assistive Technology Ltd. Through the acquisition, Tobii Dynavox will further consolidate its market leading position and strengthen its sales channels in key geographical markets. Smartbox will be fully integrated into Tobii Dynavox. The acquisition brings together the industry leading communication software Grid from Smartbox with Tobii Dynavox’s industry-leading touch and eye-tracking solutions for assistive communication. Tobii Dynavox will now extend its product line by integrating Grid into the portfolio, forming a comprehensive and strong offering that meets a broad range of communication needs for users with disabilities. “Smartbox has played an important role in the assistive technology for communication market globally. With their innovative software Grid and entrepreneurial spirit, they are a perfect match for Tobii Dynavox. By integrating the two entities we will have the strongest sales channels and the best products on the market,” said Fredrik Ruben, President Tobii Dynavox. Smartbox Assistive Technology Ltd, up until now owned by Paul Hawes and family who founded the business, with main offices in Malvern and Bristol, United Kingdom, employs about 70 people. Net sales in 2017 were GBP 9,3 million, corresponding to approximately SEK 110 million. Profit margin is in line with that of Tobii Dynavox. The acquisition is expected to be closed on October 1, 2018, and the process of integration will begin shortly. Tobii pays the owners/founders GBP 11 million in cash, corresponding to approximately SEK 130 million. The acquisition will be accretive to EPS and is financed through debt. Tobii Dynavox’s long-term financial targets remain intact. Additional financial information will be disclosed in Tobii’s interim report for the fourth quarter 2018. This information is information that Tobii AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on August 20, 2018, at 8.20 a.m. CET.